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1
1.1

CHAPTER 1: THE PROTEIN CONTEXT OF POLYGLUTAMINE DISEASES
Introduction
The polyglutamine (polyQ) disease family is a group of nine neurodegenerative disorders

that are caused by the anomalous expansion of a CAG repeat in the protein-coding region of each
disease gene[2-4]. These CAG expansions encode a prolonged polyQ tract in each disease protein
that causes a host of shared features: slow progression of neurodegeneration that manifests in the
adult years of life, an inverse correlation between the length of the polyQ expansion and the age
of onset, and an autosomal dominant inheritance pattern that is shared by all but one of the
diseases[2-4]. The current list of polyQ diseases includes dentatorubral-pallidoluysian atrophy
(DRPLA), Huntington’s disease (HD), spinal and bulbar muscular atrophy (SBMA or Kennedy’s
disease), and spinocerebellar ataxias (SCAs) 1, 2, 3, 6, 7, and 17[2-4]. While each of these disorders
shares the same genetic cause and characteristics described above (other than SBMA being an Xlinked and not autosomal dominant), they are all clinically distinct[2-4]. Their disease proteins are
all widely expressed in both the body and brain, but each disease features accumulation and
degeneration in particular brain regions resulting in unique sets of symptoms and presentations[24].

This work will highlight the advancements that have been made in the study of polyQ
disorders and what differentiates the members of the polyQ family from one another. It is an
examination of the factors outside of the polyQ expansion that play a role in the toxicity of each
disease protein. For each of these proteins, there is a network of protein-protein interactions and
domains that exist outside of the polyQ that help to establish the ‘context’ of pathogenesis for
every polyQ disorder. This ‘protein context’ is critical in building our understanding of these
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diseases and paints a more comprehensive picture of the toxic pathways and interactions that can
be targeted as potential therapeutic entry points.
In this chapter, I will introduce each member of the family of polyQ diseases and then
highlight some of the prominent domains and interactions involved in establishing the protein
context of each disease protein. This work will be expanded into a future comprehensive review
paper covering the entire established protein context of each disease.
1.1.1

Dentatorubral-Pallidoluysian Atrophy (DRPLA)
DRPLA is a progressive ataxia characterized by movement, cognitive, and emotional

abnormalities[2,3,5-8]. Additional manifestations vary depending on the age of onset with those
developing the disease before the age of 20 typically experiencing epilepsy, myoclonus, and
progressive intellectual deterioration and those with onset after age 20 exhibiting cerebellar ataxia,
choreoathetosis and dementia with the most clinical similarity to HD[2,3,5]. Repeat expansion
occurs in the ATN1 gene located on chromosome 12p which encodes the atrophin-1 protein, a
transcriptional corepressor whose function is relatively unknown[2,3,5,9-13]. The normal CAG tract
of this protein ranges from 3-38 repeats with a pathogenic threshold beginning at expansions to 49
or more repeats[2,3,5].
Atrophin-1 is a hydrophilic, 1184 amino acid protein with several simple repetitive motifs
including a serine-rich region, the variable polyQ tract, a polyproline tract, and a region of
alternating acidic and basic residues[2,3,5,14,15]. It also possesses a reported nuclear localization
signal (NLS) in its N-terminus (amino acids 16-32) and a reported nuclear export signal (NES) in
its C-terminus (amino acids 1033-1041) [2,3,5,16,17]. With these intrinsic signals, atrophin-1 has
been shown to localize to both the cytoplasm and the nucleus of neurons and appear in both
neuronal nuclear inclusions (NI) as well as cytoplasmic polyQ aggregates, neither of which
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necessarily correlate directly with toxicity[2,3,5,14,18-21]. While it is expressed widely in the brain
of both normal and affected individuals[13,15,18], the primary targets for degeneration and cell
death upon expansion are the dentate nucleus of the cerebellum, red nucleus, globus pallidus, and
subthalamic nucleus[2,3,5]. This range of pathological of clinical and pathological presentations
among patients with similar mutations may hint at additional genetic and environmental factors
playing a role in DPRLA pathogenesis[2,3,5].
1.1.2

Huntington’s Disease (HD)
Huntington’s disease (HD) is the most common among the polyQ disorders[2,22-24]. While

the first descriptions of it came in 1872 by George Huntington, the actual mutation in the disease
protein, huntingtin, was not discovered until 1993[25]. It is a single gene disorder with autosomal
dominant transmission and while most cases have come from families with a history of HD, 6-8%
of patients have no family history indicative of somatic expansion[2,22-24]. Motor, psychiatric, and
cognitive symptoms begin to appear in middle age and progressively get worse over the next 1015 years leading to patient death[2,22-24]. Patients will often experience psychiatric and cognitive
symptoms, along with subtle motor deficits, for years before official disease onset correlated with
the length of the CAG repeat[22]. The areas of the brain preferentially impacted in this disease are
the striatum and the deep layers of the cortex[2,22-24]. This includes atrophy of the cerebral cortex
and the subcortical white matter and, as the disease progresses, spread to other brain regions like
the hypothalamus and hippocampus[2,22-24]. The massive losses in degeneration include up to 95%
of the GABAergic medium spiny neurons that project to the globus pallidus and substantia
nigra[22].
The polyQ repeat expansion in the huntingtin protein originates from the huntingtin gene
(HTT) on the short arm of chromosome 4[22]. A non-HD allele of this gene could have anywhere
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from 6 to 35 CAG repeats and the upper limit of that non-pathogenic threshold from 27-35 repeats
referred to as an “intermediate allele” [2,22-24]. Beyond this intermediate allele is a range from 3639 repeats that not fully penetrant, and 40 to as many as 121 repeats representing a fully penetrant
mutation[2,22-24]. As is the case with almost every polyQ disorder, huntingtin expansions exhibit
anticipation and longer repeats are inversely correlated with the age of onset. It is suspected that
this anticipation is a result of intrinsic instability in the CAG repeat of the HTT during meiosis in
dividing cells and DNA repair in somatic cells that leads to further expansion with successive
generations[22].
The 350 kDa huntingtin protein has an N-terminal polyQ tract that beings at residue 18[2,2224]. This repeat tract is immediately followed by two consecutive polyproline repeat domains of

11 and 10 residues making up the external loop structure of the N-terminus[22-24]. The rest of the
protein is mostly comprised of a series of four ~40 amino acid HEAT (huntingtin elongation factor
3) repeats that are found in a variety of proteins involved in intracellular transport and
chromosomal segregation and help mediate huntingtin’s protein-protein interactions[22-24].
Although no NLS has been detected in the protein, huntingtin does have a NES near the Cterminus[23].
Huntingtin is ubiquitously expressed and is present in nearly all tissues[24]. Its widespread
subcellular localization shows association with the nucleus, endoplasmic reticulum (ER), Golgi
complex, synaptic vesicles, and mitochondria[24]. Many of huntingtin’s interactions with other
proteins occur through its N-terminal region (amino acids 1-588) and are associated with either
gene transcription or the pathways of intracellular signaling, trafficking, endocytosis, and
metabolism[2,23,24]. The role of huntingtin in all these interactions may be that of scaffold,
organizing sets of proteins for signaling processes and intracellular transport[24]. In addition to
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protein interactions, huntingtin is also cleaved by multiple proteases, resulting in several Nterminal fragments[22-24,26-28]. These N-terminal fragments tend to appear in higher
concentrations in the nucleus than the full-length protein and are more susceptible to accumulation
and aggregation following polyQ expansion[23]. Whether these aggregates are harmful or
protective remains up for debate but may involve several proteins and pathways that will be
discussed later in this chapter. Whatever its exact function is, huntingtin does appear to be an
essential protein, indicating a loss-of-function mechanism of neurodegeneration; however, there is
also evidence that the expanded polyQ is also linked to a toxic gain-of-function that could play a
role in HD pathogenesis adding to the complexity of this disease.
1.1.3

Spinal and Bulbar Muscular Atrophy (SBMA or Kennedy’s Disease)
Spinal and bulbar muscular atrophy (SBMA), also known as Kennedy’s Disease, is a late-

onset neuromuscular disorder caused by the expansion of a polymorphic polyQ repeat in the
androgen receptor (AR) protein. In 1991, SBMA became the first identified polyQ disease and has
several features that make it unique among the family of disorders[29]. It is the only X-linked
polyQ disorder and thus the only polyQ disorder that is not inherited in an autosomal dominant
manner[2,30,31]. The existence of the polyQ expansion in the AR protein also means that SBMA
is the only ligand-dependent polyQ disorder and shares the disease protein with many other
diseases including androgen insensitivity syndrome (AIS) and prostate cancer[30-33]. On top of the
late-onset, progressive neurodegeneration, dysarthria, and dysphagia shared among most polyQ
disorders, the overlap of disease proteins means that men with SBMA also experience mild signs
of AIS like gynecomastia and some degree of infertility[30,31]. Some of these effects, in both
SBMA and AIS, are suspected to be a result of AR loss-of-function, but the presence of AIS
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symptoms in SBMA, and of any neuromuscular phenotypes in AIS suggests that the polyQ
expansion of AR must lead to a gain-of-function that is selectively harmful to motor neurons[30,31].
While the X-linked nature of the disease means that full penetrance only occurs in males,
women who are heterozygous for the polyQ AR mutation may experience subclinical effects like
muscle cramps and electrophysiological abnormalities, but their low circulating levels of AR
ligands protects them from neurodegeneration[2,30,31]. For males, SBMA is also detrimental to
skeletal muscle and can cause progressive muscle cramps, weakness and wasting, and
twitching[30,31]. These neuromuscular symptoms have resulted in a large fraction of SBMA
patients being initially misdiagnosed with other neuromuscular disorders, including amyotrophic
lateral sclerosis (ALS) or autosomal recessive spinal muscular atrophy (SMA)[30]. Distinguishing
between these diagnoses is critically important for the patient because while the mean survival
time after an ALS diagnosis is only a few years, the life expectancy for SBMA patients is normal
or only minimally reduced[30,31].
Pathologically, SBMA is characterized by the loss of lower motor neurons of the brainstem
and anterior horn of the spinal cord, and to a lesser extent the sensory neurons of the dorsal root
ganglia[2,30,31]. This degeneration leads to weakness and atrophy of the bulbar, facial, and limb
muscles in concordance with the identified role of skeletal muscle in SBMA disease
pathogenesis[30,31]. It has been theorized that the toxicity of polyQ expanded AR may originate in
the skeletal muscles and result in secondary motor neuron degeneration[30,31].
As mentioned above, the polyQ expansion in SBMA occurs in the AR protein, the male
steroid receptor encoded by the AR gene on the short arm of the X chromosome. This gene contains
8 coding exons consisting of three functional domains that are shared among the super-family of
steroid-binding transcription factors[30,31]. The highly polymorphic CAG repeat is in the first exon
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of the AR gene and would normally possess 5-34 repeats but gets expanded to 37 or more repeats
in alleles that have reached the SBMA pathogenic threshold, while shorter CAG tract lengths have
been associated with an increased risk of prostate cancer[30,31]. The AR sequence actually has 3
polyQ tracts, but the first one (located in exon 1) is by far the longest[30].
Another unique feature of SBMA is that unlike other polyQ disorders, whose native disease
protein function is mostly unknown, the biology of the AR is amply studied and well understood,
allowing for greater understanding of the relationship between native AR function and polyQ
expanded AR dysfunction. AR is a ligand-activated transcription factor and member of the nuclear
receptor super-family[30,31]. AR consists of an N-terminal domain (NTD) that modulates
transcriptional activation, a central DNA-binding domain (DBD) that binds androgen-responsive
elements (AREs), and a C-terminal ligand-binding domain (LBD) [30,31]. It also has several
subdomains that are involved in nuclear localization, dimerization, and interaction with heat shock
proteins (HSPs), co-activators and other proteins[30,31]. In the absence of androgens, AR usually
resides in the cytoplasm in a multi-heteromeric inactive cytosolic complex with HSPs[30,31]. Upon
binding of the AR-ligand testosterone, or its metabolite 5α-dihydrotestosterone (DHT), the AR
undergoes a conformational change that promotes its dissociation from the HSP chaperone
complex and exposes the AR NLS, DBD, and dimerization domains[30,31]. This exposure then
promotes dimerization and nuclear translocation, allowing AR to then bind AREs directly in target
promoter regions and selectively recruit transcriptional co-activators and machinery for
transcription initiation of androgen-sensitive genes[30,31]. Wild-type AR also interacts with
proteins involved in several pathways including RNA-splicing, protein translation,
proteasome/protein

ubiquitination,

transcription,

and

male

sexual

differentiation

and
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development[30,31]. Each one of these normal mechanisms have been implicated in SBMA
pathogenesis upon polyQ expansion of AR, some of which will be explored later in this chapter.
1.1.4

Spinocerebellar Ataxia Type 1 (SCA1)
Spinocerebellar ataxia type 1 (SCA1) was first described in 1993 when an unstable CAG

repeat was identified in the ATXN1 gene[34]. Like many polyQ disorders, SCA1 is an adult-onset
and progressive inherited ataxia that presents with cognitive impairments, difficulty with speaking
and swallowing, and eventually chronic lung infections and respiratory failure[2,35-37]. Diagnosis
is typically in the third or fourth decade of life, with the disease duration ranging from 10-30 years
depending on the size of the repeat expansion[2,35-37]. Symptoms typically begin with gait ataxia
and progress to the point of wheelchair necessity within 15 years[2,35-37]. Patients of SCA1 make
up approximately 6% of all autosomal dominant cerebellar ataxias, with large variances across
ethnic groups[35]. The primary pathological pathways of SCA1 are degeneration of the cerebellum
and brain stem, as well as atrophy of the ventral pons and middle cerebellar peduncles[2,35-37].
There is major loss of cerebellar Purkinje cells and neurons of the inferior olivary nucleus, cortical,
subcortical, and spinal structures[2,35-37].
The ATXN1 gene is located on chromosome 6p and encodes the 816 amino acid, 87 kDa,
ataxin-1 protein[2,35,38]. This protein is widely expressed across neuronal and glial populations
throughout the central nervous system. Of the 9 exons in the ATXN1 gene, only exons 8 and 9
contain protein-coding sequences and exon 8 contains the polyQ tract[35]. This polyQ tract
normally contains anywhere from 4 to 36 repeats and any alleles with over 21 repeats also
possessing 1 to 3 interrupting CAT codons encoding histidine[2,35-37]. These interrupting histidine
residues reduce the aggregation kinetics of expanded ataxin-1 and are often lost upon fully
penetrant pathogenic expansion[35]. With that said, uninterrupted CAG repeats of over 39, and
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interrupted CAG repeats of 43 or more, result in the highly-penetrant, late-onset, and progressive
ataxia described above, and does display the typical correlation between polyQ tract length and
disease severity[35]. Tracts with 36-38 repeats have an intermediate effect that can result in ataxia
without some of the other SCA1 specific clinical features[35].
Wild-type ataxin-1’s function remains somewhat unknown although, like many polyQ
disease proteins, has suspected involvement in the regulation of transcription factors[2,35,37,39].
Without histidine interruptions, polyQ expanded ataxin-1 is highly stable and much more resistant
to degradation[35]. While the polyQ expansion has been identified as the central cause of SCA1,
ataxin-1 has several domains that mediate both its normal function and its pathogenicity upon
expansion that will be discussed in future sections. In terms of suspected normal function, these
domains allow ataxin-1 to shuttle between the nucleus and cytoplasm as well as bind RNA and
other proteins like transcription and splicing factors[35,37]. In addition to SCA1, ataxin-1 is also
implicated in other neurodegenerative diseases[35]. Intermediate polyQ expansions of 32 or more
repeats that do reach the SCA1 pathogenic threshold are associated with a greater risk of
developing sporadic amyotrophic lateral sclerosis (sALS)[35]. Additionally, a SNP in an intronic
region of the ATXN1 gene has been associated with an increased risk and earlier onset of late-onset
Alzheimer’s disease (LOAD)[37].
1.1.5

Spinocerebellar Ataxia Type 2 (SCA2)
While spinocerebellar ataxia type 2 (SCA2) was initially described in India throughout the

1960s and 1970s[40], it was not until 1996 that the disease gene, ATXN2, along with the causative
CAG expansion encoding a polyQ repeat in the causative protein, ataxin-2, were identified[41-43].
As is the case with other SCA polyQ disorders, SCA2 is an autosomal dominantly inherited
neurodegenerative disorder characterized primarily by gait ataxia, onset coinciding with muscle
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cramping, and other symptoms indicative of cerebellar degeneration[2,3,44]. Unlike other SCAs,
whose symptoms tend to involve or spread to other brain regions, SCA2 signs and symptoms are
almost entirely of cerebellar origin and include presentations such as appendicular ataxia,
dysarthria, and ocular deficits including nystagmus and ocular dysmetria[2,3,44]. Other frequently
reported symptoms are dystonia, frontal-executive dysfunction, myoclonus, muscle spasticity,
neuropathy, and slow or absent saccades[44]. Like SCA1 and SCA3 there is major pathological
involvement in the cerebellum and brainstem[2,3,44]. There is evidence of atrophy in the pontine
gray matter, middle cerebellar peduncles, cerebellar white matter and folia, and inferior
olives[2,3,44].
The ATXN2 gene is located on chromosome 12q24 and normally possesses a CAG tract of
15-32 repeats[2,3,44]. SCA2 pathogenicity is reached when repeats are expanded beyond 32 and
can reach as high as 77, with the possibility of reduced penetrance in those possessing repeats of
32-34 CAGs in length[2,3,44]. As with many polyQ disorders, there is a strong inverse correlation
between the repeat length and the age of onset of the disorder along with anticipation as the gene
is passed from one generation to the next. Consisting of 25 exons, ATXN2 has a transcript of 4699
base pairs and two in-frame start codons[44]. The purpose of these two translational pathways
remains undetermined, but it is known that the translation from the first start codon produces a
144kDa protein while translation from the second, only four codons upstream of the CAG repeat,
produces an ataxin-2 protein that is 17kDa smaller[44]. In addition, an even smaller 42kDa ataxin2 fragment has been observed in patient brain extracts and SCA2 mice[45-47].
It is thought that expansion within these transcripts causes a toxic gain of function of the
ataxin-2 protein resulting in abnormally slow Purkinje cell firing frequency and eventual
degeneration. Normally, ataxin-2 is cytoplasmic protein with proposed functions in RNA
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metabolism[2,3,44]. It has reported interactions with multiple RNA binding proteins and contains
N-terminal Lsm and LsmAD domains that are common in spliceosomal small nuclear
ribonucleoproteins and aid in ataxin-2’s ability to bind RNA and other RNA-associated
proteins[46,48]. In addition, ataxin-2 can localize to the trans-Golgi network, and can be
phosphorylated as well as cleaved by caspase-3 at cleavage consensus site (aa 396-399)[49,50].
These traits and others open the door for additional roles for ataxin-2 in stress granule
formation/regulation, secretion and endocytosis, calcium homeostasis, and apoptotic and receptormediated signaling.
Apart from SCA2, ataxin-2 is also implicated in multiple diseases with variant ataxin-2associated phenotypes that are entirely outside of the cerebellar spectrum: most prominent being
L-DOPA responsive Parkinsonism and ALS[44].
1.1.6

Spinocerebellar Ataxia Type 3 (SCA3 or Machado Joseph Disease)
Spinocerebellar ataxia type 3 (SCA3), also known as Machado Joseph Disease (MJD), is the

most common dominantly inherited ataxia worldwide[51-54]. Like other polyQ SCAs, SCA3 is a
progressive ataxia defined by cerebellar and brainstem dysfunction[51-54]. Onset is typically in the
young to mid adult years and initially manifests as progressive gait imbalance along with vestibular
and speech difficulties[51-57]. As the disease progresses, visual and oculomotor problems appear
including nystagmus, jerky ocular pursuits, slowing of saccades, disconjugate eye movements,
ophthalmoplegia, and apparent bulging eyes[51-57]. The most advanced stages of the disease leave
the patient wheelchair bound with severe dysarthria and dysphagia[51]. Other potential symptoms
include facial atrophy, dystonia, spasticity, amyotrophy, and non-dementia mild cognitive
impairment[51,58-60]. Life expectancy following disease onset is approximately 20-25 years[51,61].
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The polyQ expansion occurs in a gene first identified in 1994 as MJD1, also referred to as
the ATXN3 gene, that encodes the deubiquitinating enzyme (DUB) ataxin-3 protein[62]. The
disease protein has been shown to accumulate within nuclear inclusions of specific populations of
neurons in several brain regions that experience degeneration; particularly pontine neurons but
also other brainstem neuronal populations, dentate nuclei, thalamus, substantia nigra, globus
pallidus, cranial motor nerved nuclei, and, rarely, in the striatum[51-54,63-65]. The increase in CAGtract length in the ATXN3 gene causes an expanded polyQ in the ataxin-3 protein that misfolds,
aggregates, and forms the intranuclear inclusions in the affected regions listed above[51-54,62,66].
Whereas normal alleles possess anywhere from 12 to 43 repeats, pathogenic ATXN3 alleles
contain 60-87 repeats with milder forms of ataxia and restless leg syndrome appearing in patients
with mid-range repeats[51-54,67]. In the repeat range that is full penetrant, the largest repeats will
often lead to more pyramidal signs and dystonia[68] while repeats on the lower end of the
pathogenic range (<73) are associated with peripheral neuropathy[51,69,70].
Ataxin-3 is a 42 kDa protein that is widely expressed in the central nervous system and, like
many of the neurodegenerative diseases covered in this chapter, has selective tissue vulnerability
that cannot be explained by restricted protein expression[51-54]. As a DUB, it is believed that
ataxin-3 plays a role in the clearance of misfolded proteins in the ubiquitin-proteasome system
(UPS), and while the exact role of ataxin-3 remains unclear, it is thought that the expansion of its
polyQ domain somehow burdens the protein quality control of cells in the affected regions[51-54].
The ataxin-3 protein consists of several domains and multiple splice isoforms outside of the polyQ
tract that are crucial to its native function and its pathogenesis upon expansion in SCA3. These
domains, isoforms, and the protein-protein interactions associated with them will be the focus of
the following chapters of this dissertation.
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1.1.7

Spinocerebellar Ataxia Type 6 (SCA6)
Spinocerebellar ataxia type 6 (SCA6) is caused by small polyglutamine expansions in the

bicistronic CACNA1A gene that encodes for the 𝛼1A subunit of the P/Q-type voltage-gated
calcium channel called Cav2 and the transcription factor 𝛼1ACT[2,3,71]. Identified in 1997, it is
the first polyQ disease attributed to mutations in an ion channel gene[72]. The disease has been
found with variable frequency in many populations worldwide and has particular prominence in
the Netherlands and Japan where it is the second most common SCA behind SCA3[2,71,73].
Clinically, SCA6 is a pure cerebellar ataxia with a dominant inheritance pattern and typical
appearance later in life[2,3,71]. Patients show pure cerebellar dysfunction, slowly progressive gait
ataxia and imbalance, dysarthria, and late-onset nystagmus[2,3,71]. While the age of onset can range
anywhere from 19 to 71 years age, the mean age of onset is 43-52 and is inversely correlated with
the size of the expansion[71]. After onset, SCA6 manifests much slower than other SCAs and does
not usually shorten the patient’s lifespan, but even with slow progression there can be large
variances in symptom severity, even within the same family[2,3,71]. In addition to SCA6, mutations
in the CACNA1A gene are associated with at least two other dominantly inherited neurological
disorders, episodic ataxia type 2 and familial hemiplegic migraine, that both have clinical overlap
with SCA6[2,71,74].
The pathological presentation of SCA6 is defined by diffuse loss of Purkinje cells,
primarily in the cerebellar vermis with very limited degeneration in associated cortical and
cerebello-olivary regions[2,3,71]. The remaining Purkinje cells in the most degenerated regions
undergo extensive morphological changes including heterotypic nuclei, unclear cytoplasmic
outline, somatic sprouts, dendritic swelling with increased numbers of spine-like protrusions, and
disorganization of axonal arrangements[71].
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The SCA6 disease gene, CACNA1A, is located on chromosome 19p13 and contains 47
exons, the last of which is home to the expanded CAG repeat[3,71]. Normally this repeat exists in
a range of 4-18 CAGs but is expanded to a range of 19-33 repeats in the disease state[2,3,71]. SCA6
does show variable penetrance within its pathological range where heterozygous individuals with
19 repeats are usually asymptomatic while those possessing 20 or more repeats showing full
penetrance[71]. The CACNA1A gene is bicistronic and has a novel internal ribosomal entry site
(IRES) that allows it to encode two structurally unrelated proteins. These proteins have distinct
functions and have overlapping open reading frames within the same mRNA[71]. The first of these
proteins is the 𝛼1A subunit of the Cav2 P/Q-type voltage-gated calcium channel. The second is a
newly recognized transcription factor known as 𝛼1ACT that possesses the C-terminal polyQ
repeat. Both proteins are expressed abundantly in the Purkinje cells of the cerebellum and the Cterminal 𝛼1ACT peptide with an expanded polyQ tract has been shown to be toxic in tissue culture
in manner that is dependent on nuclear localization[71].
𝛼1ACT is a functional transcription factor that coordinates the expression of neuronal genes
involved in cerebellar and Purkinje cell development. In addition to the expanded polyQ and an
NLS, it contains residues that are typically associated with channel inactivation and modulation
by intracellular signaling proteins[2,3,71]. One hypothesis is that SCA6 is an ion channel disorder
and the polyQ expansion of 𝛼1ACT causes ataxia by altering calcium channel function, but the
investigations into this theory have yielded conflicting findings[71]. Other evidence has shown
nuclear accumulation of the 𝛼1A subunits which suggests that pathogenesis could be more closely
related to the nuclear accumulation of expanded polyQ proteins/fragments that could lead to
transcriptional dysregulation as seen in other polyQ disorders[75]. This accumulation and
expansion could also promote a toxic gain-of-function that could exacerbate disease progression
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through several mechanisms including sequestration of housekeeping genes and transcription
factors, disruption of UPS pathways, direct DNA damage, or even the induction of apoptotic
pathways[76,77]. Although SCA6 was identified as the first ion channel polyQ mutation, the
evidence of that polyQ mutation existing in the second cistron encoded transcription factor 𝛼1ACT
points to a more likely mechanism of toxicity involving transcriptional dysregulation because of
expansion instead of the typical mechanisms of channelopathies seen in many other CACNA1A
disorders.
1.1.8

Spinocerebellar Ataxia Type 7 (SCA7)
Spinocerebellar ataxia type 7 (SCA7) is caused by a polymorphic polyQ expansion in the

ATXN7 gene encoding the ataxin-7 (ATXN7) protein[78]. The gene and expansion were identified
in 1997, making SCA7 the eighth of nine currently known polyQ disorders[79]. Clinical
presentation is similar to that of SCAs 1, 2, and 3: spastic ataxia, dysarthria, dysphagia, slow eye
movement, opthalmoplegia, prominent hyperflexia with crossed supraclavicular, pectoral, and hip
adductor reflexes, spasticity, and pyramidal signs[78]. What makes SCA7 unique is that it is the
only SCA and polyQ disorder that is characterized by retinal degeneration in addition to ataxia[78].
Visual impairment begins with cone photoreceptor degeneration that progresses toward cone-rod
dystrophy and eventually complete blindness[78]. Postmortem pathology from patient cerebellum
shows substantial loss in the Purkinje cell layer, dentate nuclei, and to a lesser extent the granule
cell layer[78]. The initial, ataxia-like symptoms that appear early in SCA7 match well with the
primary neuropathology and then become increasingly diverse and the degenerative process
becomes more widespread as the disease progresses[78].
Repeat expansions in the ATXN7 gene have some of the widest ranges among polyQ
disorders. The ATXN7 gene is widely expressed in neuronal and non-neuronal tissue and the CAG
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tract of wild type ATXN7 typically has 4-35 repeats, with an estimated 70-80% of all ATXN7 genes
carrying 10 CAGs and [78,79]. Alleles with 28-35 repeats are prone to expansion and repeats of 3436 are associated with reduced penetrance and a mild- and late-onset of disease symptoms[78,79].
SCA7 repeats show the highest tendency to expand upon transmission and show strong
anticipation so while 36 repeats are the pathological threshold, these repeat expansions can reach
as high as 460 repeats[78,79]. This means that there is a wide range of fully penetrant manifestations
of SCA7: 36-55 repeats present as adult-onset SCA7; greater than 70 repeats present as a juvenileonset form of SCA7 with an accelerated disease progression; and greater than 100 repeats present
as a severe infantile form of the disease with death in the first few years or months of life[78,79].
Longer repeats are not only inversely correlated with the age of onset, but also result in an earlier
appearance of retinal degeneration and vision loss prior to any cerebellar ataxia[78].
The ATXN7 protein is a member of the multiprotein Spt-Ada-Gcn5 (SAGA)
complex[78,80,81]. The SAGA complex is responsible for interactions with transcriptional
machinery and chromatin modifications though both histone deacetyltransferase (HAT) and DUB
activities[78]. In this complex, ATXN7 functions in several proposed roles. The first is in the DUB
module where it anchors the DUB to the rest of the SAGA complex[78]. ATXN7 is also a functional
scaffold of SAGA that plays a role in the regulation of H2B Ub levels and has been suggested as
being important for the full differentiation of Purkinje neurons in the cerebellum and maintenance
of differentiated photoreceptors[78].
The protein is localized to the cytoplasm and nucleus of neurons, and the ratio between the
two varies in different brain regions[78]. It is also present in all neurons of the retina[78]. PolyQ
expanded ATXN7 has been shown to form large nuclear inclusions and aggregates in cell nuclei
across degenerating and spared brain regions but does seem to accumulate faster in vulnerable
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nuclei (Purkinje cells and photoreceptors) indicating that accumulation, not localization, is a better
indicator of toxicity[78]. The polyQ domain is in the N-terminal portion of the ATXN7 protein and
is followed by a small proline repeat that resembles the polyQ/proline-rich regions of HD and other
transcription factors[78,79]. Additional domains include 3 NLSs and 1 NES[78,82]. The effects of
polyQ expanded ATXN7 have been shown in mice to be both cell autonomous and non-cell
autonomous[78].
1.1.9

Spinocerebellar Ataxia Type 17 (SCA17)
The most recently discovered polyQ disorder, spinocerebellar ataxia type 17 (SCA17) is a

rare disease accounting for approximately 0.5-1% of dominantly inherited ataxias[83-85]. It is
caused by a polyQ expansion in the TATA-box binding protein (TBP), a general and essential
transcription initiation factor[83-85]. Clinically, it can resemble the presentations of Parkinson’s
and Huntington’s diseases as well as psychiatric symptoms ranging from psychosis to
multitudinous cerebellar syndromes[83,86,87]. Patients experience many of the early signs of ataxia
with gait imbalance, dysarthria, dystonia, and choreic movements, but also encounter more
intellectual decline, dementia, psychiatric abnormalities, seizures, and basal ganglia symptoms that
can help diagnostically distinguish it from other SCAs and HD[83,86,87]. At the pathological level,
SCA17 manifests as marked cerebellar atrophy and degeneration, as well as moderate and diffuse
cortical, subcortical, and brainstem atrophy[83,86,87]. Purkinje cell loss and gliosis are also
prominent features of this disease[83,86,87].
The 18,528bp TBP gene is located on chromosome 6q and the 1867bp transcript spanning
from exon 2 to exon 8 encodes the TBP protein[83]. The polyQ repeat sequence of TBP is in exon
3 of this transcript, and wild-type alleles typically have 25-42 repeats, with the most common range
in human alleles being 32-39 repeats[83,86,87]. The TBP polyQ tract contains two polymorphic
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(CAG)n stretches interrupted by polyQ-encoding CAAs in the following pattern: (CAG)3 (CAA)3
(CAG)n CAA CAG CAA (CAG)n CAA CAG[83]. These interruptions stabilize the repeat
sequence, and it is though that intergeneration instability and anticipation result from the loss of
the interrupting CAA CAG CAA element and fusion of the (CAG)n blocks, also seen in SCA1
and SCA2[83]. The stabilization by CAA interruptions in tandem with the narrow gap between
normal and abnormal repeats makes it difficult to determine an exact pathological cutoff. Our
current understanding is that the range for SCA17 is 46-55 repeats, with 43-48 repeats constituting
an intermediate range with incomplete penetrance[83,86,87]. Juvenile-onset SCA17 has been
reported in patients with repeats exceeding 62 and experience different set of symptoms including
ataxia, intellectual deterioration, muscle weakness, growth retardation, faster disease progression,
and early death[86].
TBP is a saddle shaped protein that is recruited to the basal promoter elements of RNA
polymerases I, II, and III and can directly bind the TATA boxes in DNA or, in the case of TATAless promoters, have protein-protein interactions in order to initiate transcription[83,86]. It is also
one of the more well reported polyQ disease proteins in the family as its dysfunction is implicated
in several neurodegenerative disorders, including other polyQ disorders[83,86]. Bound TBP
functions as the ‘nucleus’ of the initiation complex and provides docking sites for several
additional transcription factors in the RNA Pol II in particular[83,86]. TBP has a variable Nterminal domain and highly conserved C-terminal domain and it has been suggested that the Cterminal core domain houses the large DNA-binding domain that interacts with the DNA directly
while the N-terminal assists in modulating that DNA-binding activity[83,86]. The polyQ stretch of
TBP is located at the N-terminus starting at amino acid 58 and is followed by the remaining 244
residues of TBP[83]. As it is in the N-terminal half of the protein, another suggestion is that the
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subregions surrounding the polyQ synergistically promote the formation of the TBP-DNA
complex, and that neurodegeneration upon polyQ expansion could arise from a toxic gain-offunction rather than a loss-of-function[86]. Multiple models have shown an age-dependent
accumulation of polyQ expanded TBP aggregates in neuronal nuclei and cerebellar degeneration,
especially Purkinje cell death, but their actual role in the degenerative process remains
unclear[83,86].
1.2
1.2.1

Advancements in establishing disease protein context
Dentatorubral-Pallidoluysian Atrophy (DRPLA)
The DRPLA protein, atrophin-1, is reported to have multiple interactions with caspases that

cleave the protein and form atrophin-1 fragments that may alter its regulatory mechanisms upon
polyQ expansion and increase cellular toxicity[5,88,89]. Many of these cleavages and their
purported toxic effects center around separating the atrophin-1 N-terminal nuclear localization
signal (NLS) or C-terminal nuclear export signal (NES) from the remainder of the fragment and
polyQ expansion[5]. Caspase cleavage separating the NLS from the rest of the protein results in a
C-terminal fragment that is more prone to cytoplasmic accumulation and has been observed in
DRPLA patient tissue[5,88]. Without an NLS, this fragment is normally exported to the cytoplasm
as a nucleocytoplasmic protein, and upon exportation, caspases play a direct role in its cleavage to
regulate accumulation[5,88]. However, polyQ expansion of atrophin-1 (and subsequently its
fragments) reduces caspase activity leading to accumulation of the fragment in the cytoplasm,
suppression of nuclear transport of full-length atrophin-1, and a furthering of cytoplasmic
aggregation and potential toxicity[5,88]. The N-terminal Asp109 residue of atrophin-1 represents
an additional cleavage site separating the NLS from the fragment protein. Cleavage at the Asp109
site (N-terminal 106(DSLDG)110) in an expanded state by caspase-3 separates the NLS from the
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rest of the protein and produces a pro-apoptotic fragment that could contribute to aggregation but
does not effect atrophin-1 localization[16,89]. Mutation of this site to prevent cleavage blocks the
creation of this fragment and dramatically reduces cellular toxicity; however, whether this caspase3 specific effect occurs in vivo has not been confirmed[89].
The NES also seems to be important, with fragments generated by unknown caspases that
separate the NES from the polyQ and NLS showing increased nuclear retention and toxicity[5].
Both patients and DRPLA transgenic mice have nuclear accumulation of atrophin-1, particularly
a ~120 kDa fragment that would be representative of a cleavage product[5]. Mutation of full length
polyQ expanded atrophin-1 to render the NES non-functional in Neuro2a cells resulted in
increased nuclear labeling of the protein and an increase in cellular toxicity. Furthermore, mutating
the NLS in the fragment lacking an NES shifted atrophin-1 more to the cytoplasm and reduced
cellular toxicity[5]. So far, it has been shown that this fragment is not a result of caspase 2, 3, 6, 7,
or 8 cleavage and the exact enzyme that creates it has not been determined[5]. These studies
indicate that the NLS and NES both play critical roles in normal atrophin-1 function and polyQ
expanded atrophin-1 toxicity, and that multiple caspase cleavages involving these sites act as
modulators of aggregate formation and toxicity in DRPLA. They also show that both nuclear and
cytoplasmic localization of expanded atrophin-1 fragments are factors in pathogenesis.
On top of cleavage products, atrophin-1 also has a few recorded direct interactions that could
play a role in toxicity. The first is an interaction through one of two arginine-glutamic acid (RE)
dipeptide repeats in the atrophin-1 protein[90]. The interaction is with a protein, RERE, that shares
67% sequence homology with atrophin-1, including the proximal RE-repeat through which they
can form a heterodimer[90]. RERE and atrophin-1 interact and colocalize with one another in what
appers as a speckled pattern in the nucleus, and this interaction is strengthened (~3.3 fold) when
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the atrophin-1 polyQ is expanded[90]. This increased interaction results in the formation of larger
atrophin-1 aggregates and, as RERE over-expression is toxic to cells, could mean that further
interaction between polyQ expanded atrophin-1 and RERE is also toxic[90]. Additional
interactions that will require further investigation to determine their exact physiological relevance
to the disease include atrophin-1’s interaction with the transcriptional regulator ETO/MTG8[91];
Drosophila atrophin-1 homolog Atro’s interaction with Drosophila even-skipped[92]; and the
Drosophila brakeless homolog ZNF608 interaction with atrophin-1 that all play a part in atrophin1’s proposed function as a transcriptional corepressor[93].
1.2.2

Huntington’s Disease (HD)
The interactions and protein context of the expanded huntingtin protein can be sorted into a

few major categories: caspase cleavage, post-translational modification, changes to intracellular
trafficking and signaling interactions, and gene transcription alterations. There have been several
sites within the huntingtin protein, primarily the first 550 amino acids, that have been identified as
caspase cleavage sites[27,94-96]. In HD mouse models, modification of huntingtin to prevent
caspase-6 cleavage at amino acid 586 helped maintain normal neuronal function and eliminate the
striata neurodegeneration and motor dysfunctions normally observed in HD phenotypes[97,98].
This indicated that caspase-6 cleavage may be a potentiating event in HD. In conjunction with
post-translational modification changes in HD, it has been shown that huntingtin is phosphorylated
by Cdk5, and that this phosphorylation reduces the cleavage of huntingtin by capsae-3 at amino
acid 513[99,100]. Phosphorylation, and resulting protection from cleavage, reduces aggregation and
toxicity in cell models of HD[99,100]. However, in HD there are lower levels of Cdk5 which leads
to reduced phosphorylation of huntingtin and any afforded protections from cleavage and
subsequent aggregation and toxicity are lost[99,100]. Given the more toxic nature of N-terminal
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huntingtin fragments and the evidence of natural generation and accumulation of N-terminal
expanded huntingtin fragments in HD mouse brains[23,24,101-106], it stands to reason that cleavage
at these sites plays a role in enhancing toxicity in HD.
Post-translational modifications play additional roles in huntingtin toxicity beyond
changing accessibility to casapase-3 cleavage sites. Huntingtin undergoes extensive posttranslational modification and has sites for phosphorylation, SUMOylation, acetylation,
ubiquitination, and palmitoylation. Each of these modifications can alter the toxicity of the
expanded huntingtin protein. The first of these modifications, phosphorylation, generally seems to
protect cells from the toxic effects of expanded huntingtin. The Akt-mediated phosphorylation of
S421 of expanded huntingtin has been shown to relieve neurotoxicity in cell models of HD[107112]. The same amelioration was observed upon phosphorylation of expanded huntingtin at sites

S536, S13, and S16[100,113,114]. The mechanisms of these protections are not yet fully understood
but it seems that N-terminal phosphorylation targets huntingtin for degradation[113,114], while
S536 phosphorylation limits calpain cleavage[100] and S421 phosphorylation increases trophic
support in intracellular transport[107,112]. Acetylation and palmitoylation also appear to be
protective against huntingtin-induced neurodegeneration. Mutations to prevent the acetylation of
huntingtin K444 resulted in increased accumulation and neurodegeneration in both cultured
neurons and mouse brains[115]. Similar results were observed upon mutation of huntingtin’s C214
palmitoylation site[116]. At this site, palmitoylation is performed by huntingtin-interacting protein
14 (HIP14) [116]. The association between huntingtin and HIP14 is reduced when the huntingtin
polyQ is expanded resulting in reduced palmitoylation and increased inclusion formation, a
potential contributor to HD pathogenesis[116].
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Huntingtin’s K6 and K9 residues are sites of post-translational modification with influence
on two fronts. SUMOylation at both sites reduced the ability of an expanded N-terminal huntingtin
fragment to aggregate and promoted its capacity to repress transcription in a cell model[117].
However, in a Drosophila model expressing exon 1 of huntingtin, SUMOylation at the same sites
enhanced neurodegeneration while ubiquitination was protective[117]. These conflicting results
point to a role for SUMOylation in HD pathogenesis that requires further elucidation and further
establishes the importance of understanding the protein context surrounding and influencing these
factors in toxicity.
In addition to cleavage and post-translational modification, expanded huntingtin also has
several direct protein-protein interactions that influence its toxicity, particularly with proteins
involved in intracellular trafficking and signaling. Huntington-associated protein 1 (HAP1),
among its many influential associations and interactions, was found to interact with both huntingtin
and the type 1 inositol (1, 4, 5)-trisphosphate receptor (IP31) to form an IP31-HAP1-huntingtin
ternary complex[118,119]. The presence of an expanded huntingtin in this complex enhances the
sensitivity of IP31 to inositol (1, 4, 5)-trisphosphate and provides an explanation for the changes
in calcium signaling observed in HD patients[118]. Another huntingtin associated protein,
huntingtin-interacting protein (HIP1), has decreased binding to mutant huntingtin compared to
wild-type[120-122]. It has been theorized that this decreased binding increases the amount of free
HIP1, which can then associate with HIP1-protein interaction (HIPPI) and induce caspsae-8
cleavage and apoptosis[122]. Mutant huntingtin also has a decreased interaction with postsynaptic
density 95 (PSD-95), a scaffold protein that causes clustering and activation of postsynaptic
membrane receptors[123]. HD patients release more PSD-95 than unaffected individuals which
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results in an over activation of N-methyl-D-aspartate (NMDA) receptors and associated abnormal
synaptic transmission that has been validated in HD mouse models[124,125].
The final set of huntingtin interactions that will be discussed in this section are those that
impact transcriptional activity. Wild-type huntingtin interacts with repressor element-1
transcription factor in the cytoplasm[126,127]. REST, in association with neuron restrictive silencer
element (NRSE), affects the nuclear transcription of neuronal genes, including brain-derived
neurotrophic factor (BDNF) [126,127]. The interaction between huntingtin and REST-NRSE is
much weaker when the polyQ if huntingtin is expanded[126,127]. So, while wild-type huntingtin
may interact with REST-NRSE in the cytoplasm to prevent entry into the nucleus and reduce the
REST-NRSE-induced suppression of gene expression, mutant huntingtin limits this prevention
which subsequently inhibits the expression of BDNF and other neuronal genes[126,127]. PolyQexpanded huntingtin inhibits the function of several transcriptional coactivators, in a similar
manner to REST-NRSE, including p53 and CBP[128,129], and represents a pathway to toxicity
through transcriptional dysregulation that connects several polyQ disorders and will be useful in
understanding polyQ toxicity more generally.
1.2.3

Spinobulbar Muscular Atrophy (SBMA or Kennedy’s Disease)
The unique nature of native AR’s function compared to other polyQ disease proteins makes

SBMA the only ligand-dependent polyQ disease. Many of the protein-protein interactions and
domains of influence in expanded AR toxicity are only possible when AR-LBD is in a ligandbound state with either testosterone or DHT. The binding of a ligand to AR along with polyQ
expansion in the AR-NTD promotes conformational changes in the AR protein, ligand-dependent
unfolding, and nuclear translocation of the mutant protein[130]. All these steps have been shown
to be necessary in SBMA pathogenesis and can alter the AR interactome[130].
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In the presence of the AR ligand DHT, retinoblastoma protein (Rb) showed a much
stronger association with polyQ expanded AR compared to wild-type AR[131]. Rb normally acts
as neuroprotective factor that recruits the histone deactyltransferase 1 (HDAC) in the co-repression
of E2F1 – a transcription factor whose target genes regulate apoptosis, development, and
differentiation[131]. The stronger association between Rb and expanded AR suppresses Rb’s ability
to recruit HDAC1 and leads to aberrant E2F1 transcriptional activation and neurotoxicity. Another
ligand-dependent AR interaction involves DHT-induced cell cycle arrest and how polyQ
expansion alters the function of AR in cell cycle regulation[131]. Under both normal and expanded
conditions, AR interacts in complex with anaphase promoting complex/cyclosome (APC/C) and
its adaptor protein, Cdh1, in a DHT-dependent manner[132]. Cell studies revealed the possibility
that expanded AR acts as a pseudo-inhibitor, competing with substrates for binding with APC/CCdh1 through a toxic gain-of-function upon polyQ expansion that results in abortive neuronal
differentiation followed by mitotic entry[132].
The AF-2 domain also plays a prominent role in the interactions that facilitate expanded
AR toxicity. Within the AR protein itself, the interdomain interaction between the C-terminal AF2 domain and N-terminal FXXLF motif (N/C interaction) is important for AR aggregation and
toxicity[133-135]. While it is a normal step in wild-type AR metabolism, it is also thought to be a
critical early step in the abnormal metabolism, stabilization, aggregation, and toxicity of the polyQ
expanded AR protein[133-135]. This is supported by work in an SBMA cell model where both
ligands and mutations were introduced that prevented the interaction of FXXLF and AF-2 and
subsequently abolished toxicity and aggregation of AR and rescued primary motor neurons from
testosterone-induced toxicity[135]. There was an additional suggestion that there are coactivators
of this N/C interaction including GRIP1, F-src-1, and CBP that could further stabilize the mutant
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AR protein[135]. The AF-2 domain is also the site of AR’s interaction with transcription factor EB
(TFEB)[136]. AR normally functions as a co-activator of TFEB; however, the expansion of the AR
polyQ tract changes this interaction to an inhibitory one causing TFEB dysregulation that is
responsible for the autophagic flux impairments observed in models of SBMA[136].
In a disease mechanism of activation instead of inhibition, the AR AF-2 domain also
interacts with the protein arginine methyltransferase 6 (PRMT6)[137]. It has been previously shown
that phosphorylation of polyQ expanded AR by Akt reduced hormone binding and AR
transactivation while protecting from neurodegeneration[137]. On the other hand, PRMT6 catalytic
activity is required for the arginine methylation at those Akt consensus sites and subsequent
transactivation of AR[137]. So, while phosphorylation by Akt is generally neuroprotective, an
enhanced interaction between PRMT6 and expanded AR and increased arginine methylation at
those same Akt sites leads to neurodegeneration as demonstrated in both cell and fly models of
SBMA[137]. PRMT6 is not the only post-translational modifier of mutant AR toxicity. Nemo-like
kinase (NLK) can proliferate the accumulation and toxicity of polyQ-expanded AR through its
binding and AR-S81 phosphorylation of an N-terminal region of AR and aberrantly increasing its
activation of particular genes[138]. In another set of posttranslational studies, phosphorylation at
S516 via the p44/32 MAP kinase pathway was found to be required to induce cell death in an
SBMA cell model[139,140]. This finding suggests that phosphorylation enhanced the ability of
caspase-3 to cleave polyQ-expanded AR and generate toxic polyQ fragments[139,140]. Liganddependent hyperacetylation has also been reported in expanded AR compared to wild-type and
seems to be associated with toxicity in SBMA[141]. Finally, there is a differential interaction
between wild and expanded AR with the post-translational modifier, deubiquitinating enzyme
USP7[142]. PolyQ-expanded proteins tend to preferentially associate with USP7, which could be
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an underlying common component of pathogenesis to which polyQ-expanded AR is no
exception[142]. Lysine residue 17 of AR is a confirmed substrate of USP7, and an enhanced
interaction with expanded AR could result in changes in the AR ubiquitination pattern that would
stabilize the mutant protein and make it more prone to aggregation and toxicity[142].
Like other transcription-associated polyQ disease proteins, DNA-binding and nuclear
translocation appear to be critical to expanded AR toxicity[133,143].
1.2.4

Spinocerebellar Ataxia Type 1 (SCA1)
It has been well documented that SCA1 pathology does not depend solely on the polyQ tract

of the ataxin-1 protein. In fact, there are several domains that are essential for the induction of
disease phenotypes even in the presence of an expanded polyQ including the ataxin-1/HBP-1
(AXH) domain, the ataxin-1 NLS, and the phosphorylation site at serine 776[2,35-37]. These three
domains function both individually and in coordination with one another to shape the interactome
of ataxin-1 and understanding their functions in a polyQ expanded state is essential in building the
protein context ataxin-1 toxicity in SCA1
The AXH domain of ataxin-1 mediates many of its protein-protein interactions and RNAbinding toxicity and as such is responsible for many of the interactions that impact toxicity upon
polyQ expansion. Possibly the most important of these AXH-mediated interactions in SCA1
pathogenesis is the polyQ-expanded ataxin-1’s interaction with the transcriptional repressor
Capicua (CIC)[35,144-151]. In studies using mouse cerebellum, it was found that a majority of wildtype and expanded ataxin-1 assembles into large stable complexes with CIC[144]. This assembly
seems to stabilize ataxin-1 and allow for the induction of neurotoxicity and the direct interaction
between CIC and expanded ataxin-1 alters CIC’s transcriptional repression activity[144]. As further
evidence of the important role of CIC interaction in ataxin-1 toxicity, mutagenesis of key amino
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acids to prevent the CIC-ataxin-1 interaction also prevented toxicity in a Purkinje-cell specific
SCA1 transgenic mouse model[146,151]. Additionally, haploinsufficiency of Cic reduced disease
severity in SCA1 knock-in mice[150]. Ataxin-1’s incorporation into a CIC-containing large protein
complex appears critical for its stabilization, particularly in an expanded state, and confers toxicity
through this mechanism as well as through the alteration of CIC transcriptional repression activity.
CIC is not the only protein to interact with ataxin-1 through the AXH domain and
contribute to SCA1 pathogenesis. The AXH domain also mediates ataxin-1’s interaction with Gif1[152]. This transcription factor is necessary for the survival of Purkinje cells and is destabilized
by its interaction with the AXH domain of ataxin-1[152]. Destabilization enhances Gif-1
degradation via the proteasome which contributes to the selective Purkinje cell degeneration seen
in SCA1[152]. Like CIC and Gif-1, the AXH domain facilitates ataxin-1’s interaction with
Tip60/retinoic acid orphan related receptor alpha (ROR𝛼)[153,154] and ATXN1L[149] in a manner
that involves incorporation into larger complexes that alter the stability and activity of the
complexes when the polyQ of ataxin-1 is expanded. These changes can alter the levels of expanded
ataxin-1 and contribute to SCA1 pathogenesis.
The final interaction of interest through the AXH domain is with the leucine-nuclear
protein (LANP). This interaction occurs at both the AXH domain and polyQ tract of ataxin-1 and
occurs in a repeat-dependent manner[155]. It is thought that expanded ataxin-1 competes for LANP
binding with the transcriptional repressor P120E44F (E4F)[156] and that this gain-of-function in
conjunction with LANP expression pattern may explain the Purkinje cell-specific vulnerability
observed in SCA1[157,158]. Further evidence of this was provided when LANP reduction reversed
molecular layer thinning in SCA1 knock-in mice[157]. Apart from direct protein-protein
interactions, the AXH domain itself has been found to be a key player in the aggregation of ataxin-
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1. The isolated AXH domain from the ataxin-1 protein induces aggregation and forms β-plaques
in vitro while expanded ataxin-1 with its AXH domain replaced with a non-aggregation prone
sequence significantly reduced protein aggregation[159], further emphasizing the importance of the
AXH domain in SCA1.
The next domain in establishing protein context in SCA1 is the ataxin-1 NLS. The Cterminal NLS of ataxin-1 has been shown to be necessary for disease pathogenesis, and mutation
of the NLS eliminated ataxin-1-based toxicity in an SCA1 transgenic mouse model[160]. Near the
C-terminal NLS is another important domain in influencing expanded ataxin-1 toxicity, the 14-33 binding domain. Ataxin-1 interacts with 14-3-3 proteins through this 14-3-3 binding domain and
these interactions are enhanced by polyQ expansion[161]. The ataxin-1-14-3-3 interaction
stabilizes ataxin-1 and enhances it protein levels allowing for increased NI formation[161].
Amidst all these interactions is a post-translational modification with critical significance
in mediating ataxin-1’s ability to bind other proteins. The phosphorylation of serine 776 (S776) is
necessary for the association of ataxin-1 with CIC and 14-3-3 proteins[144,162,163]. S776
phosphorylation and polyQ expansion allow ataxin-1 to more readily bind RBM17 which, in turn,
interferes with RNA polymerase 2 and cell death through a toxic gain-of-function mechanism[148].
In contrast to S776 phosphorylation, SUMOylation of expanded ataxin-1 targets it for nuclear
degradation via the SUMO-dependent ubiquitin ligase RNF4[164], providing an aspect of protein
context with interesting potential for therapeutic investigation.
1.2.5

Spinocerebellar Ataxia Type 2 (SCA2)
The ataxin-2 protein has been implicated as having a role in several neurodegenerative

diseases, including other polyQ disorders like SCA1, SCA3, and HD. In terms of its SCA2 specific
protein context, ataxin-2 interacts with multiple RNA binding proteins in its wild-type and polyQ
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expanded forms that provide hints towards understanding how those interactions alter its toxicity
in a disease state. Ataxin-2 binding protein 1 (A2B1) is a regulator of RNA alternative splicing
and was the first RNA binding protein that was discovered as having an interaction with ataxin2[44,165]. A2B1 interacts with the C-terminal half of ataxin-2 in the residue range of 760-1313 and
has been labeled in granules in SCA2 patient dentate neurons and Purkinje neurons[44]. This
interaction with wild-type ataxin-2 hints at the protein’s potential role in alternative splicing, and
the tissue specific sequestration in patient samples points to that role occurring in a tissue-specific
manner or subset of RNAs that renders those areas or genes particularly vulnerable upon polyQ
expansion[44].
Another altered ataxin-2 interaction upon polyQ expansion is with the E3 ubiquitin ligase
Parkin. This ligase directly interacts with the N-terminal domain of ataxin-2 in the first 396 amino
acids[165]. This interaction has been shown to occur with ataxin-2 possessing a polyQ tract in wildtype, patient, and hyperexpanded ranges in both cell and knock-in mouse SCA2 models[165-167].
In these models, ubiquitination was far more pronounced when the polyQ tract of ataxin-2 was
expanded and overexpression of Parkin resulted in increased turnover of ataxin-2[165-167]. These
studies indicate that Parkin may act as a regulator of ataxin-2 toxicity through ubiquitination and
triggering proteasomal degradation.
Staufen1 is a regulator of stress granule formation that also has a proposed interaction with
ataxin-2 and altered function upon ataxin-2 polyQ expansion[44]. In a wild-type state, ataxin-2 is
thought to be involved in multiple staufen and stress granule mediated pathways; however,
staufen1 expression increases in SCA2 cell and mouse models[44]. This information in
combination with the finding that staufen1 overexpression causes systems to constitutively present
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stress granules suggests that staufen1’s interaction with polyQ expanded ataxin-2 could be
contributing to aggregate formation and increasing cellular toxicity[44].
Some final pathways of toxic influence in SCA2 are the calcium signal production and
slow excitatory postsynaptic potential that are essential for neuronal communication. Calcium
influxes via the transient receptor potential ration channel 3 facilitate slow excitatory postsynaptic
potentials, and that channel is gated by diacylglycerol and IP3R[168]. Through an interaction with
mutant ataxin-2, IPR3 is aberrantly activated and triggers an abnormal release of calcium from
intracellular stores[169]. This interaction and overactivation of IPR3 by ataxin-2 has only been
shown to occur when the polyQ of ataxin-2 has been expanded and does not occur with normal
ataxin-2[169]. All of this is in association with the reduced mRNA translation of Rgs8 observed in
SCA2 that could be a result of sequestration by stress granules[168,169]. Rgs8 is an inhibitor of
mGluRS whose normal functioning in Purkinje neurons and motor neurons includes the production
of local dendritic calcium signal and slow excitatory postsynaptic potential that is disrupted by the
direct interaction of ataxin-2 and IP3R[168,169].
1.2.6

Spinocerebellar Ataxia Type 3 (SCA3 or Machado Joseph Disease)
While the bulk of the work that is presented in this dissertation covers the recent

advancements made by our lab in establishing protein context in ataxin-3 toxicity, there is a great
deal of work being done in the SCA3 field that compliments what has been uncovered here. Much
of this work will be referenced and discussed in the following chapters of this work. There are,
however, a few studies published more recently that have added to growing body of work
surrounding ataxin-3 protein toxicity. Some highlights from these studies include, but are not
limited to, the identification of pre-mRNA processing factor (Prpf19/prp19) as a regulator of
expanded ataxin-3 ubiquitination and degradation[170]; the recruitment of ataxin-3 to
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promyelocytic leukemia protein (PML) nuclear bodies by PML isoform II (PML-II) and reduction
of its deubiquitinase activity[171]; and the proposal that, through its interaction with autophagy
adaptors LC3C and GABARAP, ataxin-3 plays a role in stimulating autophagy in response to
proteotoxic stress or nutrient starvation that could be disrupted following polyQ expansion[172].
These findings further the idea that protein context is critically important in understanding ataxin3 toxicity and, like all the works discussed throughout this chapter, expand our knowledge of
polyQ expansion toxicity as a whole.
1.2.7

Spinocerebellar Ataxia Type 6 (SCA6)
The protein context of SCA6 begins with the bicistronic mRNA of the disease gene

CACNA1A and its IRES. While the first cistron encodes the well-characterized 𝛼1A subunit of the
Cav2 P/Q-type voltage-gated calcium channel, it is the second cistron encoding the 𝛼1ACT
transcription factor that harbors the polyQ expansion that causes SCA6[71,173-177]. Upon
expansion, 𝛼1ACT l loses its transcription factor function and neurite outgrowth properties leading
to cell death in culture and ataxia and cerebellar atrophy in transgenic mice[176]. Without the IRES,
the CACNA1A gene would no longer encode the second cistron 𝛼1ACT and no protein product
from the disease gene could be translated that possessed a polyQ expansion and could confer
SCA6-specific toxicity[176]. In addition to the necessity of the IRES for translation of the
pathogenic second cistron, there is also evidence that the polyQ-mediated toxicity is dependent on
the nuclear localization of the pathogenic protein[178].
After translation of the polyQ-containing 𝛼1ACT protein, there are a few known proteinprotein interactions that can alter 𝛼1ACT toxicity. The first is with the J-protein co-chaperone
DnaJ-1. Expression of DnaJ-1 greatly reduces polyQ expanded 𝛼1ACT degeneration and lethality,
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along with a reduction in aggregation and nuclear localization of the toxic protein[179]. The same
goes for the nuclear importer karyopherin 𝛼3. Mutating this protein in the eye of Drosophila also
reduced pathogenic 𝛼1ACT toxicity[179]. Overall, it seems that DnaJ-1 and karyopherin 𝛼3 are
suppressors of 𝛼1ACT toxicity in SCA6.
1.2.8

Spinocerebellar Ataxia Type 7 (SCA7)
Although disruptions to transcriptional regulation and activation have already been heavily

implicated in many aspects of SCA7 pathogenesis[78], there are several domains and proteinprotein interactions with the ATXN7 protein itself that are worth highlighting in this review. The
first of which is the cleavage of the expanded ataxin-7 protein by caspsase-7. Aspartic acid residues
at positions 266 and 344 of ataxin-7 have been identified as caspase-7 cleavage sites[82]. Caspase7 cleavage at these sites appears to be a critical step in SCA7 pathogenesis as preventing cleavage
through mutation of polyQ-expanded ataxin-7 mitigated the cell death, aggregate formation, and
transcriptional interference normally observed in SCA7[82]. In addition, expression of the caspase7 truncation product of ataxin-7 with two different pathogenic repeat lengths that also removes the
ataxin-7 NES and NLS increased cellular toxicity[82]. One hypothesis is that the active form of
caspase-7 cleaves ataxin-7 in the nucleus rather than the cytoplasm, and that the location of ataxin7’s cleavage sites would separate the polyQ tract from the NES and disrupt export of ataxin-7 out
of the nucleus[82]. This nuclear retention of polyQ-expanded ataxin-7 could lead to the
accumulation of toxic N-terminal fragments of ataxin-7 that could impair or sequester ataxin-7’s
normal interactors in the SAGA complex[82]. The accumulation of expanded ataxin-7 fragments
has also been associated with an increased level of acetylation at lysine 257 (K257)[180]. This
acetylation site is close to one of the two caspase-7 cleavages sites and seems to prevent the
clearance of expanded ataxin-7[180].
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K257 is also the site for ataxin-7 SUMOylation and polySUMOylation[181,182]. In this
case, SUMOylation is having a contrasting effect at this site compared to acetylation. SUMO2 is
added to the polyQ-expanded ataxin-7 substrate and this modification leads to the recruitment of
SUMO-targeted ubiquitin ligase RNF4[181,182]. Ataxin-7 is then ubiquitinated by RNF4 and,
following recruitment of clastosomes, is subsequently degraded by the proteasome[181,182].
SUMO2 has been colocalized in ataxin-7 NIs, and while SUMOylation at K257 seems to promote
the clearance of expanded ataxin-7 it is possible that chronic expression of this polyQ protein could
produce enough misfolded proteins to eventually overwhelm the SUMO pathway and clastosomes,
especially as they become compromised with age[181,182]. An overwhelmed processing system
would cause aggregate sizes to increase and possibly explain the delayed onset of the disease.
Along with caspase cleavage and posttranslational modification, the interface between
ataxin-7 and components of the SAGA complex presents numerous interactions that all play a role
in expanded ataxin-7 toxicity. Upon polyQ expansion, ataxin-7’s interaction with the SAGA
complex alters SAGA function through the sequestration of SAGA components into NIs[183-187],
the undermining SAGA integrity[188,189], and aberrantly interacting with SAGA components and
associated transcription factors[81]. The cone-rod homeobox protein (Crx) is a photoreceptor
transcription factor that has been shown to have a polyQ-dependent interaction with ataxin7[190,191]. The Crx and STAGA (human ortholog to yeast SAGA) interaction is mediated by
ataxin-7 and controls Crx-dependent gene activation in the retina[188,192]. PolyQ expansion of
ataxin-7 disrupts this pathway leading to the downregulation of retinal specific genes and
contributing to disease progression, as seen in transgenic SCA7 knock-in mice[188,190-193]. PolyQ
expanded ataxin-7 has also been shown to aberrantly bind the Gcn5 catalytic core along with its
adaptor proteins, Ada2 and Ada3, through a highly conserved zinc binding domain between
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residues 311 and 406 of ataxin-7[81]. This interaction caused significant decreases in Gcn5 histone
acetyltransferase activity in vitro and in vivo[81]. These findings in SAGA complex components
suggests that polyQ expanded ataxin-7 dominantly inhibits the function of the SAGA complex and
helps explain the prominence of transcriptional dysregulation in SCA7 pathogenesis.
Other interesting protein-protein interactions with expanded ataxin-7 include histone
deacetylase 3 (HDAC3), whose activity increases in SCA7 mouse retinas and whose interaction
with ataxin-7 stabilizes the protein in a deacetylase-independent manner[194]. Ataxin-7, through
its N-terminal region of residues 1-230, is also able to interact with the SH3P12 gene products,
R85 and CAP, in both a wild-type and expanded state[195]. It is suggested that in a wild-type state,
this interaction helps to facilitate the physiological regulation, ubiquitination, and degradation of
ataxin-7; however, when ataxin-7 is expanded, ubiquitinated proteins still accumulate in NIs in
SCA7 brains suggesting that the normal function of these gene products is disrupted and they may
be contributing to SCA7 progression[195]. The final ataxin-7 interaction that will be discussed in
this section is with the ATPase subunit S4 of the 19S regulatory complex of the proteasome.
Uncovered in a yeast-two-hybrid assay, the ataxin-7-S4 interaction is inversely correlated with the
length of the polyQ tract, and it is suggested that S4 functions in the ubiquitin-mediated
proteasomal degradation of ataxin-7[196]. As the polyQ tract becomes expanded, and the
interaction between S4 and ataxin-7 weakens, it may create abnormalities in the recognition or
degradation of ubiquitin protein conjugates by the 26S proteasome complex and contribute to
accumulation of ataxin-7/ubiquitin-protein conjugates and SCA7 pathogenicity[196].
1.2.9

Spinocerebellar Ataxia Type 17 (SCA17)
Dysfunction of TBP results in broad clinical presentations ranging from Parkinson’s to

Huntington’s to psychiatric symptoms and may have impacts beyond just SCA17[83,86,87]. In
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Drosophila, loss of TBP expression not only caused age-related neurodegeneration in SCA17
disease fly models, but also exacerbated polyQ-expansion-induced retinal degeneration in disease
models of SCA3 and HD[197]. Findings like these suggest that TBP dysfunction may play a larger
role in polyQ-induced neurodegeneration and highlight the significance of understanding the
protein context of TBP toxicity to clarify the causes of SCA17 and the entire family of polyQ
diseases.
One such TBP protein context change upon polyQ expansion comes from a potential
conformational change that results in a disruption of one of TBP’s native functions, binding DNA.
It has been reported that the polyQ expansion of TBP reduces its in vitro binding to DNA and that
mutant TBP fragments that lack an intact C-terminal DNA-binding domain have been identified
in transgenic mouse models of SCA17[198]. In addition to this reduced binding, polyQ-expanded
TBP with a deletion in the DNA-binding domain that prevents DNA-binding has been shown to
form nuclear aggregates and inhibit TATA-dependent transcription in cultured cells as well as
causing early death and neuronal nuclear inclusions in transgenic mice with the same double
mutant[198]. All these findings suggest that the expanded polyQ tract of TBP negatively affects its
ability to bind promoter DNA and that this disruption can induce neuronal aggregation and toxicity
in SCA17.
In addition to DNA-binding, TBP also has several new or altered protein-protein
interactions that occur because of its polyQ expansion. The first is with the transcription factor
nuclear factor-Y (NF-Y). It was found that in TBP transgenic mice, expanded TBP bound more
tightly to NF-Y and seemed to sequester it into TBP nuclear inclusions, possibly altering its
function as a master regulator of the chaperone system and impairing NF-Y-mediated expression
of chaperones like Hsp70, Hsp25, and HspA5[199]. Expanded TBP has also been found to
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abnormally bind another transcription factor, Sp1, and seems to sequester it away from its normal
function in a manner similar to NF-Y[200,201]. In this case, it was shown in SCA17 knock-in mice
that the mutant TBP-Sp1 interaction leads to reduced transcription of Inpp5a, a gene that is critical
in the maintenance of Purkinje cells and neurite growth pathways and whose knockout in wildtype mice results in Purkinje cell degeneration[200,201]. A final example of the polyQ expansion
enhancing TBP’s interaction with a protein is another transcription factor, RBP-J/Su(H)[202]. This
transcription factor participates in Notch signaling and was shown in Drosophila to interact more
efficiently with expanded TBP than wild-type TBP[202]. Its dysfunction, and subsequent alteration
of the Notch signaling pathway, contributed to TBP expanded polyQ-induced phenotypes[202].
These three interactions form a trend that points to the possibility of enhanced interaction of mutant
TBP with other transcription factors which – like NF-Y, Sp1, and RBP-J/Su(H) – could be
sequestering them away from their normal functions leading to toxic transcriptional alterations.
While polyQ expansion increases several TBP interactions, there are also cases where it
does the opposite. The transcription factor XBP1 recognizes the ER stress response element in the
promoter of MANF, an ER-stress inducible protein that is enriched in Purkinje cells[203,204]. XBP1
and TBP are normally present in the same transcriptional complex to help mediate the expression
of MANF; however, mutant TBP has decreased association with XBP1 leading to reduced
expression of MANF and a lowered ER-stress response[203,204]. Another normal interaction that
is impacted by the polyQ expansion of TBP is with the muscle-specific transcription factor
MyoD[205]. The TBP-MyoD interaction stabilizes MyoD’s binding to a DNA promoter, but the
association between TBP and MyoD is reduced upon TBP polyQ expansion causing decreased
transcriptional activity and protein levels because of destabilization and enhanced
degradation[205]. The lowered MyoD levels and activity negatively impacts muscle-specific gene
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expression and leads to muscle degeneration in SCA17 knock-in mice[205]. This model also
showed that larger polyQ repeats in TBP created an even greater reduction in association with
MyoD and more severe muscle degeneration[205].
1.3

Conclusions
What has been covered in this review only begins to scratch the surface of all the great

investigations that have helped advance the understanding of the protein context surrounding the
nine polyQ disease proteins. There are countless examples of toxic effects specific to each disease
that are outside the scope of this work but certainly provide valuable information about the
contributors to polyQ protein toxicity. These contributors may not involve direct protein
interactions, but mechanisms of toxicity such as transcriptional dysregulation, sequestration of
essential proteins away from their normal functions and into aggregates, and non-protein level
contributions like RAN translation and mRNA toxicity all play an important role in establishing
the distinct pathogenesis of each disease. Additionally, there are several areas of overlapping
protein context between these disease proteins that share functions, interactions, and pathway
disruptions that should be investigated further as they may hold clues to broader therapeutic
approaches that could target polyQ disorders more generally.
The ever-growing list of investigations into protein context have been a continual inspiration
for this dissertation and have laid the groundwork for the studies building the protein context of
the ataxin-3 protein highlighted over the next five chapters. Included verbatim are four manuscripts
that have either been published or submitted for publication at the time of this writing.
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2
2.1

CHAPTER 2: DIFFERENTIAL TOXICITY OF ATAXIN-3 ISOFORMS IN
DROSOPHILA MODELS OF SPINOCEREBELLAR ATAXIA TYPE 3

Introduction
Several ataxias are caused by specific genetic mutations. Among these is the most common

ataxia in the world, Spinocerebellar Ataxia Type 3 (SCA3), also known as Machado-Joseph
Disease[53,206]. An age-related disorder, SCA3 is a member of the family of polyglutamine
(polyQ)-dependent diseases alongside other SCAs (1, 2, 6, 7 and 17), Huntington’s Disease,
Kennedy’s Disease, and Dentatorubropallidoluysian Atrophy. PolyQ diseases are caused by
abnormal lengthening of a CAG triplet repeat in the respective genes, which translates into an
expanded polyQ stretch in the encoded proteins. Expanded polyQ in each of these disease proteins
causes misfolding and the formation of aggregates, neuronal dysfunction and death [2-4,207-210].
SCA3 is a progressive ataxia accompanied by dystonia, dysarthria, spasticity, rigidity,
ophthalmoparesis, dysarthria, dysphagia and neuropathy. Pathology includes degeneration of
cerebellar pathways and nuclei, pontine and dentate nuclei, substantia nigra, globus pallidus,
cranial motor nerve nuclei and anterior horn cells. SCA3 is caused by abnormal triplet CAG repeat
expansion in the gene ATXN3 that is normally 12-42 repeats in length, but is expanded to ~52-84
in patients[53,206]. Expansion occurs in the protein ataxin-3, a deubiquitinase (DUB) implicated in
quality control[53,206]. Although ataxin-3 is widely expressed, degeneration is constrained to
specific

areas

of

the brain.

Histopathologically,

the SCA3

protein

is found

in

macroaggregates/inclusions in the cytoplasm and in the nucleus[51,53,211].
Extensive work by various laboratories has provided insight into enzymatic properties and
potential functions of the SCA3 protein. As a DUB, ataxin-3 binds and cleaves ubiquitin chains of
a specific length and type[53,206,212,213]. Ataxin-3 may have different types of substrates,
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depending on the needs of the cell, and might even function as a monitor of ubiquitin homeostasis.
In cultured mammalian cells and in the fruit fly, Drosophila melanogaster, ataxin-3 is important
during proteotoxic stress[214-216]. In vivo, according to different atxn3 knockout lines, this protein
appears dispensable[206,217-220].
PolyQ expansions in ataxin-3 most likely cause disease though a toxic gain-of-function,
although the precise nature of the dominant toxic properties remains elusive. What is clear is the
fact that nuclear ataxin-3 is markedly more toxic than its cytoplasmic portion, and that aggregation
of disease-causing ataxin-3 precedes and correlates with cellular dysfunction and disease
[64,221,222]. Preventing aggregation of the SCA3 protein is beneficial to cells, tissues and

organisms harboring polyQ-expanded ataxin-3 [53,206,216,220,222,223]. Still, our understanding of
SCA3 biology remains incomplete.
Towards understanding SCA3, we reasoned that it will be beneficial to comprehend the
toxicity of the products of its causative gene, ATXN3. Two major isoforms of ataxin-3 arise by
alternative splicing of ATXN3 mRNA [1]. The original ataxin-3 variant isolated from SCA3 human
brain[62],which we refer to as isoform 2 in this work, encodes an isoform containing 2 Ubiquitininteracting motifs (UIMs), the polyQ repeat and a C-terminal stretch of hydrophobic amino acids.
Subsequent studies identified another variant, referred to as isoform 1, that encodes a third UIM
at its C-terminus [224] (figure 2.1). Isoform 1 of ataxin-3 is the predominant form in the
mammalian brain; isoform 2 is also present in this organ, but at lower levels than isoform 1 [1].
Due to a lack of reagents that can readily and reliably distinguish these isoforms, it is unclear
whether specific forms are enriched in certain types of cells or tissues in the normal and diseased
brain.
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Isoform 2 appears to aggregate more rapidly in vitro and in cultured mammalian cells. In
cultured cells, isoform 2 protein is also less stable than isoform 1 [1]. These informative
observations notwithstanding, a comprehensive understanding of the relative toxicity and
pathogenic contribution of each isoform is presently lacking in vivo. Here, we investigated the
toxicity of each isoform of pathogenic ataxin-3 by generating novel, isogenic Drosophila
melanogaster transgenics that encode ataxin-3 protein with a polyQ of 80, within human disease
range. We observe that isoform 1 of ataxin-3 is much more toxic than isoform 2 as a result of
higher turnover and lower steady state levels of the latter variant. We also find that both isoforms
are degraded by the proteasome and autophagy. Collectively, our results yield new information on
the pathogenicity of the ataxin-3 isoforms in vivo, present new genetic tools to be used to further
assess toxic products of the ATXN3 gene and expand overall understanding of SCA3 biology.
2.2
2.2.1

Materials and Methods
Constructs and plasmids
We used the company Genscript (genscript.com) to generate human ataxin-3 cDNA with

a CAGCAA repeat that encodes 80Q. The nucleotide sequences used for isoforms 1 and 2 were
based on ataxin-3 sequences described in prior publications[1,212,223,225], but with a CAGCAA
repeat instead of a pure CAG tract to circumvent the possibility of RAN translation and mRNA
toxicity [226-233]. Constructs were sub-cloned into pcDNA3.1 for mammalian expression and
pWalium-10.moe for fly line generation by using EcoRI (5’) and XbaI (3’) restriction digest sites.
A Kozak sequence, shown in figure 2.1D, was added 5’ onto the ataxin-3 cDNA sequence for fly
expression and the endogenous Kozak of pcDNA3.1 was utilized for expression in mammalian
cells. An HA tag-encoding sequence was added immediately after the last nucleotide of the ataxin3 sequence, as shown in figure 2.1A. Each construct was sequence-verified before utilization for
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its intended purposes. Genscript was also used to synthesize the ataxin-3 constructs in figure 2.9
and sub-clone them into pcDNA3.1 through EcoRI (5’) and XbaI (3’) digestion/ligation.
2.2.2

Drosophila stocks and new transgenic lines
All fly stocks and crosses were maintained at 25˚C and ~60% humidity in diurnal

incubators with 12 h light/dark cycles. Common stocks were from Bloomington Drosophila Stock
Center (BDSC). New transgenic lines were generated through phiC31-dependent integration of
transgenes into the attP2 site of the fly’s third chromosome, as we have done in the
past[174,216,222,223]. New lines generated were verified to ensure insertion at the right site (PCRbased assays), in the correct orientation (PCR-based assays) and sequence-verified for transgene
nucleotide sequence. The lines generated for the work in this manuscript all contain a CAGCAA
repeat to encode the expanded polyQ of ataxin-3. The only exception is the fly line that we denote
here as “weaker expressing isoform 1”, which contains a pure CAG repeat and was described in
our prior publications[222,223,234]. This latter transgene is also inserted on chromosome 3 of
Drosophila, and on the same genetic background as the other two isoform lines.
Fly lines used here are as follows: GMR-Gal4 (#8121) and the isogenic host strain attP2
(#36303) were from the Bloomington Drosophila Stock Center (BDSC). RNAi lines were from
BDSC and the Vienna Drosophila RNAi Center (VDRC): RNAi to Atg7 (BDSC34369 (#1),
BDSC27707(#2)); Atg8a (BDSC34340 (#1), BDSC28989(#2)); Atg12 (BDSC27552 (#1),
BDSC34675 (#2)); Rpn1 (BDSC34348 (#1), VDRC25549 (#2), VDRC103939 (#3)); prosα5
(BDSC34786); prosβ2 (BDSC67363). The following lines were gifts: sqh-Gal4 driver (Dr. Daniel
P. Kiehart, Duke University), elav-Gal4(GS) driver (Dr. R. J. Wessells, Wayne State University),
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elav-Gal4 driver and repo-Gal4 driver (Dr. Daniel F. Eberl, University of Iowa). Unless otherwise
stated in the figure legends and text, all flies were heterozygous for driver and transgene.
2.2.3

Longevity and motility assays
Adult flies were collected after eclosion from their pupal case and were aged at 25˚C on

conventional cornmeal fly media or RU486-containing media, as noted in the text and figure
legends. Flies were switched to vials with fresh food every 2-3 days. Each vial was examined for
death each day, until all flies were dead. Motility was tested weekly through negative geotaxis.
Approximately 10 flies per vial were forced to the bottom of the vial by gentle tapping on the
bench. The total number of adult flies that reached the top of the vial at 5, 15 and 30 seconds was
recorded and expressed as a percentage of total flies. Adults were transferred to fresh vials 1 hour
before assessment, and every 2-3 days for the duration of the experiment; their longevity was
monitored daily.
2.2.4

Mammalian cells and assays
HeLa and HEK-293T cells were purchased from ATCC and cultured in DMEM

supplemented with 10% FBS and 5% Penicillin-Streptomycin, under conventional conditions. The
day before transfection, cells were seeded in 12-well plates. Cells were transfected using
Lipofectamine LTX (Invitrogen) per manufacturer’s directions. Twenty-four hours after
transfection, cells were treated as indicated in figure legends with cycloheximide (100 µg/ml; A.G.
Scientific), and/or MG132 (20 µM; R&D Systems), or chloroquine (100 µM, A. G. Scientific).
Cells were harvested in hot SDS lysis buffer for western blotting (see below).
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2.2.5

Western blotting
Five whole flies, 10 pupae or 10 dissected adult fly heads per group were homogenized in

boiling lysis buffer (50mM Tris pH 6.8, 2% SDS, 10% glycerol, 100mM dithiothreitol), sonicated,
boiled for 10 minutes, and centrifuged at 13,300 RPM at room temperature for 10 minutes. The
same lysis buffer and procedures were used for extraction of protein from mammalian cells.
Samples were electrophoresed on 4-20% gradient gels (BioRad). Western blots were developed
using the charge-coupled device-equipped VersaDoc 5000MP system (BioRad) or Syngene PXi
4. Blots were quantified using Quantity One software (BioRad) or GeneSys (Syngene). Direct blue
staining was used for loading: PVDF membranes were submerged for 5 minutes in 0.008% Direct
Blue 71 (Sigma-Aldrich) in 40% ethanol and 10% acetic acid. PVDF membrane was then rinsed
briefly in 40% ethanol and 10% acetic acid solvent, then ultrapure water, air dried, and imaged.
2.2.6

Differential Centrifugation
Ten whole flies per group were lysed in 200 µL of NETN buffer (50 mM Tris, pH 7.5, 150

mM NaCl, 0.5% Nonidet P-40), supplemented with protease inhibitor cocktail (PI, SigmaFast
Protease Inhibitor Cocktail Tablets), sonicated at 50% for 15 seconds with a probe solicitor
(Thermo Scientific) and centrifuged at 20,000 x g for 30 minutes at 4˚C. The supernatant was
transferred to a new microfuge tube and quantified by the BCA assay (Thermo Scientific). The
pellet was resuspended in 200 µL of PBS + 1% SDS, vortexed, and boiled. Thirty µg of the
supernatant fraction and 7 µL of the pellet fraction were supplemented with 6x SDS, boiled, and
loaded onto SDS-PAGE gels gels for western blotting.
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2.2.7

Filter-Trap Assay
Three whole flies per group were lysed in 200 µL of NETN+PI. Lysates were diluted with

200 µL PBS containing 0.5% SDS, sonicated at 50% for 15 seconds with a probe sonicator, and
centrifuged at 4,000 x g for 1 minute at room temperature. 100 µL of supernatant were diluted with
400 µL PBS. 70 µL of sample were filtered through a 0.45 µm nitrocellulose membrane
(Schleicher & Schuell) using a Bio-Dot apparatus (BioRad) and analyzed by Western blotting.
2.2.8

Nuclear/Cytoplasmic Extraction
Fractionation

was

conducted

using

the

ReadyPrep

Protein

Extraction

Kit

(Cytoplasmic/Nuclear; BioRad) to separate cytoplasmic and nuclear proteins. Five whole adult
flies were lysed in cytoplasmic extraction buffer (BioRad). Nuclei were resuspended in Protein
Solubilization Buffer (BioRad). Samples were analyzed by western blotting, where,
proportionally, 3X nuclear fraction was loaded compared to cytoplasmic fraction to eliminate need
for over-exposure. Through this protocol, sometimes we are able to observe a main band for ataxin3, and other times we are not, likely as a result of the buffers used. This is highlighted through two
different examples in figures 2.2C and S2.2. For quantification purposes, we quantified signal from
the entire lane, including main band when visible, as well as the smear above it.
2.2.9

Antibodies
Anti-Ataxin-3 (mouse monoclonal 1H9, 1:500-1,000; Millipore) (rabbit polyclonal,

1:15,000; [211]), anti-GAPDH (mouse monoclonal MAB374, 1:500; Millipore), anti-tubulin
(mouse monoclonal T5168, 1:10,000; Sigma-Aldrich), anti-HA (rabbit monoclonal, 1:500-1,000;
Cell Signaling Technology), anti-lamin (mouse monoclonal ADL84.12-5, 1:1,000; Developmental
Studies Hybridoma Bank), peroxidase conjugated secondary antibodies (goat anti-mouse and goat
anti-rabbit, 1:10,000; Jackson Immunoresearch).
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2.2.10 qRT-PCR
Total RNA was extracted from whole adult flies using TRIzol (Life Technologies).
Extracted RNA was treated with TURBO DNAse (Ambion). Reverse transcription was carried out
using the high capacity cDNA reverse transcription kit (ABI). mRNA levels were quantified using
the StepOne Real-Time PCR system with Fast SYBR Green Master Mix (ABI). Primers used:
ATXN3 F: 5!-GAATGGCAGAAGGAGGAGTTACTA- 3!;
ATXN3 R: 5!-GACCCGTCAAGAGAGAATTCAAGT- 3!;
rp49 F: 5"!-AGATCGTGAAGAAGCGCACCAAG- 3!;
rp49 R: 5"!-CACCAGGAACTTCTTGAATCCGG- 3!
2.2.11 Statistics
Student's t-tests, ANOVA with post-hoc assays and log-rank tests were conducted for
statistical comparisons, as indicated in the figure legends. Software utilized was GraphPad Prism
and Apple Numbers. Graphs were generated in Apple Numbers.
2.3
2.3.1

Results
New Drosophila lines to investigate SCA3
As summarized in figure 2.1A, earlier studies[62-64,235-237] established that two major,

full-length isoforms arise from alternative splicing of ATXN3 mRNA; a polymorphism in what we
term isoform 2 in this study also gives rise to a slightly shorter variant, denoted by the arrowhead
in figure 2.1A. The ataxin-3 variants are identical, except for their respective C-termini. As noted
above, both of these forms are present in mammalian brain, but isoform 1 is predominant. Here
we focus on the pathogenic property of the two full-length isoforms, depicted in the lower part of
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figure 2.1A. We generated constructs that encode either human ataxin-3 isoform, with an expanded
polyQ (80), which is within patient range. The transgenes are used through the Gal4-UAS binary
expression system in the fly [238], which enables expression in a tissue- and time-dependent
manner[174,216,222,223].
We designed the polyQ of ataxin-3 to be encoded by CAGCAA doublet repeats. Expanded
ATXN3 may lead to neuronal toxicity not only through the ataxin-3 protein, but also via mRNA
toxicity as a result of a long, homogenous CAG trinucleotide repeat [228]. Moreover, in addition
to encoding polyQ, the expanded CAG repeat of ATXN3 could lead to repeat-associated non-AUG
(RAN) translation of non-polyQ homopolymers, as observed in other polyQ disorders [239-241].
For the purposes of this study, we sought to focus on toxicity from the polyQ-expanded ataxin-3
protein. Therefore, to avoid the potential confound of RAN translation and mRNA toxicity, the
polyQ of ataxin-3 is encoded by alternating CAGCAA repeats. This approach precludes the
production of proteins in alternative frames and eliminates potential ATXN3 mRNA toxicity [226233]. The polyQ-reading frame has an HA epitope tag at its C-terminus and we capped the other
two sense reading alternatives with in-frame MYC and V5 epitope tags (figure 2.1B). As shown
in figure 2.1B, we do not observe specific protein signal from unintended reading frames. Blotting
for the HA epitope tag for the polyQ frame yields clear protein signal, whereas blotting for MYC
and V5 tags (alternative reading frames of the sense strand) does not yield signal above
background, indicating that RAN translation is unlikely to be occurring with this design. We say
“unlikely” since there is still the formal possibility of RAN from anti-sense frames, for which we
were unable to generate in-frame tags. Nonetheless, based on the results in figure 2.1B and other
similar data not included, as well as on prior work showing that CAGCAA repeats circumvent
RAN [226-233], we are confident that any RAN translation occurring from our constructs is likely
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negligible. We therefore proceeded with using the CAGCAA design to encode the polyQ of both
isoforms. We reiterate here that both isoforms contain 80Q, which is within the range of polyQ
repeats observed in SCA3 patients[206].
The new Drosophila lines were generated with the phiC31 site-specific integrase system,
which enables insertion of a single construct in the same orientation at site attP2 on the third
chromosome of Drosophila [242]. The new ataxin-3 isoform 1 and 2 lines were verified for

Figure 2.1 New Drosophila lines for SCA3.
A) ATXN3 isoforms. U: untranslated region; DUB: deubiquitinase; polyQ: polyglutamine; UIM: ubiquitin-interacting motif. 2-UIM
transcript is termed here isoform 2 since it is less common[1]. Isoform 1 results from alternative splicing linking exon 10 to 11 for
UIM3 (⧫). (★) Isoform 2 with a different tail, lacking UIM3. (▲) A SNP results in an early stop within isoform 2. In this work, both
isoforms are capped by an HA tag. B) Ataxin-3 constructs were designed with a CAGCAA repeat to encode polyQ. PolyQ frame is
HA-tagged. Isoform 1 is shown. The other, non-polyQ sense frames are MYC and V5 tagged. NS: non-specific. C) qRT-PCR from
adults expressing either isoform in all neurons. Means ± SEM. P value from student's t-test. Flies were one day old. D) Start and end
sequences for the ataxin-3 lines from genomic sequencing. Italics: nucleotides. Sequence between nucleotides is ataxin-3 amino acid
sequence. Bold: sequences added for Kozak (front) and HA tag (end).

49

insertion at the proper site, in the same orientation and as a single copy through PCR, and were
also sequence-verified from genomic DNA [174,179]. The phiC31 integrase system enables
expression of transgenes at a similar level, as shown in figure 2.1C and as demonstrated in our
prior work with other proteins and transgenes[174,216,222,223]. Figure 2.1D shows that the “start”
and “end” genomic DNA sequencing results of the ataxin-3-encoding areas in the new fly lines
are identical.
When we examine the protein levels of isoforms 1 and 2 when expressed in all fly neurons
as well as in all fly tissues, we notice clear differences between the two. Even though at the mRNA
level the two isoforms are similar and their “start” regions are the same (figure 2.1C and D), at the
protein level they differ markedly. Isoform 1 protein is present at much higher levels than isoform
2 when expressed in all fly neurons (throughout development and in adults; figure 2.2A) as well
as in all fly tissues (figure 2.2B). This difference is not due to the antibody used, as anti-HA blots
show a similar difference between the two isoforms at the protein level (supplemental figure S2.1).
The significantly lower levels of isoform 2 protein compared to isoform 1, coupled to our
observations that their mRNA levels are similar, suggest that isoform 2 protein is degraded more
rapidly in flies. This difference in protein levels between the two full-length ataxin-3 isoforms is
not entirely unexpected, as prior work had shown that isoform 2 is more rapidly degraded in
cultured mammalian cells [1].
Next, we examined whether the two ataxin-3 isoforms are similarly partitioned in the
nucleus and the cytoplasm. This is an important point since nuclear pathogenic ataxin-3 is
significantly more toxic than cytoplasmic ataxin-3 [221]. Figure 2.2C and supplemental figure 2.2
summarize our findings from cytoplasmic/nuclear fractionations: both isoforms are found
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similarly in these two fractions. With these new tools and an initial impression about their
expression, protein levels and localization, we next investigated their toxicity in the fly.

Figure 2.2 Expression of the two ataxin-3 isoforms in flies.
A & B) Western blots when isoforms are expressed in all neurons (A) or ubiquitously (B). Adults were used for panel A and pupae
for panel B. For quantification, the entire signal in each lane was used. Means ± SD. P values from student's t-tests. Black arrow:
unmodified ataxin-3. Blue arrows: ubiquitinated ataxin-3[215,225,243,244]. Black bar: SDS-resistant species. In all blots,
isoform 2 migrates slightly lower than isoform 1. C) Western blots from cytoplasmic (C) / nuclear (N) separation of fly lysates
expressing isoforms in all neurons. The entire signal - the main band as well as smear above it - was quantified, as denoted by the
bar on the right side of the blots. Isoforms were loaded on separate gels to avoid over-exposure. Means ± SD. N.S.: nonsignificant P value from student's t-test. Flies were one day old.

2.3.2

Isoform 2 of pathogenic ataxin-3 is less toxic than isoform 1 in Drosophila
We assessed the toxicity of isoforms 1 and 2 of pathogenic ataxin-3 in Drosophila with the

aid of several Gal4 drivers that we have employed in the past to examine the toxic properties of
various proteins[174,179,215,216,222,234]. We began by expressing either isoform in all tissues,
throughout fly development and in adults, via the sqh-Gal4 driver [245-248]. As shown in figure
2.3A, ubiquitous expression of isoform 1 leads to developmental lethality in flies: flies die during
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late pupal and early pharate adult stages, before they can emerge as adults. Expression of isoform
2 instead leads to successful eclosure of adults from their pupal cases; these flies survive for nearly
60 days. Control flies, which contain the sqh-Gal4 driver on the background line of the
chromosome targeted for transgene insertion, live up to ~90 days. Co-expression of both isoforms
in all tissues leads to a phenotype that is more severe than expression of isoform-1 alone
(supplemental figure S2.3).

Figure 2.3 Differential toxicity from pathogenic ataxin-3 isoforms in developing and adult flies.
A & B) Adult fly longevity when isoform 1 or 2 of pathogenic ataxin-3 was expressed in the noted tissues. Ubiquitous driver was
sqh-Gal4, pan-neuronal driver was elav-Gal4. P values from log-rank tests. C) Negative geotaxis assays of flies with the noted
genotypes. P values from student's t-tests comparing motility of isoforms 1 and 2 to control flies for their respective time course.
None of the flies set aside for motility assays for isoform 1 survived to day 21. At least 50 flies per group were used.

These data were corroborated by expression of either pathogenic ataxin-3 isoform in other
tissues. As shown in figure 2.3B, expression of isoform 1 in all fly neurons, during development
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and in adults, leads to higher lethality than isoform 2. Flies expressing isoform 1 in all neurons
successfully emerged as adults, but die within one month. Isoform 2-expressing adults live for
about 80 days, and the control flies, which contain the elav-Gal4 driver but without ataxin-3
expression, die by ~100 days. Observations from longevity assays were complemented with
motility tests, performed with the negative geotaxis assay. Through this method, flies in a vial are
forced to the bottom by tapping and the number of flies that reach the top of the vial at 5, 15 and
30 seconds is calculated and expressed as a percentage of total flies in the vial. As shown in figure
2.3C, flies expressing isoform 1 pan-neuronally are impaired in their climbing ability compared to
control flies and flies expressing isoform 2. Slower mobility from isoform 1-expressing flies is
noticeable as early as day 7 and escalates throughout testing. Isoform 2-expressing flies also show
reduced ability to climb, but later than isoform 1 counterparts. Still, for most of the time that we
conducted this study, isoform 2 flies resembled controls (figure 2.3C).
Data from figures 2.3B and C were obtained using a driver that expresses ataxin-3 isoforms
throughout development and adulthood. We next assessed whether expression of either isoform in
all fly neurons solely at adult stages shows a different pattern of lethality. The rationale behind this
approach rests on the fact that SCA3 is an adult-onset disease. What if the differential toxicity we
observe with isoforms 1 and 2 of SCA3-causing ataxin-3 is due to developmental problems? We
utilized a pan-neuronal driver, elav-Gal4-GS (Gene Switch), which requires the compound RU486
to initiate expression of ataxin-3 (figure 2.4A) [249-251]. Flies are raised in media without RU486.
On day 1 after they emerge as adults, flies are placed in media with RU486 to induce protein
expression [222,252]. Flies are then maintained in media with RU486 until they die and longevity
is tracked daily. As summarized in figure 2.4B, expression of either isoform leads to increased
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lethality compared to controls, with lethality occurring earlier with isoform 1. Control flies
contained the elav-Gal4-GS driver on the genetic background used to generate ataxin-3 lines.

Figure 2.4 Differential toxicity from pathogenic ataxin-3 isoforms in adult neurons and in glia.
A) Western blots from whole fly lysates. Flies heterozygous for both elav-Gal4-GS driver and either isoform were raised in media
without RU486 until they emerged as adults, when they were placed in RU486-containing media for the indicated amount of time.
NS: non-specific bands we sometimes observe with the indicated antibody. NS*: another non-specific band present only in lanes 1
and 5, running immediately below/near the ataxin-3-positive band. In the isoform 2 blot, 4/5th less lysate was loaded for isoform
1 compared to the other lanes. Iso: isoform. B, D) Adult fly longevity when isoform 1 or 2 of pathogenic ataxin-3 was expressed
in the noted tissues. Pan-neuronal driver dependent on RU486 was elav-Gal4-GS, and glial cell driver was repo-Gal4. P values
from log-rank tests. C) Western blots from adult flies expressing isoform 1 or 2, driven by repo-Gal4. Shown in histograms are
means ± SD. P value from student's t-test. Flies were one day old.

Finally, we targeted either isoform to glial cells using the Repo-Gal4 driver, which leads
to transgene expression in development and adults. Here, we notice again markedly lower protein
levels in glial cells for isoform 2 compared to isoform 1 (figure 2.4C). As shown in figure 2.4D,
expression of isoform 1 again leads to accelerated incidence of death than expression of isoform
2; only a handful of adult flies are able to emerge and die within 12 days. Most isoform 1expressing flies do not manage to eclose from their pupal cases. By contrast, isoform 2 is not toxic
to glial cells; adults that express isoform 2 only in glia emerged successfully as adults and live
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similarly to control adults that contain the Gal4 driver but do not express isoform 2. Collectively,
these observations demonstrate that isoform 1 of pathogenic ataxin-3 is significantly more toxic
than isoform 2 in flies.
2.3.3

Aggregation of isoforms 1 and 2 of pathogenic ataxin-3 in flies
A defining property of pathogenic ataxin-3 is its propensity to aggregate[206]. This feature

presents as macro-inclusions in SCA3 mammalian brain and in cultured cells, its partitioning into
soluble and insoluble (pellet) species through centrifugation protocols, and the retardation of
aggregated species on filter-trap assays [53,213,220,222,253-256].
We first utilized centrifugation to separate each isoform of pathogenic ataxin-3 into a pellet
and soluble fraction. For this set of experiments, we used the elav-Gal4 driver to express either
ataxin-3 isoform in all neuronal cells, and adults were collected on days 1, 7 and 14. Due to the
much higher levels of isoform 1 protein than isoform 2, blots in figure 2.5A were imaged separately
to avoid the need for over-exposure to obtain isoform 2 signal. We notice that each isoform of
pathogenic ataxin-3 partitions both into soluble and pellet fractions on day 1 (figure 2.5A).
However, unlike isoform 1, which by two weeks is mostly found in the pellet fraction, isoform 2
continues to be present in both fractions. Additionally, at every time point more isoform 1
fractionates into the pellet than isoform 2, indicating a higher aggregative propensity of this variant
of the SCA3 protein (figure 2.5A). Another feature of isoform 1 that we do not observe with
isoform 2 is the clear presence of species at higher molecular weight (HMW) regions present in
the pellet fraction (denoted by black lines in figure 2.5A). These HMW are SDS-resistant species
of pathogenic ataxin-3 that we have reported before and which accumulate in fly tissue [222]. Their
unambiguous presence with isoform 1 underscores the higher propensity of isoform 1 to aggregate
than isoform 2.
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Figure 2.5 Ataxin-3 isoform aggregation in fly neurons.
A) Western blots from adult flies expressing isoform 1 or 2 of pathogenic ataxin-3 in all neurons throughout development and in
adults, harvested on the indicated days. Fly lysates were separated into soluble (S) and insoluble (P) fractions and loaded onto SDSPAGE gels. Signal from the entire length of each isoform lane was quantified, normalized to loading control and expressed as
percent ataxin-3 signal in the pellet fraction compared to the total signal. Black bars on the right side of longer exposure blots
indicate SDS-resistant species whose migration over time shifts to higher molecular weight markers for isoform 1. Shown in
histograms are means ± SD. P values from ANOVA with Tukey's post-hoc. Samples from isoforms 1 and 2 were loaded onto
different gels to avoid the need for over-exposure of isoform 1 to visualize and quantify isoform 2. Black arrow: main ataxin-3
band. Red arrow: potentially phosphorylated form of ataxin-3. Blue arrows: ubiquitinated species of ataxin-3. B) Filter-trap assay
of flies expressing isoform 1 or 2 in neurons, harvested at the indicated days. C) Independent filter-trap assays from isoforms 1 and
2 were loaded separately to avoid the need for over-exposure of isoform 1 to visualize and quantify isoform 2. Shown in histograms
are means ± SD. P values from ANOVA with Tukey's post-hoc. For panels (B) and (C): Iso: isoform.
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We next examined the aggregation of both isoforms through filter-retardation. We loaded
samples of each isoform side by side (figure 2.5B) as well as separately (figure 2.5C) to show how
much lower isoform 2 protein levels are compared to isoform 1 in this assay, similar to what we
observe in western blots. For quantification, however, we loaded preparations from both isoforms
on separate filter papers and membranes, which were then processed simultaneously. Over the
course of 14 days, we observe a clear and statistically significant increase in the amount of
aggregated isoform 1 trapped on the membrane (figure 2.5B, C). We do not observe the same trend
with isoform 2 over the same time course. In fact, we notice lower levels of filter-trapped species
on days 7 and 14 compared to day 1 (figure 2.5C). Reduced levels of filter-trapped ataxin-3 isoform
2 from day 1 to day 7 could be due to different types of aggregates formed over time by isoform 1
than 2, as hinted at by the SDS-resistant smears in figure 2.5A. Future work, utilizing pure
isoforms, is necessary to precisely differentiate the types of oligomeric and higher-order species
that each isoform generates. At this point, we can conclude that over the course of two weeks in
fly neurons we observe increased aggregation of pathogenic ataxin-3 isoform 1, but not of isoform
2, in two independent assays. Increased aggregation of isoform 1 over this time course could be
due to the much lower protein levels of isoform 2—if there is less protein available to aggregate,
quality control processes might more easily “handle” it, rendering the protein less toxic.
2.3.4

Isoform 2 at protein levels comparable to isoform 1 is no less toxic in Drosophila
Above, we observed that isoform 2 is much less toxic in flies than isoform 1 of pathogenic

ataxin-3. This property of isoform 1 coincides with its higher protein levels. If both isoforms are
expressed at the same protein level, is isoform 2 still less toxic to Drosophila? To address this
question, we used fly genetics to express isoform 2 so that its protein levels are similar to isoform
1.
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We used a different isoform 1-expressing fly line for these assays. As we showed in figure
2.3A, expression of isoform 1 in all tissues leads to developmental lethality. However, for work
that we published before[223,234] we prepared another fly line that expresses isoform 1 of
pathogenic ataxin-3 at protein levels lower than the current transgene (this line is denoted as
“weaker line” figure 2.6A and supplemental figure S2.4). The ataxin-3-encoding transgene in this
line is also inserted on the third chromosome of the fly and is on the same genetic background as
the other two isoform lines we described above. Flies expressing the “weaker” version of isoform
1 in all tissues can eclose as adults and survive for a number of days. We generated flies that
contain one or two copies each of the driver and isoform 2 and used the sqh-Gal4 driver to examine
their relative toxicity in all fly tissues. We selected this driver, because ataxin-3 is a ubiquitously
expressed protein and because in the above studies isoform 1 was consistently more potently toxic
than isoform 2, regardless of expression pattern. Thus, we proceeded with ubiquitous expression
for this set of investigations.
Increased copy number of driver and isoform 2 leads to higher isoform 2 protein levels
(figure 2.6B) and increased lethality (figure 2.6C) compared to trans-heterozygous flies, as
expected. Based on western blotting, double-homozygous driver;isoform 2 flies express ataxin-3
at protein levels comparable to the weaker isoform 1 (figure 2.6B). Flies that harbor two copies
each of driver and transgene are able to emerge as adults and survive for ~25 days. When we
compare the longevity of these flies to those expressing the weaker isoform 1 line, we observe
comparable survival curves (figure 2.6D; statistical analysis indicates that there is a significant
difference in overall longevity of flies expressing isoform 2 compared to the weaker isoform 1expressing line). Based on these results, isoform 2 is decidedly toxic in the fly when at protein
levels similar to isoform 1.
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Figure 2.6 Isoform 2 is no less toxic than isoform 1 when at comparable protein levels.
A) Western blots of flies expressing the noted ataxin-3 isoform transgenes in all neurons. Flies were one day old. Shown in
histograms are means ± SD. P values from student's t-tests comparing isoform 1 and isoform 2 to the weaker isoform 1. For these
blots we utilized the pan-neuronal Gal4 driver, since use of the ubiquitous one results in late pupal and pharate adult lethality from
isoform 1. For a blot showing levels of the three ataxin-3 transgenes when expressed ubiquitously in flies, see Supplemental fig. 4
where we show results from pupal lysates. B) Western blots of one-day-old adult flies with the noted genotypes. Each lane is an
independent repeat. Shown in graph are means ± SD. P values from ANOVA with Tukey's post-hoc. Iso: isoform. C) Longevity
assays when flies express isoform 2 in all tissues. sqh-Gal4 was the driver. For perspective, flies without pathogenic ataxin-3 live
>70 days (e.g. Fig. 3). P values from log-rank tests. D) Longevity of adult flies with the noted copies and transgenes. Curve from
isoform 2 is the same as in panel C, since these assays were conducted at the same time. P value from log-rank test.

2.3.5

Degradation of ataxin-3 by autophagy and the proteasome in Drosophila
Isoforms 1 and 2 mRNA levels are similar in the fly (figure 2.1C), but isoform 2 protein

levels are much lower in all tissues tested (figures 2.2, 2.3, 2.4, 2.5, 2.6) suggesting that it is turned
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over more rapidly than isoform 1. The two major degradative routes in the cell are the proteasome
and autophagy. We used fly genetics to examine the role of each pathway in determining the levels
of ataxin-3. We expressed ataxin-3 isoform 1 or 2 by itself or in the presence of RNAi constructs
targeting autophagy or proteasome components. For these analyses we limited expression to the
eye, because knockdown of these genes more widely is lethal in flies, whereas targeting in fly eyes
is tolerated ([252] and other observations from the Todi lab). Our findings from these assays are
summarized quantitatively in figure 2.7A. Expression of isoform 2 in fly eyes results in its lower
protein levels compared to isoform 1 (figure 2.7B), similar to what we observe in all other fly
tissues examined. Where available, we used more than one RNAi line per gene, but in some cases
we only had one line available. We reasoned that this approach is not unreasonable to explore the
role of autophagy and of the proteasome on isoform protein levels, since we are focusing on a
general pathway rather than a specific gene.
For autophagy we targeted Atg7, Atg8a and Atg12, which are critical for the formation and
expansion of the autophagosome [257,258]. Atg8, a member of the ubiquitin-like proteins of the
LC3 family, becomes conjugated to phosphatidylethanolamine at autophagosome-forming sites,
where it plays a role in membrane dynamics and substrate recruitment [257]. Atg12 is constitutively
conjugated to Atg5. The Atg12-Atg5 conjugate is essential for Atg8 lipidation and thus essential
for autophagosome formation [257,258]. We observe that targeting Atg12 and Atg8a though RNAi
leads to a significant increase in protein levels for both isoforms (figure 2.7A and blots 2.7B-G).
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Figure 2.7 Knockdown of autophagy or proteasome components leads to increased isoform protein levels in Drosophila.
A) Summary of quantification of the data in panels B-J and other experimental repeats not included. Histograms show
means ± SD. P values from student's t-tests. N ≥ 3 for each group. B–J) Western blots of dissected fly heads expressing either
isoform 1 or 2 of pathogenic ataxin-3 on RNAi control background or with RNAi constructs targeting the noted genes. Numbers
associated with RNAi lines indicate different constructs targeting the same gene. Lack of numbers means that only one RNAi line
was at hand for that gene. Black arrow: main ataxin-3 band. Red arrow: potentially phosphorylated form of ataxin-3. Blue arrows:
ubiquitinated species of ataxin-3. Black bar in panel (B): SDS-resistant species. In panels D and E, images are from the same
membrane, same exposure, cropped and rearranged for viewing. C: controls, containing the driver (GMR-Gal4) and either isoform
of ataxin-3 on the genetic background of the RNAi line. Signal was quantified from the entire lane for each well and used in panel
(A).
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Overall, the effect is not very robust, ranging from 50%-100% increase in protein levels. These
findings are limited to the effect from one RNAi line for each gene; results from the other RNAi
line do not reach significance, probably due to differential capacity from each RNAi construct to
reduce mRNA levels of the intended gene.
Next, we turned to the proteasome. The proteasome comprises a 20S degradative core and
one or two 19S regulatory components[259-263]. We focused on Rpn1 (part of the 19S, where it
helps with proteasome substrate binding [264]) and the 20S proteolytic core components α5 and
β6[259-263]. Targeting of each of these genes by RNAi leads to a statistically significant and robust
increase in the protein levels of isoform 2, reaching as high as 400% (figure 2.7A, F, H, I). For
isoform 1, targeting of Rpn1 and β6 also leads to higher protein levels (figure 2.7A, C, E). For
Rpn1, three different RNAi lines lead to statistically increased protein levels for isoform 2, but
only one line leads to higher levels for isoform 1 (figure 2.7A, C, E, F, H, I, J).
Collectively, we interpret these results to suggest that the proteasome and autophagy are
both involved in the degradation of isoform 2 of pathogenic ataxin-3. The results are not as
significant with isoform 1, but since targeting of at least one gene in each pathway leads to
increased protein levels of this isoform as well, we are confident in concluding that isoform 1 is
also a target of both pathways, in concurrence with prior reports[53,206,220]. Based on our
observations, the proteasome is critically important for ataxin-3 degradation, with contribution
from autophagy.
2.3.6

Isoform 2 is turned over more rapidly than isoform 1 in mammalian cells
All of our assays thus far employed an intact organism, the fruit fly. The isoforms we

examined are of human origin and thus would benefit from investigations in a mammalian
environment. We used the same constructs from fly-based work to examine the levels of both
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pathogenic ataxin-3 isoforms in mammalian cells. The objective for this next set of experiments
was to determine whether isoform 2 of pathogenic ataxin-3 is degraded more rapidly than isoform
1 and whether the proteasome and autophagy are involved.
As shown in figure 2.8A, when either isoform is transiently transfected in HeLa cells, we
observe much lower protein levels of isoform 2 than isoform 1. Inhibiting the proteasome (MG132)
markedly increases the levels of isoform 2, approaching the protein levels of isoform 1 (figure
2.8A). Similarly, when we inhibit autophagy (chloroquine), we observe modestly, but statistically
significantly increased levels of isoform 2 (figure 2.8B). We do not see a clear upregulation of
isoform 1 in the presence of MG132 or chloroquine (figure 2.8A and B). This is likely because of
the long half-life of ataxin-3 [243,265,266] requiring prolonged incubation with inhibitors to observe
an effect, as shown in supplemental figure S2.5.
We next determined that the lower levels of isoform 2 protein are due to its expedited
degradation in cells. We inhibited new protein translation with cycloheximide (CHX). Isoform 1
is rather stable over the course of 6 hours whereas isoform 2 is degraded quite rapidly (figure
2.8C). Considering the strong effect of proteasome inhibition on the levels of isoform 2 (figure
2.8A), we examined whether MG132 halts the degradation of isoform 2. As shown in figure 2.8C,
in the presence of MG132 degradation of isoform 2 is essentially halted.
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Figure 2.8 Isoform 2 is turned over more rapidly in HeLa cells.
A & B) Western blots from HeLa cells transiently transfected with plasmids encoding either isoform of pathogenic ataxin-3 and
treated, or not, with the proteasome inhibitor MG132 (20 μM) or with chloroquine (100 μM) for 6 h before harvesting. Every lane
is from an independent repeat. Each well of cells received 1 μg plasmid of the indicated isoform. Arrow in (B): main ataxin-3 band.
Histograms are from blots above and other independent repeats. P values from student's t-tests comparing treated lanes to respective
untreated lanes of the same construct. C) Western blots of whole cell lysates from HeLa cells transiently transfected as noted then
treated with cycloheximide (CHX; 100 μg/ml) for the indicated amounts of time, as well as MG132, where applicable (20 μM).
Wells received a higher amount of isoform 2 than isoform 1 (4:1 ratio; isoform 1 plasmid was supplemented with empty vector to
bring it to the same total amount as isoform 2) to more closely approximate the amount of isoform 2 protein to isoform 1 at time
0 h. The two sets of blots are from independent experiments. Quantifications are from blots on the top and other, independent
repeats. P values from student's t-tests comparing isoform 2 to isoform 1 for the middle graph, and the two right columns to the
left-most column in the bottom graph. Shown in graphs are means ± SD.

The experiments above were conducted in HeLa cells. We conducted similar studies in
HEK-293T cells in order to recapitulate our findings in another mammalian cell line. Again we
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observe lower levels of isoform 2 than isoform 1 (supplemental figure S2.6), mirroring the results
we observed in HeLa cells (figure 2.8A-C). Proteasome inhibition has a strong impact on the levels
of isoform 2, whereas application of chloroquine does not lead to noticeable changes in its protein
levels. As in HeLa cells, we again observe that isoform 1 is not readily impacted by the application
of proteasome or autophagy inhibitors in HEK-293T cells. Based on these results, we conclude
that isoform 2 is degraded more rapidly by the proteasome than isoform 1 in mammalian cells,
with additional, minor contribution from autophagy.
2.3.7

The role of the C-terminus on the stability of isoform 2
The only difference between the two ataxin-3 isoforms is at their C-termini and isoform 2

is degraded decidedly more rapidly than isoform 1. Rapid turnover of isoform 2 could be due to
the recognition of its tail end by degradative machineries, with its C-terminus essentially
functioning as a degron (amino acid sequences that signal host protein turnover). Degron
sequences function alone or in conjunction with internal lysine residues that enable their
ubiquitination to target host proteins for degradation, and can be found at either terminus or
internally in a protein [267-269]. If the tail of isoform 2 acts as a degron, then its addition to isoform
1 should lead to lower protein levels. It is also possible that the C-terminus of isoform 1 instead
stabilizes its host protein; thus, its fusion onto isoform 2 might increase its protein levels.
We fused the C-terminus of isoform 1 onto the end of isoform 2 and vice versa (figure
2.9A). As shown in figure 2.9B, C, and F, addition of the C-terminus of isoform 1 onto isoform 2
leads to higher levels of this protein in a proteasome-dependent manner; autophagy does not seem
critical. The levels of the new construct now approach those of isoform 1 (figure 2.9B, C and F),
and are much higher than the levels of the original isoform 2. Conversely, fusion of the C-terminus
of isoform 2 to the end of isoform 1 leads to significantly lower protein levels (figure 2.9D, E); the
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new resulting protein is at levels comparable to those of isoform 2 (figure 2.9F). Proteasome
inhibition results in higher levels of isoform 1 with the C-terminus of isoform 2 (figure 2.9D, F);
autophagy again does not seem to have a noticeable impact (figure 2.9E, F).

Figure 2.9 The C-termini of isoforms 1 and 2 are important for host protein levels.
A) Summary of constructs generated and used in panels B–E. B–E) Western blots of whole cell lysates from HEK-293T cells
transiently transfected with 0.5 μg of the indicated plasmids and then treated, or not, for 6 h with MG132 (20 μM; panels B & D)
or chloroquine (100 μM; panels C & E). Each lane is from an independent repeat. F) Histograms from samples in panels B–E and
other experimental repeats. N ≥ 3 for each group. P values from ANOVA with Tukey's post-hoc. For all panels, Iso: isoform. MG:
MG132, CQ: Chloroquine.

From these assays, it appears that the C-terminus of isoform 2 has a destabilizing effect on
its host protein. At the same time, the C-terminus of isoform 1 might also protect ataxin-3 protein
from degradation. The current setup does not entirely exclude the possibility that the stabilizing
effect of the C-terminus of isoform 1 onto isoform 2 prevents the recognition of the tail-end of
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isoform 2 as a potential degron. It should be noted, however, that all of the ataxin-3 constructs
used here are capped by an HA epitope tag at their C-termini (figure 2.9A); if the C-terminus of
isoform 2 must be at the very tail-end of ataxin-3 to destabilize it, then the HA tag should have
also precluded its recognition for degradation and would have presumably led to protein levels
comparable to isoform 1. Thus, it is still quite possible that the C-terminus of isoform 1 has a
stabilizing effect on the rest of ataxin-3. Altogether, these data suggest that the C-terminus of
ataxin-3 is important for the overall levels of the SCA3 protein, unlocking new paths to consider
for the handling of this protein in the cellular environment.
2.4

Discussion
The work presented here sheds new light on the relative pathogenic contribution of the two

major ataxin-3 isoforms in SCA3. Two full-length ataxin-3 protein variants arise from alternative
splicing of the ATXN3 gene, in which the abnormal expansion of a polyQ-encoding CAG triplet
repeat causes SCA3. Each isoform contains the same N-terminal portion and polyQ domain but
differs at the C-terminus. The objective of this study was to investigate the possibility of
differential toxicity from the two main, full-length isoforms that are expressed in the mammalian
brain. Our fly-based investigations show that polyQ-expanded isoform 2 is less toxic than polyQexpanded isoform 1, as a result of lower protein levels. Isoform 2 is more rapidly degraded,
principally by the proteasome, leading to reduced aggregative propensity and toxicity in all fly
tissues tested. Thus, polyQ-expanded isoform 2 of pathogenic ataxin-3 is not likely to be a major
contributor to SCA3. (We note here that expression of ataxin-3 with a normal polyQ repeat (2225Q) is not toxic when present throughout the fly or in select tissues (e.g. neuronal, eye or glial)
using the same drivers as in this work ([215,216] and additional, unpublished observations by the
Todi lab).)
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Prior work with isoforms 1 and 2 in vitro and in mammalian cells observed higher
aggregation of isoform 2 than isoform 1 [1], which differs from what we observe in flies. The tail
of isoform 2 is inherently more hydrophobic than that of isoform 1 [1], most likely accounting for
its enhanced aggregation in the earlier study. However, the isoforms might behave differently in
an intact organism, leading to higher aggregation of isoform 1 than 2. Another key point that may
explain this difference is the fact that isoform 2 is present at much lower protein levels in fly
models, thus presenting a reduced challenge for quality control pathways that regulate its folding
and aggregation. There may also be cell type- and tissue-specific differences in the aggregative
propensity of one isoform over the other in the mammalian brain. Addressing this last point will
require the generation of additional tools that can reliably and consistently identify one species
over the other in the mammalian brain. Based on our work in fly neurons, we can only conclude
that the two isoforms behave differently, with isoform 1 more likely to aggregate than isoform 2.
A recent study investigated ataxin-3 isoform properties in cultured mammalian cells (HEK293T) by utilizing ATXN3 knockout cells and transiently expressing the ataxin-3 isoforms
described here [213]. This other work included yet another variant of ataxin-3 with a premature
stop codon in isoform 2 (figure 2.1A), a variant which we did not investigate, choosing instead to
focus on the full-length proteins for this manuscript. Both versions of isoform 2 (early-stop and
full-length) exist in SCA3 patients. Results from this prior publication do not mirror our
observations: it concluded that full-length isoforms 1 and 2 harboring the polyQ expansion are
degraded similarly in HEK-293T cells and that autophagy, rather than the proteasome, primarily
mediates their turnover [213]. Instead, we observed clear proteasome involvement and rapid
degradation rates for isoform 2 compared to 1. Supporting the present observations, an earlier
investigation also found that isoform 2 is more rapidly cleared in a proteasome-dependent manner
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in cultured Cos7 cells [1]. How might we resolve these differences? Autophagy likely participates
in the degradation of pathogenic ataxin-3 and has been reported before as a key component in
ridding the cell of the SCA3 protein[53,54,206,220,270,271]. Depending on specific conditions and
types of stress, one pathway may predominate over the other in importance for ataxin-3
degradation. With respect to the degradation rates of each isoform, our overall results and prior
published work [1] lead us to propose that under most cases isoform 2 is less stable than isoform 1
of pathogenic ataxin-3, regardless of the mechanism of clearance.
Our work raises an intriguing question: what property of isoform 2 renders it more rapidly
degraded? We suggest that the C-terminus of isoform 2 might act as a degron, signaling the
degradation of the host protein. Whether the tail of isoform 2 is directly recognized by degradative
machineries as a signal, or whether its ubiquitination is required for the protein to be eliminated,
awaits determination. We have shown before that ataxin-3 does not require its own ubiquitination
to be degraded [266]; it may well be that the C-terminus of isoform 2 directly targets the host protein
to the proteasome through specific protein-protein interactions. Our studies also present the
additional possibility that the C-terminus of isoform 1 stabilizes its host protein. The tail of isoform
1 could protect the rest of the protein from degradation through specific binding partners that
preclude the degradation of ataxin-3, similar to what we have observed for ataxin-3 and
Rad23[223,266]. As argued in work by other scientists [213], the two different C-termini of ataxin3 have differing binding partners—e.g. ubiquitin can bind the tail of isoform 1 but not isoform 2
due to the lack of UIM3—that may dictate their stability and functions. Additional explorations
into the precise nature of isoform 2 degradation may unlock new mechanisms of protein quality
control that could be of importance not only to understanding SCA3 but also more generally the
principles guiding protein turnover in this and other disease states.
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In conclusion, we investigated whether the two main, full-length ataxin-3 isoforms are
differentially toxic in vivo when harboring an abnormally expanded polyQ repeat. Our results
reveal marked differences in isoform toxicity due to differences in the stability of the two variants
of the SCA3 protein. Defining the properties and propensities of various products expressed by a
disease gene, as done here for SCA3, is necessary to comprehend how that disease arises and how
to treat it.
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3.1

CHAPTER 3: UBIQUITIN-INTERACTING MOTIFS OF ATAXIN-3 REGULATE
ITS POLYGLUTAMINE TOXICITY THROUGH HSC70-4-DEPENDENT
AGGREGATION
Introduction
Spinocerebellar Ataxia Type 3 (SCA3; also known as Machado-Joseph Disease) is the

most frequent dominant ataxia worldwide. SCA3 is caused by CAG repeat expansion in the gene
ATXN3 that is normally 12-42 repeats long, but is expanded to ~60-87 repeats in patients [2,206].
This triplet repeat encodes a polyglutamine (polyQ) tract in the protein ataxin-3, a deubiquitinase
(DUB; figure 3.1) implicated in protein quality control and DNA repair [206,272]. The precise
molecular details of SCA3 pathogenesis remain unclear.
SCA3 is one of nine neurodegenerative disorders caused by abnormal polyQ expansion in
diverse proteins [2,206]. The polyQ family includes Huntington’s Disease (HD), SCAs 1, 2, 3, 6,
7, and 17, Dentatorubral–pallidoluysian atrophy, and Kennedy’s Disease. Together, HD and SCA3
are the two most common among the nine known polyQ diseases. Although each polyQ disorder
is caused by aberrant lengthening of the same domain, they are clinically distinct diseases
[2,3,37,206,273,274]. Fundamental to polyQ disorders is the role of protein context: regions outside

of the polyQ that modulate properties of the elongated tract [2,3,37,216,222,223,266,273,274]. It is
protein context that differentiates polyQ diseases; why, for example, expansions in ataxin-3 cause
SCA3 instead of another disorder. While studies of other polyQ diseases provided insight into the
role of protein context in polyQ neurodegeneration [2,3,37,273,274], for SCA3 protein context has
not been clarified. For instance, in SCA1 the nuclear localization signal directs its disease protein,
ataxin-1, to the nucleus and is necessary for pathogenesis [37,160]. Studies in SCA7 also identified
interactions with other proteins that show a role for non-polyQ domains in the toxicity of its disease
protein, ataxin-7 [3,194,273]. Another good case of polyQ protein biology and expression pattern
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being connected to phenotype is Kennedy's Disease. In this disorder, polyQ expansion occurs near
the amino terminus of the androgen receptor (AR) resulting in a partial loss of AR function that
leads to androgen insensitivity. AR is expressed in motor neurons of the spinal cord and the
brainstem, where it mediates neurotrophic responses. It is these neurons that degenerate in
Kennedy's Disease [2,3,130,275,276].
To understand the role of protein context in SCA3, we focused on the domains of ataxin3. Ataxin-3 contains a ubiquitin-protease (Josephin) domain on its N-terminal half [206,272] (figure
3.1A). Within it are the catalytic triad that enables ataxin-3 to cleave ubiquitin bonds, as well as
two ubiquitin-binding sites (UbS) that either interact with ubiquitin (UbS1), or with ubiquitin and
the proteasome-associated protein, Rad23 (UbS2) [206]. Downstream are two ubiquitin-interacting
motifs (UIMs 1 and 2), followed by a site that binds the AAA ATPase, VCP (VCP-binding motif;
VBM), and the polyQ tract [206]. At the end resides a third UIM (UIM3) [206,272]. In another, less
common isoform UIM3 is replaced by a hydrophobic C-terminus [1,62,277]. UIMs enable ataxin-3
to bind poly-ubiquitin [212,225,244].
We previously examined the role of three domains of ataxin-3 in its pathogenicity: UbS2,
VBM and the catalytic site. UbS2 regulates ataxin-3 turnover and toxicity [216,223,266]; the VBM
controls its aggregation and toxicity, but not turnover [216,222,266]; and the catalytic site is
necessary for ataxin-3's inherent neuroprotective functions in [215,216,223]. These findings led us
to examine the role of other domains of ataxin-3 by using novel, isogenic lines of the model
organism, Drosophila melanogaster. Here, we show that toxicity from ataxin-3's polyQ tract is
markedly impacted by the UIMs. Whereas the isolated polyQ is decidedly pathogenic, UIM
addition enhances toxicity. Mutating the UIMs of full-length, pathogenic ataxin-3 renders it less
pathogenic. UIMs interact with heat shock protein cognate 4 (Hsc70-4), which enhances ataxin-3
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aggregation and toxicity in a manner dependent on these ubiquitin-binding domains. Additional
studies indicate that Hsc70-4 enhances the aggregation of other polyQ proteins and provide a
comprehensive view of the relative impact of various ataxin-3 domains on its pathogenicity. We
introduce unique genetic tools to understand SCA3 biology and to discover and optimize
therapeutic options for it. Our studies provide novel insight into protein context in SCA3 and
highlight Hsc70-4 as a new target for intervention.
3.2
3.2.1

Materials and Methods
Antibodies
Anti-ataxin-3 (mouse monoclonal 1H9, MAB5360, 1:500-1,000; Millipore), anti-MJD

(rabbit polyclonal, 1:15,000 [211]), anti-HA (rabbit monoclonal C29F4, 1:500-1,000; Cell
Signaling Technology), anti-V5 (mouse monoclonal R960-25, 1:500-1,000; ThermoFisher), antitubulin (mouse monoclonal T5168, 1:10,000; Sigma-Aldrich), anti-lamin (mouse monoclonal
ADL84.12-5, 1:1,000; Developmental Studies Hybridoma Bank), anti-HSPA8/Hsc70-4 (rabbit
monoclonal D12F2, 1:1,000; Cell Signaling Technology), peroxidase conjugated secondary
antibodies (goat anti-mouse, goat anti-rabbit, 1:5,000-10,000; Jackson Immunoresearch).
3.2.2

Drosophila materials and procedures
Flies were housed at 25°C in diurnal environments on conventional cornmeal or RU486-

containing media. Common stocks were from Bloomington Drosophila Stock Center: GMR-Gal4
(#8121); isogenic host strain attP2 (#36303); Hsc70-4 RNAi lines #1, 2, and 3 (#28709, #34836,
and #35684, respectively), GMR-QF2W (#59283), and ATXN3TR-Q78 (#8141). Gifts included:
sqh-Gal4 (Dr. Daniel Kiehart, Duke University), elav-GS-Gal4 (Dr. R. J. Wessells, Wayne State
University), elav-Gal4 and repo-Gal4 (Dr. Daniel Eberl, University of Iowa). All flies were
heterozygous for driver and transgene.

73

Ataxin-3

cDNAs

were

based

on

sequences

from

previous

publications

[1,212,216,222,223,225,265,277]. These include Ataxin-3(SCA3): -Intact, -Catalytically Inactive, -

UbS2 mutated, -VBM mutated; as well as isolated polyQ80, UIM1-2-Q80, Q80-UIM3, UIM1-2Q80-UIM3, and Ataxin-3(SCA3)-UIMs mutated. Transgenes were sub-cloned into pWalium10.moe. Transgenic lines were generated via phiC31 integration into attP2 on chromosome 3
[174,216,222,223,277]. An additional ataxin-3 line was generated for figure 3.8 with the same

sequence as in figure 3.1A, but with a V5 tag, using plasmid pQUASp and driven by GMR-QF2W.
All transgene insertions were validated by PCR and genomic sequencing and Western blotting,
using procedures described before [174,216,222,223,252,277].
For longevity and motility, adults were collected on day of eclosion. Deaths were recorded
daily. Motility was tested weekly. For motility, adults were transferred into fresh vials 1h before
assessment. Then, the percentage of flies per vial to reach the top at 5, 15, and 30s was recorded
after flies were forced to the bottom.
3.2.3

Western blotting and quantification
Unless otherwise specified, 3 or 5 flies (depending on experiment), or 10 dissected adult

heads per group were homogenized in boiling lysis buffer (50mM Tris pH 6.8, 2% SDS, 10%
glycerol, 100mM dithiothreitol), sonicated, boiled for 10m, and centrifuged at 13,300xg at room
temperature for 10m. Western blots were developed using PXi 4 (Syngene), or ChemiDoc (BioRad). Blots were quantified with GeneSys (Syngene), or ImageLab (Bio-Rad), respectively. For
direct blue staining, PVDF membranes were submerged for 10m in 0.008% Direct Blue 71 (SigmaAldrich) in 40% ethanol and 10% acetic acid, rinsed in 40% ethanol / 10% acetic acid, air dried,
and imaged.
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3.2.4

Filter-trap assay
Three adult flies, or 10 dissected heads per group were homogenized in 200μl NETN buffer

(50mM Tris, pH 7.5, 150mM NaCl, 0.5% Nonidet P-40), supplemented with protease inhibitor
cocktail (PI; S-8820, Sigma-Aldrich). Lysates were diluted with 200μl PBS containing 0.5% SDS,
sonicated briefly, then centrifuged at 4,500xg for 1m. One hundred μl supernatant was diluted with
400μl PBS. Thirty or 70μl (depending on experimental setup) of each sample was filteredvacuumed using Bio-Dot (Bio-Rad) through a 0.45μm nitrocellulose membrane (Schleicher &
Schuell) that was pre-incubated with 0.1% SDS in PBS. Membrane was rinsed twice with 0.1%
SDS/PBS and analyzed by Western blotting.
3.2.5

Soluble/pellet centrifugation
Ten whole flies per group were lysed in 300μl NETN buffer with PI, sonicated, then

centrifuged at 20,000xg at 4°C for 30m. Supernatant was quantified with the BCA assay
(ThermoFisher). Pellet was resuspended in 200μl of PBS/1% SDS. Thirty μg of supernatant
fraction and 7μl of resuspended pellet was each supplemented with 6X SDS, boiled, and loaded
for Western blotting.
3.2.6

Nuclear/cytoplasmic separation
Fractionation was performed using the ReadyPrep Protein Extraction Kit (Bio-Rad) using

5 whole flies per group that were lysed in Cytoplasmic Extraction Buffer (Bio-Rad). Three times
as much nuclear fraction was loaded onto gels compared to cytoplasmic fraction to eliminate the
need for over-exposure.
3.2.7

Co-immunopurification
Fifteen whole flies or 30 dissected fly heads per group were lysed in 600μl NETN+PI,

tumbled at 4°C for 30m, then centrifuged for 5m at 10,000xg at 4˚C. Supernatant was incubated
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with bead-bound antibody for 2-4h. Then, beads were rinsed 5X with NETN+PI. Bead-bound
complexes were eluted by boiling in Laemmli buffer.
3.2.8

Mass spectrometry
Forty whole flies per group were homogenized in 1mL NETN+PI, sonicated, centrifuged

at 4˚C for 5m at 10,000xg and supernatant was transferred into a fresh microfuge tube. Half of
each sample was incubated with anti-HA beads (ThermoFisher) for 2h, rinsed 4X with NETN and
bead-bound proteins were eluted with Laemmli buffer. The other half was tumbled for 30m with
an equal mixture of Tandem Ubiquitin Binding Entities (TUBEs) 1 and 2 (Lifesensors),
centrifuged to isolate TUBE beads and supernatant was incubated for 2h with anti-HA beads,
rinsed and eluted as above. Eluates were resolved on an SDS-PAGE gel that was stained with
Sypro Ruby (ThermoFisher). Bands of interest were excised and examined by LC/MS/MS at
Wayne State University Mass Spectrometry Core.
3.2.9

Histological preparation
The proboscises and wings of adult flies were removed before fixing overnight in 2%

glutaraldehyde/2% paraformaldehyde in Tris-buffered saline/0.1% Triton X-100. Fixed bodies
were dehydrated in a series of 30, 50, 70, and 100% ethanol for 1h each, washed in propylene
oxide overnight, embedded in Poly/Bed812 (Polysciences), sectioned at 5μm, and stained with
toluene blue.
3.2.10 Statistical analyses
Statistical tests used are specified in figure legends. Log-rank tests with Holm-Bonferroni
adjustments, ANOVA, and Kruskal-Wallis tests were conducted in Prism 8 (GraphPad); student's
t-tests were conducted in Excel (Microsoft) or Numbers (Apple). P values are noted as reported by
the software used. The number of biological replicates is noted on figures and corresponding
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legends. We have also noted in legends whether two-tailed or one-tailed tests were used. Twotailed tests were used where a directionality of change was not necessarily predicted. One-tailed
tests were used where we expected a specific directionality in change between control and
experimental groups. In figures, non-statistically significant outcomes are noted in italicized font,
whereas statistically significant outcomes are in normal font.
3.3
3.3.1

Results
The modulatory role of ataxin-3’s domains on its toxicity

Protein context is a key determinant of polyQ degeneration [2,3,37,130,206,272-275], but its
importance in SCA3 has not been investigated systematically. We previously examined the role of
non-polyQ domains of ataxin-3, UbS2 [216,223,266] and VBM [222] (figure 3.1A). Prior work from
us, spearheaded by pioneering studies from the Bonini lab, also showed that the catalytic site of
ataxin-3 is important for toxicity [214-216,223]. However, the contribution of different domains to
ataxin-3 pathogenicity has not been investigated side-by-side.
Using isogenic fly lines (figure 3.1B), we examined the toxicity of pathogenic ataxin-3
when expressed pan-neuronally in adults using the binary, Gal4-UAS system of expression
[238,278] and a driver that requires the drug RU486 to induce transgenes [250,251,279,280]. We
selected this approach since SCA3 is adult-onset and progressive, and because neurons are the type
of cell impacted. We compared the following full-length, human ataxin-3 versions: intact domains,
catalytically inactive, mutated UbS2 (UbS2* [222,223,266]) and mutated VBM (VBM* [222]; figure
3.1B). The polyQ repeat is 78-80, within patient range [206]. Each transgene is inserted into the
same chromosomal location, attP2, as one copy and in the same orientation, leading to similar
expression [174,179,222,242,252].
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Figure 3.1 Ataxin-3 domains impact its polyQ toxicity.
(A) Diagram of ataxin-3. Josephin: deubiquitinase domain necessary for ataxin-3's ability to cleave ubiquitin bonds ]. UbS:
ubiquitin-binding site; UIM: ubiquitin-interacting motif; RKRR: amino acid sequence necessary for ataxin-3 to bind directly to
VCP, known as VCP-binding motif, VBM. QQQ: polyQ that is expanded in SCA3. Also shown is the amino acid sequence of
human ataxin-3 used. (B) Summary of transgenic fly lines, mutations, and abbreviations. (C) Longevity results when pathogenic
ataxin-3 versions are expressed pan-neuronally in adults. P values: log-rank tests with Holm-Bonferroni adjustment. Italicized P
value: not statistically significant. (D) Means -/+ SD from negative geotaxis tests. Groups are the same as in (C). P values: onetailed, Student’s t-tests comparing lines to control flies of the same day and time point. ‘One-tailed’ tests were chosen based on
the outcomes from longevity data in panel (C), which indicated specific directionality in expectations. If no P value is noted, it was
equal to or greater than 0.05. Exact P values are given in other cases. The total number of flies in each group is shown in panels.
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For panel (D), the number of independent groups of flies per genotype was: Ctrl: 5, Intact: 5, Inactive: 6, UbS2*: 5, VBM*: 5.
Repeats were biological replicates.

Adult, pan-neuronal expression of pathogenic ataxin-3 with intact domains caused early
lethality (figure 3.1C). Catalytically inactive ataxin-3 led to significantly shorter lifespan, as did
the version with mutated UbS2. Mutating the VBM led to markedly longer lifespan compared to
“intact”. Still, flies expressing pathogenic ataxin-3 with mutated VBM did not reach normal
longevity (figure 3.1C). These data were complemented by negative geotaxis assays (figure 3.1D).
We observed reduced motility with flies expressing pathogenic ataxin-3 “intact” and further
impaired motility with those expressing inactive ataxin-3, or ataxin-3 with mutated UbS2. On the
other hand, pan-neuronal expression of pathogenic ataxin-3 with mutated VBM did not
significantly impact motility.
Next, we examined the effect of the same ataxin-3 transgenes in glial cells to obtain
information on toxicity from pathogenic ataxin-3 in this cell type. Overall trends were similar to
neuronal cells: catalytically inactive and UbS2-mutated ataxin-3 led to increased toxicity
compared with pathogenic ataxin-3 with intact domains. But, unlike in neurons, in glial cells we
did observe a statistical difference in toxicity between pathogenic ataxin-3 with mutated catalytic
site and the one with mutated UbS2. There was no statistical difference between controls not
expressing pathogenic ataxin-3 and flies expressing pathogenic ataxin-3 with mutated VBM both
in terms of longevity (figure 3.1 - figure supplement 3S.1A) and motility (figure 3.1 - figure
supplement 3S.1B). These findings highlight a need to explore the role of glia in SCA3.
Based on these collective data, we conclude that domains outside of ataxin-3's polyQ play
significant modulatory roles in pathogenicity. These outcomes led us to ask: what is the role of the
most common domain of ataxin-3, the UIM, in SCA3?
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3.3.2

UIMs enhance toxicity of the isolated polyQ of ataxin-3
To conduct an initial examination of ataxin-3 UIMs in SCA3, we synthesized transgenes

that encode its isolated polyQ by itself or with the sequential addition of UIMs, including a fulllength version (figure 3.2A). We generated isogenic lines that integrated each transgene into locus
attP2, same as flies in figure 3.1. The polyQ for these new flies is encoded by alternating CAGCAA
repeats. Long, pure CAG tracts can lead to mRNA-based toxicity [228] and unconventional
translation of non-polyQ frames [239-241]. Our approach mitigates both possibilities [226-233],
allowing us to focus solely on toxicity from the polyQ and specific domains. Insofar as we know,
ours is the first instance that this approach is undertaken to dissect in detail the role of regions
surrounding a polyQ in an intact organism.
The isolated polyQ80 was more toxic than full-length, pathogenic ataxin-3 when expressed
in all tissues or only in neurons (figure 3.2B, C). This pattern was reversed in glia; full-length
ataxin-3 was more problematic than polyQ80 in these cells, highlighting a need to better
understand glial response to polyQ proteins. Intriguingly, polyQ80 was generally less toxic than
the same peptide with appended UIMs when expressed everywhere, selectively in neurons, or in
glia; addition of UIM3 appeared particularly pathogenetic (figure 3.2B, C). Eye-restricted
expression of these transgenes also led to variable toxicity, with UIM3 addition being more
problematic than the isolated polyQ80 or polyQ80 with all UIMs (figure 3.2D).
Gal4 drivers above enable transgene expression during development and in adults.
Because, as mentioned above, SCA3 is adult-onset, we also investigated the effect of polyQ80
without and with UIMs when expressed pan-neuronally only in adults. PolyQ80 was noticeably
less toxic than versions with UIMs (figure 3.2E). Flies expressing Q80-UIM3 or UIM1-2-Q80
lived longer than those expressing polyQ80 with all UIMs (figure 3.2E).

80

Figure 3.2 UIMs modulate toxicity of the isolated polyQ of ataxin-3.
(A) Diagram (top) and abbreviations (bottom) for transgenes used. The polyQ of ataxin-3 has a lysine interruption after the first
three glutamines (QQQKQQQQ…), highlighted in yellow. (B) Summary of results when the noted transgenes are expressed in fly
tissues. 1st, 2nd, and 3rd instars are progressive larval stages as flies develop from embryos to pupae. Results in table are
representative of independent crosses conducted at least five times each. (C) Graphical summary of results from (B). Solid color
denotes primary observations. (D) Photos of adult eyes expressing transgenes through GMR-Gal4. Photos are representative of
independent crosses conducted at least five times. Protein levels are shown in Figure 3.2—figure supplement 3.2. (E) Longevity
of flies expressing transgenes pan-neuronally in adults. P values: log-rank tests with Holm-Bonferroni adjustment. Italicized P
value: not statistically significant.

There were tissue-dependent variations in toxicity from the above constructs. For example,
Q80-UIM3 was markedly more toxic in fly eyes compared to the polyQ80 alone or with the
addition of other UIMs (figure 3.2D), whereas polyQ80 with all three UIMs was the most toxic
species in adult neurons (figure 3.2E). These are intriguing finding that require future attention;
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also, they are not dissimilar from the neuronal-glial differences we observed in figure 3.1, figure
3.1 - figure supplement 3S.1, and figure 3.2B. These outcomes highlight the utility of the new fly
models that we have generated to understand tissue-selective toxicity in vivo in the future.
Collectively, data in figure 3.2 indicate a regulatory role for UIMs in the pathogenicity of the
expanded polyQ of ataxin-3, and led us to explore them in the full-length protein.
3.3.3

UIMs of full-length ataxin-3 regulate toxicity and aggregation
To investigate a regulatory role for the UIMs in the pathogenicity of full-length ataxin-3,

we generated an additional transgenic line that expresses human ataxin-3 with mutated UIMs
(figure 3A). This line was created through site-directed mutagenesis of the plasmid used to
generate flies in figure 3.2A. The mutations that we selected were previously shown to disable the
ability of ataxin-3 UIMs to bind poly-ubiquitin [212,225,244].
Expression of pathogenic ataxin-3 with mutated UIMs was consistently and markedly less
toxic than its counterpart with intact UIMs in all of the tissues tested (figure 3.3B, C). Motility
assays also showed that adults expressing UIM-mutated ataxin-3 retained mobility longer than
adults expressing pathogenic ataxin-3 with intact UIMs (figure 3.3D). We conclude that mutating
its UIMs renders ataxin-3 significantly less pathogenic.
Next, we examined if reduced toxicity from UIM mutations reflected changes in ataxin-3
levels or aggregation. Mutating the UIMs does not cause loss of ataxin-3 protein (figure 3.4A).
We used three antibodies for this assay: a rabbit monoclonal antibody that recognizes the Cterminal HA tag; a mouse monoclonal antibody that recognizes an epitope upstream of UIM1-2
(1H9); and a rabbit polyclonal antibody generated against full-length ataxin-3 (MJD; [211]). While
there is variance in the exact species recognized by each antibody, overall we conclude that
mutating the UIMs does not deplete ataxin-3 protein. Differences in species likely stem from
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epitopes recognized by each antibody, SDS solubility of different ataxin-3 species, and epitope
exposure on PVDF membrane.

Figure 3.3 Mutating the UIMs of full-length, pathogenic ataxin-3 decreases its toxicity.
(A) Amino acid sequence of full-length, pathogenic ataxin-3 and UIM mutations. (B) Summary of results when ataxin-3 flies, or
non-expressing controls, are monitored during development and in adulthood. Results are representative of independent crosses
conducted at least five times each. (C) Longevity of flies expressing transgenes pan-neuronally, throughout development and in
adults. P value: log-rank test. (D) Negative geotaxis assays of adults expressing pathogenic ataxin-3 and their non-expressing
controls. Shown are means -/+ SD. P values: two-tailed, Student’s t-tests comparing flies at each time point to their corresponding,
non-expressing controls. We selected ‘two-tailed’ tests since we did not know how ‘UIM*’ would perform compared to ‘Ctrl’. If
no P value is noted, it was equal to or greater than 0.05. Exact P values are given in other cases. The number of groups of flies
tested per genotype was: Ctrl: 6, SCA3: 8, SCA3UIM*: 6. Repeats were biological replicates.

Prior work showed that nuclear presence of polyQ disease-causing proteins is a critical
regulator of pathogenicity [3,160,221,281]. Based on sub-cellular fractionation, there was no
significant difference in distribution between ataxin-3 with intact or mutated UIMs (figure 3.4B).
However, according to two different assays, mutating the UIMs rendered pathogenic ataxin-3 less
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aggregation-prone. Centrifugation-based protocols and filter-trap assays both showed higher
aggregation of pathogenic ataxin-3 with intact UIMs (figure 3.4C, D). PolyQ protein aggregation
is a hallmark of this family of diseases [2,3,63,206,273,274]. In our Drosophila studies, aggregation
of pathogenic ataxin-3 and other polyQ proteins precedes toxicity; also, the level of aggregation
mirrors their extent of pathogenicity [174,179,215,216,222,223,277]. Based on data from figures 3.3
and 3.4, we conclude that the UIMs of pathogenic ataxin-3 enhance its aggregation and toxicity in
Drosophila.

Figure 3.4 Mutating the UIMs of pathogenic ataxin-3 decreases its aggregation.
(A) Western blots from simple lysates of adults expressing transgenes pan-neuronally. Red arrows: likely proteolytic products of
ataxin-3 that we observe sometimes. (B) Cytoplasmic/nuclear fractionation of lysates from adults expressing transgenes panneuronally. Histograms: quantification of images from the left and other, independent biological replicates. Means -/+ SD. P value:
two-tailed Student’s t-test. Italicized P value denotes lack of statistical significance. The entire ataxin-3 signal in each lane was
used for calculations, from the main band to the top. (C) Soluble/pellet centrifugation of lysates from adults expressing the noted
transgenes. Histograms are from the left and other, independent biological repeats. Shown are means -/+ SD. P value: two-tailed,
Student’s t-test. The entire ataxin-3 signal in each lane was used for calculations, from the main band to the top. (D) Filter-trap
assay of lysates from adult flies expressing transgenes pan-neuronally. Each image is from an independent biological repeat.
Histograms: quantification of images from left. Means -/+ SD. P value: two-tailed, Student’s t-test. Black arrows in panels: main
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ataxin-3 band. Blue arrows in panels: ubiquitinated ataxin-3. SDS-soluble and -resistant labels are based on our lab’s prior work
with ataxin-3.

3.3.4

UIMs mediate ataxin-3 interaction with Hsc70-4
UIMs exist in proteins with various functions and interact with poly-ubiquitin [272,282-285].

The UIMs of ataxin-3 indeed bind poly-ubiquitin [212,225,244]. Still, we wondered whether proteins
other than ubiquitin also interact with ataxin-3 through UIMs. After all, at least one other ubiquitinbinding domain on ataxin-3, UbS2, interacts with ubiquitin and a non-ubiquitin protein, Rad23
[223,266,286]. To find proteins that interact with ataxin-3 through its UIMs, we homogenized flies

expressing ataxin-3 pan-neuronally and depleted resulting lysates of poly-ubiquitin by using
Tandem Ubiquitin-Binding Entities (TUBEs; Methods). Afterwards, we immunopurified (IP-ed)
ataxin-3 from the supernatants and resolved all proteins on an SDS-PAGE gel (figure 3.5A). We
observed a band above ataxin-3 that was present with intact UIMs, but not as clearly visible when
they were mutated. Mass spectrometry from the dissected regions yielded heat shock protein
cognate 4 (Hsc70-4) only in the presence of ataxin-3 with intact UIMs (figure 3.5A).
We confirmed mass spectrometry data with co-IPs. Full-length, pathogenic ataxin-3 co-IPed endogenous Hsc70-4 in a UIM-dependent manner: whereas pathogenic ataxin-3 with intact
UIMs co-IP-ed Hsc70-4, we did not observe the same with UIM-mutated, pathogenic ataxin-3
(figure 3.5B). The interaction of ataxin-3 with Hsc70-4 could potentially rely more heavily on
UIM3. We inferred this from IPs with isolated polyQ peptides. PolyQ80-UIM3 co-IP-ed
endogenous Hsc70-4 more readily than polyQ80 alone or polyQ80 with UIMs 1 and 2 (figure
3.5C). In panel 5D we conducted co-IPs with modified conditions to approximate more the levels
of the HA-tagged polyQ forms. All three polyQ80 versions co-IP-ed Hsc70-4, but UIM3 appeared
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more important than the two other UIMs in facilitating an interaction. Collectively, these results
highlight the UIMs of ataxin-3 as an interaction site for Hsc70-4 in vivo.
3.3.5

Hsc70-4 enhances aggregation and toxicity of pathogenic ataxin-3
Hsc70-4 belongs to the heat shock protein 70 superfamily, whose closest human orthologue

is the constitutively expressed, heat shock protein family A member 8 (HSPA8 [287]). Alongside
other HSP70 members, its primary role is that of an ATP-dependent chaperone for unfolded
proteins in protein quality control [288-297]. HSPA8 is a part of the ubiquitin-proteasome
degradation system and is also involved in chaperone-mediated autophagy [293,294,298].
Chaperones are presumed to alleviate toxicity from polyQ proteins by refolding or degrading them.
Our studies above, however, counterintuitively hint at the possibility that Hsc70-4 might do the
opposite with ataxin-3, enhancing its polyQ toxicity.
Hsc70-4 is a different member of the HSP70 superfamily than fly Hsc70Cb and human
HSPA1L, both of which were previously reported to suppress polyQ-dependent degeneration
[299-302]. Also, there is recent evidence that HSP70 members have pleiotropic effects on
misfolded proteins [303]. Therefore, we knocked down Hsc70-4 in fly eyes to examine the
possibility that it exacerbates SCA3. We selected fly eyes because widespread targeting of Hsc704 in the fly was developmentally lethal (larval, pupal and pharate adult lethality), whereas
expression in fly eyes was not problematic (clearly present pseudopupil and good overall
morphology). We utilized three independent RNAi lines for Hsc70-4. Expression of each line in
fly eyes led to reduced Hsc70-4 levels (figure 3.6A). Levels of Hsc70-4 in fly eyes were likely
even lower than what was captured by blots; we expressed RNAi in eyes but conducted blotting
using whole heads that also contained tissues where Hsc70-4 was not targeted.
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Figure 3.5 Pathogenic ataxin-3 interacts with Hsc70-4 in a UIM-dependent manner.
(A) SDS-PAGE gel stained for all proteins with Sypro Ruby. Boxed areas were excised and proteins were identified with
LC/MS/MS. Two versions of immunopurifications (IPs) were conducted. Middle panel shows results from IP-ed ataxin-3 from
whole fly lysates. Right panel shows results from IP-ed ataxin-3 after lysates were first incubated with tandem ubiquitin binding
entities (TUBEs; see the main text and Materials and methods). (B–D) Western blots from anti-HA IPs from flies. Results are
representative of independent biological replicates conducted three times. NS: non-specific.

We next determined the effect of knocking down Hsc70-4 on the phenotype caused by
pathogenic ataxin-3 by scoring fly eyes, as exemplified in figure 3.6B; a higher number denotes a
worse phenotype. Hsc70-4 knockdown consistently improved eye phenotype, denoted by the
persistence of the pseudopupil − an indicator of underlying structure integrity − and fewer cases
with depigmentation (figure 3.6C). We also observed biochemical changes in ataxin-3 when
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Hsc70-4 was knocked down. Both SDS-resistant ataxin-3 species and aggregates isolated by filtertrap assays were reduced in the presence of Hsc70-4 RNAi (figure 3.6D, E). Since aggregation of
ataxin-3 is a key determinant of its toxicity in flies [216,222,223,277], suppression of eye phenotypes
by Hsc70-4 knockdown is likely a consequence of reduced SCA3 protein aggregation. Lastly, we
tested the effect of Hsc70-4 knockdown on eye phenotypes from ataxin-3 with mutated UIMs.
Knocking down Hsc70-4 did not have a detectable impact on eye phenotype caused by pathogenic
ataxin-3(UIM*) (figure 3.6F). Collectively, these data highlight Hsc70-4 as an enhancer of
pathogenic ataxin-3 toxicity in a manner dependent on UIMs.

Figure 3.6 Hsc70-4 knockdown improves ataxin-3 toxicity in fly eyes.
(A) Western blots from dissected fly heads. Histograms are from blots on top and other, independent biological repeats. Shown are
means -/+ SD. Statistics: one-way ANOVA with Dunnett's correction. Lysates were from crosses used for studies in panels (B),
(C) and other, similar experimental setups. (B) Representative images and summary of the scoring system designed to evaluate the
effect of Hsc70-4 knockdown on the phenotype caused by pathogenic ataxin-3 in fly eyes. 1: normal-looking eyes that have a
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clearly defined pseudopupil and good overall appearance; 2: eyes where the pseudopupil is not as clearly pronounced compared
with normal eyes and with some minor unevenness/irregularity in peripheral bristle arrangement; 3: eyes where the pseudopupil is
not visible; 4: eyes with depigmentation. Quantitative outcomes are shown in panels (C) intact, pathogenic ataxin-3 and (F) UIMmutated, pathogenic ataxin-3. (C) Statistics: Kruskal-Wallis tests comparing Hsc70-4 RNAi to Ctrl from independent biological
replicates when pathogenic ataxin-3 is expressed in fly eyes. Shown are means -/+ SEM. (D) Western blots from dissected fly
heads. Quantifications are from panels above and independent biological repeats. Shown are means -/+ SD. P values: one-way
ANOVA with Dunnett's correction. Black arrow: unmodified ataxin-3. Red arrow: potentially phosphorylated species that we
observe infrequently. Blue arrows: ubiquitinated ataxin-3. (E) Filter-trap assays. P values: one-way ANOVA with Dunnett's
correction. Shown are means -/+ SD. Images are from the same membrane, cropped and reorganized for clarity. Full lane is
in Figure 6—figure supplement S3.3. (F) Quantification of eye scores as in panels (B) and (C). Shown are means -/+ SEM. ‘N's
signify biological replicates. Italicized P values are not statistically significant. For panels (C) and (F), the numbers at the bottom
of each histogram show the number of flies in each scoring category for that group.

3.3.6

Hsc70-4 knockdown suppresses polyQ toxicity more generally
We were intrigued by the suppressive effect of Hsc70-4 knockdown on pathogenic ataxin-

3. Because we also observed Hsc70-4 co-IP with the isolated polyQ (figure 3.5C, D) we tested
whether its knockdown impacts polyQ80 eye phenotypes. Expression of polyQ80 led to
pseudopupil loss and depigmentation. Knockdown of Hsc70-4 improved depigmentation, even
though it did not recover the pseudopupil, indicative of ameliorated pathology (figure 3.7A).
Importantly, improved eye phenotype was accompanied by reduced polyQ80 aggregates (figure
3.7B). (We note here that we have not observed a single, non-aggregated band of polyQ80 by
Western blots; we only observe aggregated species.)
We confirmed a protective effect from Hsc70-4 knockdown in yet another polyQ model
[304]. This model contains polyQ78 and the C-terminus of an ataxin-3 isoform that lacks UIM3;
UIMs 1 and 2 are also absent. Because expression of this polyQ species does not always yield a
clear external eye phenotype, we examined internal structures. Normally, the ommatidia (eye
units) are organized in a fan-like pattern, which was absent in the presence of polyQ78 (ATXN3TRQ78; figure 3.7C). When Hsc70-4 was knocked down, the ommatidia were visible in a clear sign
of toxicity suppression. Altogether, these results suggest the possibility of a wider role for Hsc704 as an enhancer of toxicity from different polyQ proteins.
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Figure 3.7 Hsc70-4 knockdown improves toxicity from independent, truncated polyQ models.
Representative images of fly eyes (A, C) and fly eye sections (C) with the noted genotypes. Photos are representative of results
from three independent sets of crosses. (B) Western blots from dissected heads. Results from two independent biological repeats
are shown. ‘Ctrl’ in blue font did not express polyQ80. NS: non-specific.

3.3.7

UIMs are important for inter-ataxin-3 interactions
So far, we observed that Hsc70-4 affects aggregation and toxicity of pathogenic ataxin-3

and that it interacts with the SCA3 protein through UIMs (figures 3.5, 3.6). Since our data also
implicated Hsc70-4 in the toxicity of an isolated polyQ that does not contain UIMs (figure 3.7) we
wondered whether the UIMs of ataxin-3 have additional properties that might impact SCA3 protein
aggregation.
Ataxin-3 proteins bind each other [243,305-307]. Therefore, we investigated whether the
UIMs play a part in inter-ataxin-3 associations. We examined whether HA-tagged, pathogenic
ataxin-3 with intact or mutated UIMs co-IPs V5-tagged pathogenic ataxin-3 with intact UIMs in
Drosophila. We found that the UIMs were important, but not necessary, for these interactions; a
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reduced amount of full-length, V5-tagged pathogenic ataxin-3 co-IP-ed with UIM* ataxin-3
compared to ataxin-3 with intact UIMs (figure 3.8A). Additional co-IPs using truncated polyQ
fragments and ataxin-3 with a wild-type polyQ indicated that UIM3 is more important for this
interaction than UIMs 1 and 2 (figure 3.8B) and suggested that the UIMs are involved not only in
the interaction of disease-causing ataxin-3, but also in the unexpanded version. It is not unexpected
that the UIMs are not essential for ataxin-3 interactions; in vitro experiments showed that the Nterminal, Josephin domain facilitates inter-ataxin-3 associations [305-307]. Thus, the UIMs of
ataxin-3 enable inter-ataxin-3 interactions, which might additionally contribute to aggregation and
toxicity

in

SCA3.

Figure 3.8 UIMs are important for inter-ataxin-3 interactions.
(A, B) Western blots from IPs of ataxin-3 with expanded (A) or wild-type (B) polyQ repeats expressed in fly eyes. All transgenes
(HA- or V5-tagged) were expressed at the same time and in the same tissues. Gray arrow: V5-positive signal absent in IP lanes.
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Red arrows: likely proteolytic fragments. Black arrows: unmodified proteins. Blue arrows: ubiquitinated ataxin-3. NS: non-specific.
Images are representative of independent biological experiments conducted thrice.

3.4

Discussion
In this study, we systematically explored the role of protein context in SCA3 in an intact

organism. We found that the UIMs of ataxin-3 are key players in pathogenicity through an
unexpected role from Hsc70-4, which exacerbates SCA3. We propose that Hsc70-4 increases the
toxicity of pathogenic ataxin-3 by interacting with its UIMs and worsening polyQ aggregation
(figure 3.9A). Additionally, since the UIMs facilitate inter-ataxin-3 binding, misfolded ataxin-3
proteins may be brought into close proximity that can further increase their chances of interaction,
aggregation and toxicity (figure 3.9A); as mentioned earlier, in our Drosophila studies of SCA3,
ataxin-3 aggregation is consistently linked to its extent of pathogenicity. Our work provides the
first, comprehensive view of the role of non-polyQ domains on ataxin-3 toxicity (figure 3.9); it
furthermore highlights an understudied and impactful property of a member of the normally
beneficial HSP70 superfamily.
We previously reported on the role of three ataxin-3 domains on its polyQ toxicity: the
catalytic domain, UbS2 and the VBM (figure 3.9B). Based on our work in Drosophila, the catalytic
domain is important for ataxin-3's ability to induce production of DnaJ-1/Hsp40, whose
upregulation suppresses polyQ toxicity [216,223]. The capacity of ataxin-3 to upregulate DnaJ-1
also requires its binding to the proteasome-associated protein, Rad23 at UbS2 [216,223]. Through
upregulated DnaJ-1, ataxin-3 suppresses its own polyQ-dependent toxicity [215,216,223]. Therefore,
it is not surprising that mutating either the catalytic site or UbS2 on pathogenic ataxin-3 renders
the protein more toxic. The general suppressive contribution of each domain to ataxin-3 polyQ
toxicity, as measured by longevity, is similar.
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Unlike the catalytic site and UbS2, the other domains investigated here − VBM and UIMs
− act as enhancers of ataxin-3 polyQ toxicity. Elegant work by the Wanker and Bonini labs
identified a region immediately preceding the polyQ of ataxin-3 as the binding site for VCP ([308];
figure 3.9B). The stoichiometry of this interaction was suggested to be 4 ataxin-3 proteins for 1
VCP hexamer [308]. These results and our findings that VCP binding enhances ataxin-3
aggregation and toxicity [222] led us to propose that the interaction of multiple ataxin-3 proteins
with a single VCP hexamer increases their chances of interaction and accelerates aggregation
([222]; figure 3.9B). The other domains that enhance the toxicity of ataxin-3 are the UIMs. Their
relative impact on ataxin-3 polyQ toxicity might be stronger than the VBM (figure 3.9 - figure
supplement 3S.4). Our results strongly implicate Hsc70-4 as a driving force behind the role of the
UIMs as enhancers of ataxin-3 pathogenicity.

Figure 3.9 Proposed model.
(A) Ataxin-3 UIMs enable its interaction with Hsc70-4 and other ataxin-3 proteins, both of which enhance aggregation and toxicity.
UIM3 (thicker lines) appears to be a stronger contributor to these interactions than the other UIMs (thinner lines). (B) Summary of
results from the current study and our prior publications on the effect of ataxin-3 domains on its polyQ toxicity. Ub: ubiquitin.
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It is intriguing that knockdown of Hsc70-4 reduces toxicity from pathogenic ataxin-3. As
mentioned above, heat shock proteins generally work to improve toxicity from aggregated proteins
[296,299,309-314]. Hsc70-4 may perform in a context-, protein- and disease-dependent manner.
For example, studies with its mammalian orthologue, HSPA8, indicate that it can suppress
aggregation and toxicity of the HD-causing protein, huntingtin, harboring an expanded polyQ
[315-317]. However, investigations with the disease-causing protein, Tau, suggest this chaperone
as a potential enhancer of tauopathies. HSPA8 interacts with Tau and slows down its degradation;
also, HSPA8 inhibition can reduce Tau levels in brain [318-320]. These data present the possibility
of HSPA8 activities that can lead to enhanced toxicity from some proteins, similar to what we
observed with ataxin-3.
How might Hsc70-4 enhance toxicity from pathogenic ataxin-3? Perhaps, ATP hydrolysis
by Hsc70-4 is directly inhibited by binding to the UIMs of pathogenic ataxin-3, abrogating its
refolding functions. It may also be that under normal circumstances ataxin-3 forms a functional
complex with Hsc70-4, collaborating in protein quality control. Just like Hsc70-4/HSPA8, wildtype ataxin-3 is implicated in proteostasis [206,272]. During normal conditions, a complex
comprising wild-type ataxin-3, Hsc70-4 and other proteins could triage various substrates. When
the polyQ of ataxin-3 is expanded, in a UIM-dependent manner it may cause Hsc70-4 to adopt a
dominant negative role and to enhance pathogenic ataxin-3 aggregation. Our study provides a
roadmap towards testing these possibilities and uncovering others.
The model above focuses on the role of the UIMs facilitating an interaction between ataxin3 and Hsc70-4, because pathogenic ataxin-3 with mutated UIMs does not co-IP Hsc70-4. But, we
also observed that the isolated polyQ80 co-IP-ed some Hsc70-4 and that the chaperone’s
knockdown reduced its toxicity. Two earlier studies also reported suppression of truncated polyQ
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toxicity by the knockdown of Hsc70-4 in flies [300,313]; as far as we know, no additional findings
have supplemented these data since their original publication. Binding of Hsc70-4 to an isolated
polyQ is not surprising. PolyQ peptides aggregate and heat shock proteins interact with misfolded
proteins [309,310,314]. However, it is compelling that reducing levels of Hsc70-4 improves,
instead of worsening, truncated polyQ toxicity. Other proteins involved with refolding, such as the
HSP40 members Dnaj and mrj, and the HSP70 members Hsc70Cb and HSPA1L reduce polyQ
protein aggregation and toxicity [179,216,223,299,300,312,321]. But, these proteins are not the same
as Hsc70-4/HSPA8, which may function differently depending on protein identity and cellular
circumstances. In fact, HSPA8 is not the only member of the HSP70 superfamily to enhance the
aggregation of a misfolded disease protein. Recent work in cultured mammalian cells indicated
that HSPA1L− previously reported as a polyQ suppressor [299,301,302] − can in fact increase the
aggregation of a non-polyQ misfolded protein, SOD1; the mechanism behind this effect is not
entirely clear, but it appears to involve HSPA1L binding partners [303]. Consequently, it is not
outside of reasonable biological expectations that not all HSP70 members, such as Hsc70-4,
function similarly; they may trigger different outcomes on misfolded proteins depending on their
binding partners, the identity of the misfolded protein, the cellular environment and physiological
conditions.
How might Hsc70-4 worsen polyQ fragment toxicity? The interaction of Hsc70-4 with
severely truncated polyQ peptides could inhibit its ability to refold them, especially if additional
proteins or binding partners are necessary to steer Hsc70-4 towards refolding, as suggested by
studies of other HSP70 members [303]. This point pertains to isolated polyQ fragments. In the
case of full-length ataxin-3, the UIMs’ interaction with Hsc70-4 appears stronger and likely
supersedes binding through the polyQ, leading to the models of aggregation postulated above. We
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draw this conclusion based on our results that mutating the UIMs of full-length, pathogenic ataxin3 seems to abrogate its interaction with endogenous Hsc70-4. Additionally, knockdown of Hsc704 does not significantly change eye phenotype scores when the UIMs of full-length ataxin-3 are
mutated. Nevertheless, we cannot fully discount the possibility that Hsc70-4 activities on the SCA3
protein may also depend on polyQ-based interactions, once UIM-based binding is established. At
this point, the primary takeaway is that Hsc70-4 can enhance polyQ toxicity, in the case of ataxin3 through its UIMs.
In summary, we demonstrated that non-polyQ domains of disease-causing ataxin-3 are key
regulators of its toxicity, and that the UIMs are important determinants of the SCA3 protein's
pathogenicity. Our studies establish a clear role for protein context in SCA3 and, through Hsc704, provide a unique entry point into further examinations and potential therapeutic solutions for
this incurable ataxia. Lastly, our findings that Hsc70-4 can enhance polyQ toxicity have broader
implications for the general understanding of chaperone biology.
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4 CHAPTER 4: TARGETING THE VCP-BINDING MOTIF OF ATAXIN-3
IMPROVES PHENOTYPES IN DROSOPHILA MODELS OF SPINOCEREBELLAR
ATAXIA TYPE 3
4.1

Introduction
Spinocerebellar Ataxia Type 3 (SCA3, also known as Machado-Joseph Disease) is the most

frequent, dominantly inherited ataxia in the world. Along with Huntington’s disease, it is the
predominant member of the family of polyglutamine (polyQ) neurodegenerative disorders that
also includes SCAs 1, 2, 6, 7, and 17, Dentatorubral-pallidoluysian atrophy, and Kennedy’s
Disease [51-53,67,322-324]. SCA3 is progressive, adult-onset and leads to neurodegeneration in
cerebellar pathways, pontine and dentate nuclei, substantia nigra, globus pallidus, cranial motor
nerve nuclei, anterior horn cells and peripheral nerves [51,53,69,70,325-340]. The underlying genetic
defect in SCA3, like the other polyQ disorders, is the abnormal expansion of a CAG trinucleotide
repeat that, once translated, results in polyQ protein aggregation and toxicity [51-53,62,341]. In
SCA3, CAG expansion occurs in the ATXN3 gene [51-53,62,341], which encodes the 42 kD protein,
ataxin-3 (figure 4.1A). The aberrant lengthening of the polyQ domain is a primary cause of all
polyQ diseases, but each one is clinically distinct [3,37,206,243,273,274]. This indicates that
determinants of toxicity in these diseases are not only the polyQ repeats, but also the domains and
interactions surrounding the expanded repeat, referred to as ‘protein context’.
A body of work in polyQ diseases has highlighted a role for various non-polyQ regions and
interactions in polyQ degeneration [2,4,37,209,220,273,342,343]. For ataxin-3, there are several
domains that contribute to protein context and pathogenesis. As a deubiquitinating enzyme (DUB),
the N-terminal half of ataxin-3 contains a ubiquitin-protease (Josephin) domain housing the
catalytic triad that enables the protein to cleave isopeptide bonds [206,212,272]. The Josephin
domain also contains two ubiquitin binding sites (UbS) that interact with ubiquitin (UbS1 and
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UbS2), or the proteasome-associated protein Rad23 (UbS2)[206,272,286,344]. Downstream of the
Josephin domain are two ubiquitin-interacting motifs (UIMs 1 and 2), a site that binds the AAA
ATPase known as valosin-containing protein (VCP, or p97; this site is termed the VCP-binding
motif or ‘VBM’), and the polyQ domain [206,212,243,272]. The C-terminus of ataxin-3 following
the polyQ domain commonly contains an additional UIM, although an isoform also exists that
does not contain the third UIM [206,272].
We recently showed that the VBM is a significant contributor to ataxin-3 pathogenicity
[222,223]. The VBM comprises the arginine-rich sequence ‘RKRR’ which, when mutated into the

amino acid sequence ‘HNHH’, no longer binds VCP [308]. VCP is a ubiquitous, homo-hexameric
AAA ATPase that is bound directly at its N-terminus by ataxin-3 through the VBM [308,345]
(figure 4.1A). VCP regulates the proteasomal degradation of various proteins [345-348]; however,
mutations that disable binding of ataxin-3 to VCP do not impact ataxin-3 protein levels
[216,222,223,266] or its subcellular distribution [222].

Our previous work exploring the role of the ataxin-3-VCP interaction utilized Drosophila
melanogaster models of SCA3 expressing full-length, human ataxin-3 with and without the
mutation that prevents VCP-binding. Mutating the pathogenic ataxin-3 VBM improved fly
motility and longevity compared to counterparts expressing pathogenic ataxin-3 Q80 with an intact
VBM [222]. Biochemically, mutating ataxin-3’s VBM or reducing the levels of VCP through RNAinterference did not reduce SCA3 protein levels, but decreased pathogenic ataxin-3 aggregation
[222,343] – a critical observation given that, in our assays with pathogenic ataxin-3, its aggregation

precedes toxicity [222,223,277,343]. These and other findings led us to conclude that pathogenic
ataxin-3 with a mutated VBM is less aggregation-prone and less toxic. They also described an
important

role

for

VCP

in

determining

ataxin-3

toxicity, suggesting
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a model where multiple ataxin-3 proteins bind individual VCPs in a single hexamer [222]. These
interactions may bring pathogenic ataxin-3 proteins into closer proximity, increasing their chances
of interaction and aggregation – i.e., VCP seeds the aggregation of ataxin-3, exacerbating its
toxicity.
These prior findings prompted the question that we tackle in this study: might we reduce the
toxicity of pathogenic ataxin-3 by disrupting its interaction with VCP through a ‘decoy’ approach
targeting the VBM? We utilized a truncated protein that consists of the VCP N-terminus (amino
acids 1-199), denoted at ‘N-VCP’, that binds ataxin-3 [308], but cannot hexamerize [349-352]
(figure 4.1A). As VCP is a critical protein, whereas ataxin-3 is dispensable in mice [206,217220], we reasoned that it would be more practical to target ataxin-3 rather than VCP so as not to

impede VCP functions while still hindering the interaction of interest. As shown in the results, we
find that N-VCP ameliorates the toxicity of pathogenic ataxin-3 at all stages and in all tissues tested
in the fruit fly. The protective effect of N-VCP is specific to pathogenic ataxin-3 and is dependent
on its VBM. Also, the beneficial effect of the N-VCP truncated protein is enhanced by increasing
its levels. This work expands on our understanding of this critical protein-protein interaction in
SCA3 and highlights the disruption of ataxin-3’s interaction with VCP as a potential therapeutic
strategy for this neurodegenerative disease.
4.2
4.2.1

Materials and Methods
Antibodies
Anti-Ataxin-3: mouse monoclonal 1H9, 1:500-1000; Millipore, rabbit polyclonal, 1:15000

[63]. Anti-HA: rabbit monoclonal, 1:500-1000; Cell Signaling Technology. Anti-Myc: mouse

monoclonal 9E10, 1:500-1000; Santa Cruz Biotechnology. Anti-VCP: rabbit monoclonal, 1:500-
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1:1000; Cell Signaling Technology. Peroxidase-conjugated secondary antibodies: goat anti-mouse
and goat anti-rabbit, 1:5000; Jackson ImmunoResearch.
4.2.2

Construct Design
Human ataxin-3 cDNAs were based on sequences from previous publications and include

either 77 or 80Q [1,212,216,222,223,225,265,277,286,343,344,353]. We used the company Genscript
(genscript.com) to synthesize the VCP N-terminus cDNA as well as full-length fly VCP. An Nterminal Myc tag-encoding sequence was added immediately preceding the VCP start codon.
Transgenes were sub-cloned into pWalium-10.moe. Transgenic fly lines were generated via
phiC31 integration into either attP2 (ataxin-3) on chromosome 3 or attP40 (N-VCP, VCP) on
chromosome 2 [174,216,222,223,242,277,343,353-355]. Each insertion was confirmed and validated by
PCR, genomic sequencing, and Western blotting, using procedures described in previous work
[174,216,222,223,252,277,343].

4.2.3

Drosophila husbandry
Common fly lines were obtained from the Bloomington Drosophila Stock Center: GMR-

Gal4 (#8121), the isogenic host strain attP2 (#36303), and the isogenic host strain attP40 (#36304).
FlyORF was used to obtain an additional fly VCP line (TER94, #F001765) used in supplemental
figure 4.4. The following stocks were gifts: sqh-Gal4 (Dr. Daniel P. Kiehart, Duke University),
elav-Gal4-GS (Dr. R. J. Wessells, Wayne State University), elav-Gal4 and repo-Gal4 (Dr. Daniel
F. Eberl, University of Iowa). Unless otherwise stated in the figure legends and text, all flies were
heterozygous for driver and transgene(s). Whenever ataxin-3 and VCP or N-VCP were coexpressed, their expression was driven by the same Gal4 driver, in the same tissues, and at the
same developmental and/or adult time points. All crosses were conducted at 25oC in diurnal
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environments with 12h light/dark cycles and on conventional cornmeal or RU486-containing
media, and all resulting offspring were maintained in the same conditions [251,277,343].
4.2.4

Drosophila examinations
Longevity experiments were performed with adults collected on the day of eclosion and

deaths were recorded daily. Flies were observed from the embryo stage through eclosion and
deaths at each developmental stage were recorded daily, as summarized in figures. Fly eye scoring
was conducted using numerical scales where a higher score indicates a worse phenotype.
Breakdowns of the phenotypes for each scale are shown in respective figures and legends. Motility
tests were conducted using the negative geotaxis assay, where fifteen flies per vial were tapped to
the bottom of the vial and the total number of flies reaching the top was recorded at 5, 15 and 30s
and expressed as percent of total flies. Flies that reached the top were scored only once.
4.2.5

Western blotting and quantification
Depending on the experiment, 3 or 5 flies, or 10 dissected adult heads (unless otherwise

specified) per group were homogenized in boiling fly lysis buffer (50mM Tris pH 6.8, 2% SDS,
10% glycerol, 100mM dithiothreitol), sonicated, boiled for 10 min, and then centrifuged at
13300xg at room temperature for 10 min. Western blots were developed with either PXi 4
(Syngene) or ChemiDoc (Bio-Rad) and quantified with GeneSys (Syngene) or ImageLab (BioRad), respectively. To conduct direct blue stains, the PVDF membranes were submerged for 10
min in 0.008% Direct Blue 71 (Sigma-Aldrich) in 40% ethanol and 10% acetic acid, rinsed in 40%
ethanol/10% acetic acid, air dried, and imaged.
4.2.6

Filter-trap assay
For each group, 10 dissected fly heads were homogenized in 200μL NETN buffer (50mM

Tris, pH 7.5, 150mM NaCl, 0.5% Nonidet P-40) supplemented with protease inhibitor cocktail
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(PI; S-8820, Sigma-Aldrich). Following homogenization, lysates were diluted with 200μL PBS
containing 0.5% SDS, sonicated briefly, then centrifuged at 4500xg for 1 minute at room
temperature. 100μL of supernatant was then diluted further with 400μL PBS. Depending on the
experimental setup, either 20 or 30μL of each sample were filter-vacuumed using a Bio-Dot
apparatus (Bio-Rad) through a 0.45μm nitrocellulose membrane (Schleicher and Schuell) that was
pre-incubated and rinsed with 0.1% SDS in PBS. Following filter-vacuuming of the samples, the
membrane was rinsed twice with 0.1% SDS in PBS, incubated with primary and secondary
antibodies, and analyzed by Western blotting.
4.2.7

Co-immunopurifications
40-80 dissected fly heads or 20 whole flies, depending on the experiment, were lysed in

NETN/PBS (50%/50%)+PI, tumbled at 4oC for 30 min, then centrifuged at 4oC for 5 min at
5000xg. The supernatant was incubated with bead bound antibody (either Myc- or HA-tagged;
Fisher Scientific) for 2 hours. Beads were then rinsed 1X-3X with NETN/PBS+PI (depending on
experiment) followed by elution of bead-bound complexes by boiling in 2% SDS buffer with
100µM DTT.
4.2.8

Statistical Analyses
Statistical tests used are noted in the figure legends. Prism 8 (GraphPad) was used for log-

rank tests with Holm-Bonferroni adjustments, Repeated-measures and ordinary one-way ANOVA
with Tukey’s multiple comparisons test, Mann-Whitney tests, and Kruskal-Wallis tests. Additional
data collection and organization, as well as student’s t-tests, were performed in Excel (Microsoft),
or Numbers (Apple). P-values were calculated by the software used for analyses and indicated in
the corresponding figures and legends, alongside the number of biological replicates.
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Figure 4.1 N-VCP is non-toxic in Drosophila and interacts with pathogenic ataxin-3.
(A) Diagrammatic representation of the VCP-ataxin-3 interaction and the amino acid sequence of N-VCP. For VCP: L1/L2, linker
domains; D1/D2, D1 and D2 domains. For ataxin-3: UIM, ubiquitin-interacting motif; “QQQ”, polyQ region that
causes SCA3 when expanded abnormally. (B) Western blot from lysates of whole flies expressing N-VCP ubiquitously. Lysates
from two independent experiments are shown. (C) Survival analyses of flies expressing N-VCP ubiquitously (sqh-Gal4). Control:
flies that contain the ubiquitous driver without N-VCP. “ns”: non-statistically significant; log-rank test. (D) Survival analyses of
flies expressing N-VCP pan-neuronally (elav-Gal4). Control: flies that contain the pan-neuronal driver without N-VCP. “ns”: nonstatistically significant; log-rank test. (E) Co-immunopurification performed with anti-Myc antibody-tagged beads to precipitate
Myc-N-VCP. Pan-neuronal driver: elav-Gal4. Asterisk: band that we observe sometimes with Myc-N-VCP and that may represent
a proteolytic species.

4.3
4.3.1

Results
N-VCP is non-toxic to Drosophila and interacts with pathogenic ataxin-3
The N-terminus of VCP is sufficient and necessary to bind ataxin-3 at its VBM in vitro [308].

The N-VCP truncated protein that we utilize here consists of amino acids 1-199 of VCP (figure
4.1A). An N-terminal Myc-tag was added to N-VCP and expression in Drosophila was confirmed

103

with a ubiquitous Gal4 driver (spaghetti squash, sqh, figure 4.1B; additional examples are in
figures 4.3, 4.4, 4.6, 4.8). Here, as in previous studies, we take advantage of Drosophila genetics
and the Gal4-UAS binary system of expression [174,179,216,222,223,252,266,277,343,356]. Each Gal4
driver expresses ataxin-3 and N-VCP in a specific tissue either individually or together. In
longevity assays, N-VCP expression is non-toxic whether expressed ubiquitously (sqh-Gal4) or
pan-neuronally (elav-Gal4; figure 4.1C,D). This was also validated in motility assays, where the
pan-neuronal expression of N-VCP did not impact fly motility compared to controls that contained
the driver but did not express N-VCP (Supplemental figure 4S.1). Co-immunopurification assays
(co-IPs) conducted in flies pan-neuronally co-expressing N-VCP and full-length, human
pathogenic (80Q) ataxin-3 confirmed that N-VCP interacts with ataxin-3 (figure 4.1E), setting the
stage for an investigation into N-VCP’s impact on pathogenic ataxin-3 toxicity in the fly.
4.3.2

Presence of N-VCP is ameliorative in SCA3 models of different toxicity
The Drosophila lines modeling SCA3 were designed in two stages. While both express full-

length, human ataxin-3 protein with patient range repeats of 77-80Q, one of the lines is designated
as ‘stronger’ (Q80) and the other as ‘weaker’ (Q77), based on their comparative toxicity to flies.
The difference in lethality is due to the ‘stronger’ line containing an ataxin-3 transgene with an
optimized Kozak sequence that results in higher ataxin-3 protein levels [277]. However, it is
important to note that beyond the differences in toxicity, the ‘stronger’ and ‘weaker’ transgenes
are inserted into the same chromosomal site in Drosophila (attP2 on chromosome 3) and are on
the same genetic background (w1118; figure 4.2A). Expression was tested in various tissues to
obtain a comprehensive understanding of the impact of N-VCP on ataxin-3-related toxicity:
ubiquitous expression because ataxin-3 is expressed everywhere; pan-neuronal expression because
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SCA3 is primarily a neuronal disease; adult-only, pan-neuronal expression because SCA3 is adultonset; and expression in fly eyes to observe more changes across phenotypes over time.

Figure 4.2 N-VCP reduces toxicity from pathogenic ataxin-3 with 77Q.
(A) Summary of the pathogenic ataxin-3 and control fly lines along with outcomes of their ubiquitous expression in the absence of
N-VCP. Driver: sqh-Gal4. (B) Observations of developmental lethality in flies ubiquitously expressing ‘weaker’ pathogenic ataxin3 (Q77) with or without co-expression of N-VCP. The fly life cycle is outlined above the data and color coordinated with each
developmental stage shown in the graph. Means −/+ SD. p-values comparing the differences in death at each developmental stage
between groups with or without N-VCP were calculated with student's t-tests and are shown below the graph. (C) Survival analyses
from ubiquitously expressed transgenes in flies throughout development and adulthood. p-values: log-rank tests. Black font pvalue: comparison between “Ctrl” and “Atxn3(Q77) + N-VCP” groups. Red font p-value: comparison between “Atxn3(Q77) + NVCP” and “Atxn3(Q77) without N-VCP” groups. (D) Survival analyses from pan-neuronally expressed transgenes in flies
throughout development and adulthood. p-value: log-rank test. (E) Survival analyses from pan-neuronally expressed transgenes in
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adult flies only. We utilized an RU486-dependent elav-GS-Gal4 driver to initiate expression of ataxin-3 and N-VCP transgenes in
adults. Flies developed and eclosed in media without RU486 and were introduced to media with RU486 on the day of eclosion and
were maintained on media with RU486 for their entire lives. p-value: log-rank test.

We began our investigations by examining the impact of N-VCP expression on the 'weaker'
SCA3 line. As summarized in figure 4.2B, ubiquitous co-expression of pathogenic ataxin-3 and
N-VCP led to reduced lethality at various developmental stages: a significantly smaller proportion
of developing flies died in pupal, pharate and eclosing stages in the presence of N-VCP than in its
absence when pathogenic ataxin-3 was co-expressed in all tissues. Concomitantly, more adult flies
successfully eclosed from the pupal case and were tracked for longevity in the presence of N-VCP
than in its absence (figure 4.2C).
Perhaps counterintuitively at first, most 'weaker’ SCA3 adults died earlier with coexpression of N-VCP (figure 4.2C and supplemental figure 4S.2). We believe this is due to the
fact that only a small portion of SCA3 flies eclose as adults in the absence of N-VCP and that they
represent the strongest among that population of developing flies. While only the presumed
healthiest flies expressing the ‘weaker’ ataxin-3 alone emerged as adults – ~11% of the total
developing flies – ~70% of flies co-expressing ataxin-3 and N-VCP emerged as adults. Among
the latter, the longest-surviving adults lived markedly longer than flies without N-VCP
(Supplemental figure 4S.2), nearly as long as controls that do not express pathogenic ataxin-3
(figure 4.2C). Expression of the ‘weaker’ SCA3 line pan-neuronally at all times (figure 4.2D) or
only in adults (figure 4.2E) also resulted in less severe toxicity in the presence of N-VCP.
Collectively, these findings indicate that N-VCP suppresses lethality in the ‘weaker’ SCA3 line.
Encouraged by the reduction in lethality in the presence of N-VCP with the ‘weaker’ SCA3
model, we next tested if these results persist in the ‘stronger’ line. Similar to what we observed
with the ‘weaker’ model, ubiquitous N-VCP co-expression alongside the ‘stronger’ SCA3
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transgene significantly decreased the proportion of developmental deaths and was critical in
allowing pupae to enter the pharate adult stage (figure 4.3A). Among flies that ubiquitously
expressed pathogenic ataxin-3 Q80 alone, over 95% died as pupae, with only a small portion of
the remaining developing flies advancing to the pharate adult stage (figure 4.3A). Conversely, flies
co-expressing N-VCP and ataxin-3 Q80 commonly reached the pharate adult stage prior to death
(~79%), and a small percentage initiated the eclosing process from the pupal case, but died before
emerging successfully (figure 4.3A).

Figure 4.3. N-VCP reduces toxicity from pathogenic ataxin-3 with 80Q.
(A) Observations of developmental lethality in flies ubiquitously expressing the ‘stronger’ pathogenic ataxin-3 (Q80) with or
without N-VCP. Means −/+ SD. p-values below graph: student's t-tests. (B) Survival analyses from adult-only pan-neuronally
expressed transgenes. p-value: log-rank test. (C) Western blots of lysates from whole flies pan-neuronally expressing the ‘stronger’
pathogenic ataxin-3 alone or with Myc-tagged N-VCP. Black arrow: main, unmodified ataxin-3 band. Blue arrows: ubiquitinated
species of ataxin-3. (D) Co-immunopurification using whole fly lysates expressing the noted transgenes.

To allow for more longitudinal studies in adult flies and to mimic the adult-onset
characteristic of SCA3, an inducible pan-neuronal driver was once again employed to express the
‘stronger’ transgene line with and without N-VCP in adult flies only, with expression starting on
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day 1 after emergence from the pupal case. N-VCP co-expression significantly increased fly
longevity (figure 4.3B), mirroring what we observed with the ‘weaker’ SCA3 model (figure 4.2E).
As will be detailed further below, reduced toxicity from N-VCP was not due to lack of
pathogenic ataxin-3 in the presence of N-VCP. Pathogenic ataxin-3 is still abundantly present
when co-expressed with N-VCP (figure 4.3C). Additionally, co-expression of N-VCP alongside
pathogenic ataxin-3 leads to reduced levels of endogenous VCP co-precipitating with the SCA3
protein (figure 4.3D; please see figure 4.8C for additional data and quantitative information).
We also performed motility studies in flies with the inducible pan-neuronal driver
(Supplemental figure 4S.3). Although early in life flies expressing the ‘stronger’ pathogenic
ataxin-3 with N-VCP showed a slight improvement compared to those expressing ataxin-3 alone,
they did not reach the motility level of control flies that did not express pathogenic ataxin-3; also,
the improvement was no longer apparent by the third week (Supplemental figure 4S.3).
Collectively these results indicate that the presence of N-VCP is effective in reducing SCA3
toxicity in Drosophila.
As an additional counterpoint to the protective role from N-VCP that we observed so far, we
tested whether increased expression of full-length VCP has the opposite effect, as predicted by our
prior work [222]. We generated flies that contain either one or two genetic copies of fly VCP and
compared lethalities when co-expressed with either the ‘weaker’ or ‘stronger’ SCA3 model. As
shown in supplemental figure 4.4, VCP over-expression led to worse developmental outcomes that
were exacerbated by increased genetic copies of VCP in both SCA3 models, providing additional
support for our model that VCP impacts ataxin-3 toxicity.
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4.3.3

The effects of N-VCP are specific to ataxin-3 with an intact VBM
We have, so far, observed a protective effect from N-VCP on ataxin-3-dependent toxicity

(figures 4.1-4.3). Our model posits that this effect centers on the VBM of ataxin-3. To ensure that
indeed the VBM of ataxin-3 is required for the protective role of N-VCP, we examined its ability
to impact toxicity caused by pathogenic ataxin-3 with a mutated VBM, which does not interact
with VCP in vitro, in mammalian cells or in flies [222]. This VBM-mutated line of SCA3 is isogenic
to the SCA3 ‘weaker’ line introduced above [222] and was expressed in flies with or without coexpression of N-VCP.
In this modified ataxin-3 line, the VBM sequence ‘RKRR’ was mutated into ‘HNHH’.
Flies expressing pathogenic ataxin-3 with mutated VBM show reduced degenerative phenotypes
and this version of ataxin-3 is less aggregation-prone than the SCA3 protein with a functional
VBM [222]. Through co-IPs, we confirmed that N-VCP requires a functional VBM on pathogenic
ataxin-3 to interact with it specifically (Figure 4.4A). Survival analysis from these flies showed
that mutating the VBM of ataxin-3 eliminates the toxicity-mitigating effect of N-VCP panneuronally. In fact, N-VCP exacerbates lethality when it is co-expressed ubiquitously with
pathogenic ataxin-3 that it can no longer bind (figure 4.4B and 4.4C).
To further clarify that the benefits of N-VCP co-expression are specific to ataxin-3, we
conducted experiments examining the potential impact of N-VCP on a pathogenic protein linked
to a different polyQ disorder, SCA6. ɑ1ACT is a polyQ-containing transcription factor that is
generated from the bicistronic mRNA of the CACNA1A gene, which causes SCA6 [3,176]. We
selected this protein because it is not reported to have any interaction with VCP, a statement that
we would not be as confident in making with proteins related to other polyQ diseases, like SCA7
and SCA1 [357-359]. The interaction of VCP with other polyQ disease proteins, including SCA1
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and SCA7, has been confirmed by experimental evidence, as indicated in previous work and the
STRING database [357,359,360].

Figure 4.4 The ameliorative effects of N-VCP are specific to ataxin-3 and require its intact VBM.
(A) Co-immunopurification assays of whole fly lysates expressing one of two forms of ataxin-3: pathogenic ataxin-3 Q77 or
pathogenic ataxin-3 Q80 with a mutated VBM (‘RKRR’ to ‘HNHH’) without or with N-VCP. (B) Survival analyses of flies panneuronally expressing VBM-mutated, pathogenic ataxin-3 with or without N-VCP. Statistics: log-rank test. (C) Survival analyses
of flies ubiquitously expressing pathogenic, VBM-mutated ataxin-3 with or without VCP. p-value: log-rank test. (D) Summary of
transgenes and outcomes of their expression. (E) Survival analyses of flies pan-neuronally expressing ɑ1ACT(Q70) with or without
VCP. Statistics: log-rank test. “ns”: non-statistically significant.

We expressed human ɑ1ACT with a pathogenic 70Q repeat in flies with and without NVCP, either ubiquitously or pan-neuronally, throughout development and in adults. Ubiquitously
expressed ɑ1ACT(Q70) by itself was toxic: most developing flies died as pharate adults, and the
handful that emerged as adults died by day 16 (figure 4.4D). In this SCA6 model, ubiquitous coexpression of N-VCP did not improve the phenotype: all flies died as pharate adults, and no adults
emerged (figure 4.4D). Pan-neuronal expression of ɑ1ACT(Q70) was less toxic than ubiquitous
expression (figure 4.4E), as also shown before [174,179]. Co-expression of N-VCP did not provide
a detectable benefit compared to flies expressing ɑ1ACT(Q70) alone (figure 4.4D, E). We
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conclude that the reduced toxicity of pathogenic ataxin-3 observed in the presence of N-VCP is
specific to ataxin-3 with a functional VBM.
4.3.4

N-VCP alleviates SCA3 phenotype in fly eyes
To expand on our observations, we shifted our focus to a SCA3 model specific to the fly

eye. We previously utilized similar models to observe the phenotypic deterioration that occurs with
pathogenic ataxin-3 expression, as well as to perform screens of various molecules and genetic
modifications that may ameliorate SCA3 [343,361]. Observation of the eye allows for the detection
of more subtle changes among groups of flies that might go undetected in other expression patterns.
We thought it reasonable to use the fly eye to further examine the impact of N-VCP in flies that
co-express human, pathogenic ataxin-3. In models expressing the ‘stronger’ ataxin-3 in fly eyes
(GMR-Gal4), the eyes appear normal (wild-type) at eclosion and worsen continually over time
[343].
We developed the following scoring system to track the worsening of eye phenotypes for
this study: score 1) normal (wild-type-looking) eye; score 2) loss of the pseudopupil; score 3) early
signs of color variegation throughout the eye in addition to pseudopupil loss; score 4)
depigmentation of a portion of the eye in addition to color variegation and pseudopupil loss (figure
4.5A). Eyes were scored weekly for six weeks following eclosion using the scale described above,
with a higher score indicating a worse phenotype. As shown in figure 4.5B and 4.5C, the presence
of N-VCP significantly improved eye phenotypes beginning at day 14 and continuing for the
remainder of the study. Figure 4.5B shows the average score for each group at each time point,
while figure 4.5C expands those averages to display the proportion of each score in each group at
a given time point to provide further visualization of the worsening phenotype over time. Thus,
just as with other tissues, N-VCP suppresses toxicity from pathogenic ataxin-3 in fly eyes.
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Figure 4.5 N-VCP improves pathogenic ataxin-3 toxicity in fly eyes.
(A) Scoring scale and representative images. Distinguishing features from each score category are highlighted. 1) Normal (wildtype-looking) eye; 2) Loss of the pseudopupil; 3) Early signs of color variegation in addition to pseudopupil loss;
4) Depigmentation of a portion of the eye in addition to color variegation and pseudopupil loss. (B) Average eye score in each
group at each time point. Statistics: Mann-Whitney tests comparing eye scores at each time point between those expressing
pathogenic ataxin-3 alone or with co-expression of N-VCP. Shown are means −/+ SEM. p-value: **** = 0.0001. “ns”: nonstatistically significant. (C) Representation of the dispersion of eye scores at each time point for each group from (B).

A strong molecular indicator of toxicity and disease progression in polyQ disease models
is the level of disease protein aggregation [2,3,63,206,274]. In our studies using Drosophila SCA
models, we found that aggregation of pathogenic ataxin-3 and other polyQ proteins precedes
toxicity [174,179,215,216,222,223,277,343]. We also observed that the level of aggregation of these
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proteins correlates with the extent of their pathogenicity [174,179,215,216,222,223,277,343]. Next, we
sought to examine this relationship in fly eyes.

Figure 4.6 N-VCP reduces pathogenic ataxin-3 aggregation.
(A) Western blots of lysates from dissected fly heads expressing pathogenic ataxin-3 with or without N-VCP in fly eyes. Orange
outlines: SDS-resistant ataxin-3; green outlines: SDS-soluble ataxin-3. Black arrow: unmodified ataxin-3. Red arrow: potentially
phosphorylated form of ataxin-3. Blue arrows: ubiquitinated forms of ataxin-3. (B) Filter-trap assays of lysates from the same fly
lines as (A). Means −/+ SD, arbitrary units representing intensity of ataxin-3 signal. p-value: two-tailed, student's t-test.

To assess ataxin-3 aggregation, we performed Western blot analyses using lysates from
dissected fly heads expressing the ‘stronger’ pathogenic ataxin-3 alone or alongside Myc-tagged
N-VCP (figure 4.6A). The presence of N-VCP seemed to increase the amount of SDS-soluble
ataxin-3 (figure 4.6A, green outlines). Lanes with lysates from flies expressing pathogenic ataxin3 alone have lower amounts of SDS-soluble ataxin-3 in comparison to those also expressing NVCP (figure 4.6A, green outlines); additionally, the level of SDS-resistant ataxin-3 appears higher
in the absence of N-VCP (figure 4.6A, orange outlines), indicative of increased levels of
aggregated species that migrate more slowly through SDS-PAGE gels. Since these blots suggested
that the presence of N-VCP reduces aggregated species of pathogenic ataxin-3, we sought to
confirm these results through the utilization of filter-trap assays. These assays take advantage of a
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porous nitrocellulose membrane that, when a sample is passed through it via suction, captures
higher-order aggregated protein species [213,255,256,277,343]. Lysates from flies expressing
pathogenic ataxin-3 alone or with N-VCP showed that the presence of the truncated protein
significantly reduced the amount of aggregated ataxin-3 trapped on the membrane (figure 4.6B).
From these data we conclude that N-VCP leads to reduced levels of aggregated, pathogenic ataxin3.
4.3.5

Dose-dependent effects of N-VCP
Thus far, we observed improvement in developmental progression, longevity, eye

phenotypes, and pathogenic ataxin-3 aggregation of SCA3 models because of co-expression of the
N-terminal VCP truncated protein (figures 4.1-4.6). We also observed a significant worsening of
developmental outcomes with overexpression of full-length VCP in those same SCA3 models
(Supplemental figure 4S.4). As we already confirmed improvement from a single copy of N-VCP,
and an increased copy number of full-length VCP intensified SCA3 toxicity (Supplemental figure
4S.4), we next asked the question: can an additional copy of N-VCP further ameliorate SCA3
toxicity in flies?
We returned to the fly eye as our model with Drosophilae containing either zero, one, or
two copies of the N-VCP transgene alongside the ‘stronger’ pathogenic ataxin-3. Just as in figure
4.5, eyes were scored on a weekly basis for six weeks following eclosion; however, the scoring
scale for this set of studies was expanded to account for what we thought might be more subtle
differences among flies expressing one versus two copies of N-VCP. This new scale is as follows:
score 1) normal (wild-type-looking) eye with a clear pseudopupil; score 2) weaker pseudopupil
that has begun to fade and lose its clear shape; score 3) undetectable pseudopupil; score 4) color
variegation at the edge of the eye in addition to pseudopupil loss; score 5) widespread
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depigmentation throughout the eye in addition to color variegation and pseudopupil loss (figure
4.7A). Multiple statistical comparisons were made among the groups to detect differences among
the varying copy numbers of the N-VCP transgene.

Figure 4.7 Dose-dependent N-VCP alleviation of pathogenic ataxin-3 toxicity in fly eyes.
(A) Expanded scale of representative images for eye scoring system. Distinguishing features from each score category are
highlighted. Scoring system is as follows: 1) Normal (wild-type-looking) eye with a clearly defined pseudopupil; 2) Weaker
pseudopupil that has begun to fade; 3) Undetectable pseudopupil; 4) Color variegation at the edge of the eye in addition to
pseudopupil loss; 5) Widerspread depigmentation in addition to color variegation and pseudopupil loss. (B) Average eye score for
each group at each time point. Shown are means −/+ SEM. Statistics: Kruskal-Wallis and Dunn's multiple comparison tests
comparing all three groups. p-value: **** = 0.0001. “ns”: non-statistically significant. (C) Representation of the distribution of eye
scores for each group at each time point.
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Beginning on day 7, we observed significant improvement in eye phenotype in the presence
of both one (validating the observations of figure 4.5) and two copies of N-VCP compared to
expression of the ‘stronger’ pathogenic ataxin-3 alone (figure 4.7B). Additionally, starting on day
14, the data revealed a significant improvement comparing one copy to two copies of N-VCP
(figure 4.7B). Just as in figure 4.5, figure 4.7B shows the average score for each group at each time
point, while figure 4.7C expands those averages to display the proportion of each score in each
group at a given time point. The differences among the three groups persisted for the remainder of
the observation timeline with a single copy of N-VCP improving eye phenotypes over ataxin-3
alone, and two copies of N-VCP showing improvement over both of the other groups. This
indicates that the response from N-VCP on ataxin-3-dependent phenotypes is dose-dependent.
4.3.6

N-VCP reduces pathogenic ataxin-3 aggregation in a dose-dependent manner
As with a single copy of the N-VCP transgene, we again assessed whether phenotypic

improvement observed with two copies of N-VCP coincides with further reduction in ataxin-3
aggregation. Analyses of Western blots from dissected fly heads from each line showed that there
is a significant increase in the amount of N-VCP from one copy of the transgene to two, and that
this increase in N-VCP does not result in significant reduction of total ataxin-3 protein levels
(figure 4.8A).
We then focused on SDS-soluble and -resistant ataxin-3. As outlined in figure 4.8A, the
amount of SDS-soluble ataxin-3 appears to increase in the presence of N-VCP (figure 4.8A, green
outlines) coincident with a decrease in SDS-resistant species (figure 4.8A, orange outlines). This
apparent decrease in aggregated ataxin-3 was validated with filter-trap assays, which revealed a
steady decrease in higher-order ataxin-3 species from zero to one and zero to two copies of the NVCP transgene (figure 4.8B). There was also a trend in reduced levels of filter-trapped pathogenic
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ataxin-3 when comparing one vs. two copies of N-VCP (figure 4.8B). This trend did not reach
statistical significance with ANOVA (P=0.086) when comparing one copy vs. two copies, but did
reach significance with a student’s t-test (P=0.012), overall supporting the notion that higher levels
of N-VCP lead to increased reduction of higher-order ataxin-3 species.

Figure 4.8 N-VCP dose-dependent reduction of ataxin-3 aggregation and inhibition of interaction with VCP.
(A) Western blots of lysates from dissected fly heads expressing pathogenic ataxin-3 alone, or with one or two copies of the NVCP transgene in fly eyes. Two biological repeats are shown. Quantifications: Means −/+ SD, normalized to ataxin-3 without NVCP (ataxin-3 graph), or normalized to one copy of N-VCP (N-VCP graph). Statistics: one-way ANOVA with Tukey's multiple
comparisons test to compare ataxin-3 protein levels, and student's t-test to compare N-VCP levels. Orange outlines: SDS-resistant
ataxin-3; green outlines: SDS-soluble ataxin-3. (B) Filter-trap assays of lysates from the same crosses as in (A). Means −/+ SD,
arbitrary units representing intensity of ataxin-3 signal. p-value: repeated-measures one-way ANOVA with Geisser-Greenhouse
correction and Tukey's multiple comparisons test. (C) Co-immunopurification assays using bead-bound anti-HA antibody.
Statistics: one-way ANOVA with Tukey's multiple comparisons test. Means −/+ SD. “ns”: non-statistically significant.

Lastly, we examined whether N-VCP impacts ataxin-3 binding to endogenous VCP.
Through co-IPs for HA-tagged ataxin-3 using dissected fly heads, we observed that N-VCP
significantly reduced the amount of endogenous VCP that co-IPed with pathogenic ataxin-3
compared to ataxin-3 alone (figure 4.8C). We conclude that N-VCP reduces the interaction of
ataxin-3 with endogenous VCP and leads to lower levels of aggregated, pathogenic ataxin-3.
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4.4

Discussion
Domains outside of the polyQ repeat play important roles in the pathogenicity of polyQ

disease proteins. For the SCA3 protein, ataxin-3, we and others reported that the polyQ-adjacent
VBM is important for its interaction with the hexameric protein, VCP [222,308,362-364]. We also
found that VCP exacerbates the toxicity of human, full-length, pathogenic ataxin-3 in fly models
of SCA3 [222]. Based on those data [222]; on studies by others that investigated the interaction of
ataxin-3 with VCP [308]; and on studies that investigated ataxin-3 aggregation in vitro — a twostep process where the N-termini of ataxin-3 proteins interact and facilitate subsequent polyQ
length-dependent fibrilization [222,305-307] — a model emerged where VCP hexamers binding to
multiple pathogenic ataxin-3 proteins raise their local concentration and likelihood of interacting
and aggregating (figure 4.9, top). This model was supported by our prior data that inhibiting the
binding of pathogenic ataxin-3 to VCP, or knocking down endogenous VCP, decreases pathogenic
ataxin-3 aggregation and toxicity in Drosophila [222]. The VBM of ataxin-3 was reported to
contain a nuclear-localization signal [365]; however, based on our earlier research, the VBM does
not impact ataxin-3’s sub-cellular localization in Drosophila [222]. Thus, it is unlikely that
interventions involving the VBM impact the sub-cellular localization of pathogenic ataxin-3.
Collectively, these studies identified the VBM of pathogenic ataxin-3 as a potential targeting site
to combat SCA3.
Here, we presented evidence that engaging the VBM of pathogenic ataxin-3 with a truncated
protein — the N-terminus of VCP lacking the domains necessary to homo-hexamerise —
ameliorates ataxin-3-dependent toxicity in flies. Phenotypic improvement coincided with reduced
aggregation of pathogenic ataxin-3 and diminished binding of the SCA3 protein to VCP. Our
observations from this work further inform the working model in figure 4.9. We propose that VCP-
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dependent aggregation of pathogenic ataxin-3 can be decelerated through the introduction of the
N-VCP truncated protein that displaces the VCP-ataxin-3 interaction (figure 4.9, bottom). These
results strengthen the rationale to pursue the VBM of ataxin-3 as a potential target for SCA3
intervention.

Figure 4.9 Model of N-VCP-dependent benefits.
Upper panel: Endogenous VCP hexamers may bind multiple pathogenic ataxin-3 proteins, bringing them into closer physical
proximity and accelerating their aggregation. Lower panel: Pathogenic ataxin-3 is bound by N-VCP, disrupting its interaction with
VCP hexamers, preventing the seeding effect.

Ataxin-3 and VCP have been proposed to cooperate functionally in endoplasmic reticulumassociated protein degradation (ERAD) [362-364,366]. The retro-translocation to the cytosol of
substrates produced in the ER lumen is a critical step in this branch of proteasome-associated
protein quality control. Ataxin-3’s DUB activity has been implicated in regulating the flow of
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ERAD substrates in a VCP binding-dependent manner [362-364,366]. Other protein partners of
VCP possess a similar VBM and may compete with ataxin-3 to bind VCP, further regulating the
retro-translocation process [366]. These studies suggested that one of ataxin-3’s normal functions
is to modulate ERAD by altering VCP’s ability to facilitate protein retro-translocation [362364,366]. However, the physiological significance of the ataxin-3-VCP interaction in vivo is not
entirely clear, since Atxn3 knockout mice appear normal [217-219], suggesting either that ataxin-3
is not fully or always required for ERAD-dependent processes, or that another DUB is able to
conduct its functions when it is absent. Further uncovering the functional nature of ataxin-3’s
interaction with VCP, and whether that interaction is a part of a unique action, is important in
understanding ataxin-3’s physiological functions.
The RXXR sequence (where ‘X’ denotes any amino acid) within a predicted 𝛼-helix that
comprises the VBM is not exclusive to ataxin-3. The ubiquitin ligase E4b (Ube4b), ubiquitin
fusion degradation protein 2a (Ufd2a), hydroxymethylglutaryl reductase degradation protein
(Hrd1) (also known as Synoviolin 1), and the ER-resident ubiquitin ligase Mr 78 000 glycoprotein
(gp78) all possess a version of this sequence that can bind directly to the N-terminus of VCP [366];
Drosophila has well conserved orthologues of these genes and their peptides also contain the
RXXR sequence [367]. Each of these proteins is involved in ERAD [366]. Their function can be
influenced by the mutual exclusivity of their interaction with VCP in direct competition with other
VCP-interacting proteins [366]. While these VBM-containing proteins may be involved in similar
pathways, their distinct interactions, competitions, and variability in cofactor binding allows each
of them to have unique roles in ERAD [366]. Because of these interactions, one might have
considered that the N-VCP approach we described here could have led to deleterious effects. While
N-VCP suppressed toxicity from pathogenic ataxin-3, it enhanced the toxicity of pathogenic
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ataxin-3 with mutated VBM and of the SCA6 protein (figure 4.4). These observations suggest the
possibility that N-VCP disrupts some cellular processes during misfolded protein stress, perhaps
by interacting with other VBM-containing proteins; the truncated protein, however, does not
appear to be detrimental under normal conditions in the fly (figure 4.1 and supplemental figure
4S.1). Since the overarching future aim of this investigation is to inhibit direct binding of ataxin3 to VCP through a highly targeted, small molecule design, that approach would presumably
circumvent the above possibility.
The ultimate goal for studying SCA3 is to devise therapeutic interventions for it. As the
SCA3 therapeutics field forges ahead, interventions focused on biomarkers; mechanistic targets
that may upregulate specific pathways, such as autophagy; oligonucleotide-based targeting of the
ATXN3 mRNA; and others are being considered to mitigate ataxin-3-based toxicity
[53,216,223,234,277,343,368-371]. To this list we add the ataxin-3-VCP interaction and the VBM as

another potential therapeutic entry point. N-VCP is too large to be a deliverable; however, the
basic concept that we presented here can be utilized to design or discover compounds that disrupt
the interaction of ataxin-3 with VCP. Since there is benefit from the approach we described here,
studies that further evaluate this disruption at a structural level and weaponize it against SCA3 will
likely prove beneficial.
To conclude, targeting the VBM of pathogenic ataxin-3 brings phenotypic benefits in fly
models of SCA3 and provides further evidence of the importance of protein-protein interactions
in the etiology of SCA3 and of other, similar diseases.
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5
5.1

CHAPTER 5: DROSOPHILA AS A MODEL OF UNCONVENTIONAL
TRANSLATION IN SPINOCEREBELLAR ATAXIA TYPE 3

Introduction
Long, tandem repeating nucleotide sequences and resulting amino acid tracts are associated

with various human genetic disorders[239,372,373]. When expanded, tandem repeats can
detrimentally influence protein folding, function, and aggregation resulting in repeat-expansion
disorders[239,372,373]. In addition to anomalies stemming from changes at the protein level,
expanded nucleotide repeats are also implicated in altering gene structure and causing RNAmediated toxic effects[372,373]. One mechanism of RNA-based toxicity stems from repeatassociated, non-AUG-initiated (RAN) translation[232,239-241].
RAN translation allows for translation initiation and elongation through a repeat strand in
the absence of an AUG initiation codon and in all three reading frames of a specific
transcript[232,241]. This process enables the production of multiple homopolymeric or multiamino acid repeat-containing proteins[232,241]. RAN translation was discovered by pioneering
work in Spinocerebellar Ataxia Type 8 (SCA8) after the mutation of the ATG initiation codon in
the CAG-repeat containing, ATXN8 gene did not block expression of the polyglutamine (polyQ)
repeat in transfected cells[239]. Upon further investigation, homopolymeric polyQ, polyalanine
(polyA), and polyserine (polyS) proteins were found to be expressed in all three reading frames in
the absence of an AUG or near-cognate codons[239]. This type of translation not only opens the
door to the possibility of translation of long tandem repeats into potentially toxic fragments, but
also the translation of repeats in alternate reading frames[232,241].
Although RAN translation was initially described in the context of CAG-repeat expansions
in SCA8, it has since been shown to occur with expansions of CAG, CUG, GGGCC, and CGG
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repeats associated with several repeat-expansion diseases[232,239-241,374-380]. These repeats
drive RAN translation from within 5’ untranslated regions (UTRs), introns, and protein-coding,
open reading frames[232,239-241,374-380]. The exact mechanism through which RAN
translation occurs remains to be clarified; however, as evidence of RAN translation expandes
among various diseases several common themes have emerged. First, RAN translation is repeatlength dependent, with the likelihood of RAN-derived protein accumulation increasing with longer
repeat tracts[232,241]. Second, long repeat sequences form secondary structures, including hairpin
loops, which appear to be a requirement for RAN translation to take place – non-hairpin-forming
repeats (such as those with CAA in place of CAG repeats) do not produce RAN proteins[232,241].
Third, the secondary structure of repeat-expanded RNA downstream of the start codon may recruit
initiation factors and ribosomal subunits to internal ribosomal entry sites (IRESs) regardless of the
presence of initiation or near-cognate initiation codons[232,241].
There are various repeat-containing disease proteins where RAN translation has yet to be
identified as a factor in pathogenesis. One such example is another CAG-repeat expansion disease,
SCA3, also known as Machado-Joseph Disease. SCA3 is the most prevalent dominant ataxia
worldwide and, along with Huntington’s disease, is among the most common of the family of nine
polyQ repeat-expansion diseases[2,51-53,67,206,322-324]. It is caused by the expansion of the CAG
repeat of the ATXN3 gene that encodes an expanded polyQ tract in ataxin-3, a deubiquitinase
implicated in protein quality control and DNA repair[51-53,62,341]. Normally, these repeats exist in
a range of 12-42, but expand to ~60-87 repeats in patients[2,206]. This long CAG repeat, similar to
that of diseases like SCA8 and Huntington’s disease where RAN proteins have already been
detected, makes a SCA3 an intriguing candidate for another potential instance of RAN translation.
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While RAN translation is a possible detrimental factor in long-repeat expansions, mRNA
toxicity was reported as a potential contributor in polyQ diseases, and more specifically SCA3
[228,229,231,233,381]. The contribution of mRNA-based toxicity in SCA3 was tested by altering
the CAG repeat sequence of ATXN3 to have an alternating CAGCAA repeat, which significantly
reduced toxicity in Drosophila melanogaster[228]. Expression of an untranslated version of the
expanded CAG repeat also resulted in neuronal degeneration[228]. Additional studies suggested
that the expanded ATXN3 gene is prone to frameshift mutations[230,382-385] and that these
frameshifts result in the production of harmful polyA-containing proteins that have been observed
in SCA3 patient lymphoblasts and pontine neurons[382]. These studies were reported before the
discovery of RAN translation; their conclusions may have been unrecognized evidence of the
presence and influence of RAN proteins. The long CAG repeat, reliance on homomeric CAG
repeat secondary hairpin structure for toxicity, and the presence of polyA proteins in SCA3 patient
tissue point to the potential of RAN translation in SCA3.
In this study, we set out to search for evidence of the occurrence of RAN translation in
SCA3 in vivo. We took advantage of the genetic versatility of Drosophila melanogaster models of
SCA3 to express versions of human ataxin-3 transgenes with the native homomeric CAG or
interrupted alternating CAGCAA repeats that are, respectively, more and less likely to form the
secondary structure necessary to enable RAN translation. Although we were able to identify the
expression of polyA proteins when these constructs were expressed in cultured mammalian cells,
we found no evidence of RAN proteins in any of our fly models of SCA3. We also returned to the
idea of mRNA-based toxicity by expressing ATXN3 constructs that cannot be translated and found
that the presence of a homomeric CAG repeat was, albeit to a small degree, more toxic than the
interrupted repeat. Overall, this study points to a version of SCA3 pathogenesis that experiences
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little to no input from RAN translation and apparent but limited contributions from mRNA toxicity
in Drosophila, and underscores limitations with the Drosophila model system in studying RAN
translation in this specific disease.
5.2
5.2.1

Materials and Methods
Construct Design
The ATXN3-Q80(CAGCAA) cDNA was based on the human ATXN3 sequences used in

previous publications[212,216,222,223,225,265,277,286,343,344,353,386]. ATXN3-Q80(CAG) cDNA
and the Met-Null cDNA counterparts to both ATXN3-Q80 constructs were designed from the
ATXN3-Q80(CAGCAA) sequence and synthesized using the company Genscript (genscript.com).
The transgenes were subcloned into pWalium-10.moe and transgenic fly lines were generated with
the phiC31 integrase system into attP2 on chromosome 3 at Duke University Model
Systems[174,216,222,223,242,277,343,353-355,386]. All insertions were confirmed and validated with
PCR, genomic sequencing and then Western blotting using procedures described in this paper and
previous work[174,216,222,223,252,277,343,386].
5.2.2

Antibodies
Anti-ataxin-3: Rabbit polyclonal, 1:10000[63]; mouse monoclonal 1H9, 1:1000, Millipore.

Anti-HA: rabbit monoclonal, 1:1000, Cell Signaling Technology. Anti-MYC: mouse monoclonal
9E10, 1:1000, Santa Cruz Biotechnology; mouse monoclonal 9B11, 1:1000, Cell Signaling
Technology. Anti-V5: rabbit monoclonal D3H8Q, 1:1000, Cell Signaling Technology.
5.2.3

Mammalian cells and assays
Ataxin-3 constructs containing a pure CAG repeat or an interrupted CAGCAA repeat were

sub-cloned into pcDNA 3.1(+1) for expression in a mammalian cellular environment. M-17 or
HEK-293T cells were purchased from ATCC, confirmed for lack of mycoplasma contamination
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and cultured under conventional conditions at 37°C and 5% CO2 in DMEM supplemented with
10% FBS and 5% penicillin-streptomycin (Thermo Fisher). Cells were transfected as indicated in
figure 5.1 using Lipofectamine LTX (Thermo Fisher). 24 h later, cells were harvested for protein
extraction and Western blotting. Cells were scraped with boiling cell lysis buffer (50 mM Tris pH
6.8, 2% SDS, 10% glycerol, 100 mM dithiothreitol), sonicated, boiled for 10 min, centrifuged at
top speed at room temperature for 10 min and loaded onto SDS-PAGE gels (4%–20% gradient
gels, Bio-Rad).
5.2.4

Drosophila stocks and husbandry
The control fly line, isogenic host strain attP2 (#36303), and the MYC positive control line,

a MYC-tagged ataxin-3 (#33610), were obtained from the Bloomington Drosophila Stock Center.
Stocks obtained as gifts are as follows: sqh-Gal4 (Dr. Daniel P. Kiehart, Duke University), elavGal4-GS (Dr. R. J. Wessells, Wayne State University), elav-Gal4 and repo-Gal4 (Dr. Daniel F.
Eberl, University of Iowa). The fly line used as the V5-positive control was a V5-tagged ataxin-3
Q80 line that we used in a previous publication[343].
Stocks and crosses were maintained at 25°C and approximately 60% humidity in diurnal
incubators with 12-hour light/dark cycles. Flies were kept on a conventional cornmeal diet when
being kept as stocks as well as throughout crosses and experimentation. The one exception to the
standard diet was glutamine-substituted (L-Glutamine; Millipore Sigma) food that is described in
the Results section. All flies were heterozygous for both driver and transgene, unless otherwise
noted.
5.2.5

Quantitative Real-time Polymerase Chain Reaction
Five intact adults or 10 flies collected during development, depending on the experiment,

had total RNA extracted using TRIzol (Life Technologies). Extracted RNA was then treated with

127

TURBO DNAse (Ambion) and reverse transcription was carried out using a high-capacity cDNA
reverse transcription kit (ABI). Finally, mRNA levels were quantified with the StepOne Real-Time
PCR system using a Fast SYBR Green Master Mix (ABI). Primers used for original ATXN3-Q80
constructs:
ATXN3 F: 5’-GAATGGCAGAAGGAGGAGTTACTA- 3’;
ATXN3 R: 5’-GACCCGTCAAGAGAGAATTCAAGT- 3’;
rp49 F: 5’ -AGATCGTGAAGAAGCGCACCAAG- 3’;
rp49 R: 5’ -CACCAGGAACTTCTTGAATCCGG- 3’
Primers used for Met-Null constructs:
Met-Null + ATXN3 F: 5’ -GGCGATGCTTAGAGCGAAGA- 3’;
Met-Null + ATXN3 R: 5’ -AATCGAGACCGAGGAGAGGG- 3’;
rp49 F: 5’ -AGATCGTGAAGAAGCGCACCAAG- 3’;
rp49 R: 5’ -CACCAGGAACTTCTTGAATCCGG- 3’
5.2.6

Drosophila examinations
For longevity experiments, adults were collected on the day of eclosion and monitored daily

to record deaths. Flies were switched into fresh food every other day. Males and females were
tracked separately. Number of adults tracked in each experiment is noted in figures and legends.
For developmental death tracking, flies were observed from the embryo stage through eclosion or
death, and deaths at each developmental stage (outlined in figures) were recorded daily.
5.2.7

Western blotting and quantification
Western blots were performed with either 3 whole flies or 5-10 flies collected during

development per group depending on the experiment and driver being used. Samples were
homogenized in boiling fly lysis buffer (50mM Tris pH 6.8, 2% SDS, 10% glycerol, 100mM
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dithioreitol(DTT)), briefly sonicated, boiled for 10 minutes and centrifuged for 8 minutes at
13300xg at room temperature. The PXi 4 (Syngene) or ChemiDoc (Bio-Rad) were used to develop
the Western blots, which were then quantified with GeneSys (Syngene) or ImageLab (Bio-Rad),
respectively. Direct blue stains of total protein were done by submerging the PVDF membranes
for 10 minutes in 0.008% Direct Blue 71 (Sigma-Aldrich) in 40% ethanol and 10% acetic acid and
then rinsed with a solution of just 40% ethanol/10% acetic acid, before being air dried and imaged.
5.2.8

Filter-trap assays
Three intact adults or 5 flies collected during development, depending on the driver being

used, per group were homogenized in 200µL of NETN buffer (50mM Tris, pH 7.5, 150mM NaCl,
0.5% Nonidet P-40) that was supplemented with a protease inhibitor (PI; S-8820, Sigma-Aldrich).
The resulting lysates were then diluted with 200µL 0.5% SDS in PBS. Diluted lysates were
sonicated, centrifuged at 4500xg for 1 minute at room temperature and then diluted further by
combining 100µL lysate with 400µL PBS. Thirty-five µL of this final lysate of each sample were
added to a Bio-Dot apparatus (Bio-Rad) and filter-vacuumed through a 0.45um nitrocellulose
membrane (Schleicher and Schuell) that had been pre-incubated with 0.1% SDS in PBS. After
samples were filter-vacuumed through the membrane, the membrane was rinsed twice with 0.1%
SDS in PBS, incubated in primary and then secondary antibody, and analyzed via Western blotting.
5.2.9

Co-immunopurification assays
Ten intact adults or 15 flies collected during development, depending on the driver being

used, were homogenized in 400µL of RIPA (50mM Tris, 150mM NaCl, 0.1% SDS, 0.5%
deoxycholic acid, 1% NP40, pH7.4)+PI buffer, sonicated and then mixed with an additional 400µL
of RIPA+PI. Samples were then tumbled at 4oC for 30 minutes. While tumbling, bead-bound
antibodies (either MYC- or V5-tagged; Thermo Fisher Scientific) were prepped with three rinses
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of RIPA+PI buffer. Following tumbling, 40µL of sample was combined with 10µL of 6X SDS,
boiled for 10 minutes and then saved as an input. The remaining sample was combined with the
prepped bead-bound antibodies and tumbled at 4°C for 2 hours. The beads were then rinsed 3 times
with RIPA+PI with a 5-minute tumble at 4°C during each rinse. Beads then underwent 5 additional
rinses with RIPA+PI without additional tumbling. Finally, bead-bound complexes were eluted by
combining with 30µL of lysis buffer (50mM Tris pH 6.8, 2% SDS, 10% glycerol, 100mM DTT)
and boiling for 5 minutes.
5.2.10 Statistics
Statistical tests used for each experiment are stated in their respective figure legends. Prism
8 (GraphPad) was used for the Kaplan-Meier log-rank tests for survival analysis, the Welch’s ttests for RQ comparisons from qRT-PCRs, the unpaired t-test for western blot analysis, and RM
two-way ANOVA with Geisser-Greenhouse correction and Tukey’s multiple comparisons test for
developmental death stage analysis. Additional data collection, organization, and student’s t-tests
were done in Excel (Microsoft) or Numbers (Apple). P-values were calculated by the software
used for analysis and are outlined in the corresponding figures and legends, along with the number
of biological replicates.
5.3
5.3.1

Results
Development of new constructs to examine RAN in SCA3
We generated two plasmids for mammalian cell transfection that contain the full, human

ataxin-3 sequence with either a pure homomeric CAG repeat (ATXN3-Q80(CAG)) or an
interrupted, alternating CAGCAA repeat (ATXN3-Q80(CAGCAA)). Both produce the same
pathogenic 80Q tract in the translated ataxin-3 protein; however, the pure CAG repeat is
susceptible to the formation of abnormal/slippery hairpin loops and could lead to RAN translation,
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while the CAGCAA mRNA is less likely to produce hairpin loops or RAN peptides and precludes
the production of proteins in alternative reading frames[226-233,241]. Constructs were HA-tagged
in the normal, sense frame (encoding ATXN3 protein). MYC and V5 tags were added in the +1
and +2 sense reading frames respectively (Figure 5.1A). Our expectation was that these tags would
allow us to biochemically detect the presence of any possible RAN translated polyserine (polyS)
or polyalanine (polyA) proteins from the sense strand.

Figure 5.1 Designing ataxin-3 constructs for studying RAN translation
(A) Diagrammatic representation of construct design with an uninterrupted CAG triplet repeat or alternating CAGCAA repeats and
HA, MYC, and V5 tags in the ataxin-3, +1 and +2 reading frames, respectively. Also shown are the expected translated sequences
of full-length proteins from each sense reading frame. These proteins are expected to contain either polyglutamine, polyserine, or
polyalanine repeats and their associated tags for identification. (B) Western blot from lysates of two different mammalian cell lines,
HEK-293T or M-17, transfected with an empty pcDNA vector or a pcDNA-ATXN3-80(CAG) or pcDNAATXN3-80(CAGCAA)
vector. Transfection and lysis were performed independently for each cell line and then loaded together in one gel as shown.

The ATXN3-Q80(CAGCAA) fly line has been employed in previous studies in our lab and
no specific protein signal was observed in either the MYC- or V5-tagged reading
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frames[277,343,386]. Upon transfection of cultured, mammalian HEK-293T cells with either
ATXN3-Q80(CAG) or ATXN3-Q80(CAGCAA), we observed no specific protein signal from
alternate reading frames with ATXN3-Q80(CAGCAA) and its alternating repeat. However,
transfection of ATXN3-Q80(CAG) possessing homomeric CAG repeats, resulted in the detection
of polyA proteins translated from the +2 V5-tagged frame (Figure 5.1B). As SCA3 is a primarily
neuronal disease, transfections were also conducted in a human neuroblastoma (M17) cell line
producing similar results (Figure 5.1B). These results provide evidence that RAN translation is
possible with the expanded ATXN3 transcript. Our next step was to determine whether this same
phenomenon occurs in vivo.
5.3.2

Homomeric and alternating pathogenic ataxin-3 polyQ repeats are differentially toxic
in Drosophila melanogaster
To

investigate

SCA3

RAN

translation

in

vivo

we

again

used

Drosophila

melanogaster[215,216,222,223,266,277,343,386]. Utilizing the versatility of Drosophila genetics along
with the Gal4-UAS binary system of expression, we can express either the homomeric or the
alternating polyQ repeat of pathogenic ataxin-3 transgenes individually in specific
tissues[174,179,216,222,223,252,266,277,343,356,386]. Expression of each construct was validated via
quantitative real-time polymerase chain reaction (qRT-PCR). In flies pan-neuronally expressing
the transgenes individually, ATXN3-Q80(CAG) was expressed at lower levels than ATXN3Q80(CAGCAA) (Figure 5.2A). However, no significant differences in mRNA levels were
detected between the two when expressed individually in glial cells (Figure 5.2B). Western blot
analyses of samples obtained by lysing adult flies expressing either ATXN3-Q80(CAG) or
ATXN3-Q80(CAGCAA) pan-neuronally (Figure 5.2C) or in developing flies expressing either
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version only in glia (Figure 5.2D) showed no significant difference in ataxin-3 protein level
between the two transgenes.

Figure 5.2 Homomeric CAG repeats are more toxic than alternating CAGCAA in fly models of SCA3
(A) qRT-PCR of one-day-old female adult flies pan-neuronally expressing ATXN3-80(CAGCAA) or ATXN3-Q80(CAG). Means
+/- SEM. p-value from Welch’s t-test. (B) qRT-PCR of developing flies expressing ATXN3-80(CAGCAA) or ATXN3-Q80(CAG)
in glia. Means +/- SEM. “ns”: non-statistically significant; Welch’s t-test. (C) Western blot of one-day-old female adult flies panneuronally expressing ATXN3-80(CAGCAA) or ATXN3-Q80(CAG) with whole-lane quantification of total ataxin-3 protein
levels. Means +/- SD. “ns”: non-statistically significant; unpaired t-test. (D) Western blot of developing flies expressing ATXN380(CAGCAA) or ATXN3-Q80(CAG) in glia with whole-lane quantification of total ataxin-3 protein levels. Means +/- SD. “ns”:
non-statistically significant; unpaired t-test. (E) Survival analysis from male and female adult flies pan-neuronally expressing
ATXN3-Q80(CAG), ATXN3-Q80(CAGCAA), or an empty vector insertion into the attP2 site (control). No adult male flies
expressing ATXN3-Q80(CAG) eclosed as adults. “*”: p<0.0332; “**”: p<0.0021; “***”: p<0.0002; “****”: p<0.0001. p-values
from log-rank tests. (F) Survival analysis from male and female adult flies expressing ATXN3-Q80(CAG), ATXN3Q80(CAGCAA), or an empty vector insertion into the attP2 site (control) in glia. No adult flies eclose in lines expressing either
ataxin-3 transgene in glia.
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We next determined if the presence of homomeric CAG repeats, and thus the potential for
hairpin loop formation and RAN translation, resulted in differences in disease progression
compared to the alternating, CAGCAA repeats. We performed longevity experiments with flies
expressing either construct pan-neuronally. Survival analyses from males and females revealed
that ATXN3-Q80(CAG) led to significantly decreased longevity compared to those expressing the
alternating, ATXN3-Q80(CAGCAA) in either sex (Figure 5.2E). In males, particularly, flies
expressing the alternating repeat lived as long as 46 days, while none of their homomeric repeatexpressing counterparts were able to emerge as adults, dying as pharate adults instead (Figure
5.2E; Supplemental figure S5.1).
Expression of ataxin-3 in glia, regardless of the transgene used, was developmentally lethal
and no adults emerged for longevity (Figure 5.2F). The experiments conducted in figures 5.2B and
5.2D were conducted with flies collected during development from lines expressing either
construct in glia. Although we were unable to study differences in longevity between our two lines
in glia, the high levels of toxicity in these cells compared to neurons points to an interesting
potential role for glia in SCA3 pathogenesis and is an active field of investigation, including a
recent study that identified impaired oligodendrocyte maturation as a contributor to pathogenesis
in a transgenic mouse model of SCA3[387].
In addition to pan-neuronal and glial expression, we performed survival studies in flies
expressing either of the transgenes ubiquitously. This is an expression model that we suspected
would be developmentally lethal and we thus focused on tracking the stages of development when
flies died, similar to what we did in previous work[386]. Analysis yielded a similar pattern of
results as our other expression models: we observed that ATXN3-Q80(CAG)-expressing flies died
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earlier during development than ATXN3-Q80(CAGCAA)-expressing ones (Supplemental Figure
S5.1).
These data indicate that although the sequence of each ATXN3 transgene encodes the same
pathogenic 80Q ataxin-3 protein with comparable protein levels, the presence of homomeric CAG
is more toxic than the alternating repeat. This opens the possibility that factors outside of the full
ataxin-3 protein alone may influence SCA3 pathogenesis. To determine if RAN translation is one
of those factors in SCA3, we next examined the presence of proteins from alternative reading
frames that could appear due to RAN translation.
5.3.3

Lack of evidence of RAN peptides in Drosophila from pathogenic ataxin-3
To detect the presence of potential RAN proteins, we took advantage of the alternate frame

tagging of our ATXN3 constructs outlined in Figure 5.1. These tags allow us to probe for the polyS
(+1 MYC-tagged frame) and polyA (+2 V5-tagged frame) proteins that we anticipate would be
translated if RAN translation were occurring – particularly the polyA proteins that we observed in
cultured mammalian cells expressing ATXN3-Q80(CAG). We conducted these probes using
several biochemical assays in both pan-neuronal and glial expression.
Simple Western blot analysis of whole fly lysates from lines pan-neuronally expressing
either ATXN3-Q80(CAGCAA) or ATXN3-Q80(CAG) did not reveal any detectable, translated
protein in either the +1 MYC-tagged or +2 V5-tagged frames (Figure 5.3A). As aggregation of
pathogenic ataxin-3 precedes toxicity in our Drosophila models of SCA3[222,223,277,343,386], we
next wondered whether RAN species were trapped in larger aggregates, along with full-length
ataxin-3 and thus may not have migrated properly into a standard SDS-PAGE gel. Thus, we
conducted

filter-trap

assays

designed

to

capture

higher-order

aggregated
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species[213,255,256,277,343,386]. There were no detectable MYC- or V5-tagged proteins in these
assays (Figure 5.3B).

Figure 5.3 No evidence of RAN translation in pan-neuronal Drosophila models of SCA3
(A) Western blot of one-day-old adult female flies pan-neuronally expressing ATXN3-80(CAGCAA), ATXN3-Q80(CAG), or a
negative control lacking any ataxin-3 transgene to examine MYC- or V5-tagged translated proteins from alternate reading frames.
No specific signal was detected in the +1 or +2 reading frames. n ≥ 3 each. (B) Filter-trap assays of lysates from one-day-old adult
female flies pan-neuronally expressing ATXN3-80(CAGCAA), ATXN3-Q80(CAG), or a negative control lacking any ataxin-3
transgene and blotting for either V5- or MYC-tagged proteins. V5- and MYC-blotted filter traps were conducted independently.
No signal above background was detected in either case. n ≥ 3 each. (C, D) Co-immunopurification with anti-MYC (C) or anti-V5
(D) antibody-tagged beads of lysates from one-day-old female flies pan-neuronally expressing ATXN3-Q80(CAG) or ATXN3Q80(CAGCAA). No alternate ataxin-3 frame MYC- or V5-tagged proteins were detected. n ≥ 3. Asterisk (*) denotes a non-specific
band observed with the V5 antibody under some conditions. For all applicable panels, MYC-positive controls were from whole
flies ubiquitously expressing a MYC-tagged ataxin-3 acquired from the Bloomington Drosophila Stock Center; V5-positive
controls were from dissected heads of flies expressing a V5-tagged ataxin-3 in the fly eyes that was used in a previous
publication[343].
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Figure 5.4 No evidence of RAN translation in the glia of Drosophila models of SCA3
(A) Western blot of developing flies expressing ATXN3-80(CAGCAA), ATXN3-Q80(CAG), or a negative control lacking
ATXN3 in glia. No specific signal was detected in the +1 or +2 reading frames. n ≥ 3 each. (B) Filter-trap assays of lysates from
developing flies expressing ATXN3-80(CAGCAA), ATXN3-Q80(CAG), or a negative control in glia. No signal above background
was detected in either reading frame. n ≥ 3 each. (C, D) Co-immunopurification with anti-MYC (C) or anti-V5 (D) antibody-tagged
beads from lysates of developing flies expressing ATXN3-Q80(CAG) or ATXN3-Q80(CAGCAA) in glia. No alternate ataxin-3
frame MYC- or V5--tagged proteins were co-immunopurified. n ≥ 3. Asterisk (*) denotes a non-specific band observed by the V5
antibody under some conditions. For all applicable panels, MYC-positive controls were from whole flies ubiquitously expressing
MYC-ataxin-3; V5-positive controls were from the heads of flies expressing a V5-ataxin-3 in fly eyes.
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Finally, we conducted co-immunopurification (co-IP) assays targeting MYC- and V5-tagged
proteins, in case the levels of these proteins were too low for capture by simple lysis of flies or
through filter-traps. MYC and V5 beads were used in separate co-IP experiments. We again did
not observe specific signal in either our MYC (Figure 5.3C) or V5 (Figure 5.3D) co-IPs.
These experiments were repeated in glial tissue. Due to the developmental lethality of glial
expression of either ataxin-3 transgene in Drosophila, flies were collected during development for
biochemical analysis, at either pupal or pharate adult stages. Western blot analyses recapitulated
findings from pan-neuronal expression for all assays conducted (Figure 5.4). We did not detect
any proteins translated in alternative, sense frames, suggesting that RAN translation is not a factor
in SCA3 pathogenesis in Drosophila. The question still remains: why do we observe significantly
higher toxicity from pathogenic ataxin-3 transgenes with homomeric CAG repeats compared to
those with alternating CAGCAA tracts? To attempt to answer these questions, we turned to the
previously

theorized

concept

of

contributions

to

ataxin-3

toxicity

from

its

RNA[228,229,231,233,381].
5.3.4

New transgenes to investigate mRNA-based toxicity in Drosophila models of SCA3
mRNA-based toxicity can occur in genes with long repeat sequences that allow for the

formation of RNA foci; these foci can recruit mRNA away from their native functions, recruit
mRNA-binding proteins, and can become toxic[381]. To investigate mRNA toxicity in fly models
of SCA3 ATXN3, we examined the impact of ATXN3 mRNA with homomeric CAG repeats
versus CAGCAA repeats, while preventing the translation of ataxin-3 protein. We utilized the
pathogenic ataxin-3 transgenes from the previous assays (ATXN3-Q80(CAG) and (CAGCAA))
and mutated all ATG (start) codons into TGA (stop) codons. These methionine-less constructs are
referred to as Met-Null(CAG) and Met-Null(CAGCAA) throughout the rest of this work. They
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differ from their homomeric and alternating repeat, protein expressing, counterparts only at the
‘start’ to ‘stop’ mutations (Figure 5.5A). Western blots from flies expressing these transgenes in
all neurons or in all glia did not yield any specific signal in the ataxin-3 frame (Figure 5.5B, C).

Figure 5.5 ATXN3 constructs to investigate mRNA-toxicity
(A) Each start codon was mutated into a stop codon (Stop) in ATXN3. Mutations were identical for the Met-Null(CAG) and MetNull(CAGCAA) constructs, changing every ‘ATG’ into “TGA’. (B, C) Western blots of one-day-old adult female and male flies
expressing Met-Null(CAGCAA), Met-Null(CAG), or a negative control lacking ATXN3 in all neurons (B) or glia (C). n ≥ 3 each.
No ataxin-3 protein was detected. n ≥ 3 each. For B, C, MYC-positive controls were from whole flies ubiquitously expressing
MYC-ataxin-3; V5-positive controls were from dissected heads of flies expressing V5-ataxin-3 in fly eyes.

5.3.5

Minimal survival difference in flies expressing alternating or homomeric, Met-Null
CAG/A repeats
We examined if differences in longevity between alternating and homomeric ataxin-3 CAG

repeats observed in figure 5.2 resulted in part from toxicity at the mRNA level. We expressed MetNull(CAG) or Met-Null(CAGCAA) pan-neuronally in flies and examined their survival (Figure
5.6A). Analyses of these survival data revealed significant sex-specific differences in longevity in
flies expressing both homomeric and alternating Met-Null constructs, with females outliving males
in both cases (Figure 5.6A). In addition to outliving their male counterparts, females flies panneuronally expressing Met-Null(CAGCAA) lived significantly longer than those expressing MetNull(CAG) (Figure 5.6A). However, this result was reversed in male flies expressing either of the
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Met-Null constructs: males pan-neuronally expressing Met-Null(CAG) lived slightly, but
significantly, longer than ones expressing Met-Null(CAGCAA) (Figure 5.6A). qRT-PCR of these
same flies showed no difference in pan-neuronal expression between the homomeric and
alternating CAG repeat constructs (Figure 5.6B).

Figure 5.6 Homomeric CAG mRNA can be slightly more toxic than alternating CAGCAA in flies expressing Met-Null
ATXN3
(A) Survival analyses from adult male and female flies pan-neuronally expressing Met-Null(CAG) or Met-Null(CAGCAA). “*”:
p<0.0332; “**”: p<0.0021; “***”: p<0.0002; “****”: p<0.0001. p-values from log-rank tests. (B) qRT-PCR of one-day-old adult
female flies pan-neuronally expressing Met-Null(CAGCAA) or Met-Null(CAG). Means +/- SEM. “ns”: non-statistically
significant; Welch’s t-test. (C) Survival analyses from adult male and female flies expressing Met-Null(CAG) or MetNull(CAGCAA) in glia. “ns”: non-statistically significant; “*”: p<0.0332; “**”: p<0.0021; “***”: p<0.0002; “****”: p<0.0001.
p-values from log-rank tests. (D) qRT-PCR of one-day-old female flies expressing Met-Null(CAGCAA) or Met-Null(CAG) in
glia. Means +/- SEM. “ns”: non-statistically significant; Welch’s t-test.
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We repeated the same assays in glia. Male flies expressing homomeric Met-Null(CAG)
ATXN3 lived slightly shorter lives than those expressing alternating repeats, but this difference
was not significant in females (Figure 5.6C). qRT-PCR confirmed that there were no significant
differences in expression between the two transgenes in glia (Figure 5.6D). We conclude that
mRNA toxicity is unlikely to be significant in SCA3 pathogenesis.
5.3.6

Alternative mechanisms of homomeric CAG toxicity
Recently, a hypothesis emerged that translation of pure, expanded CAG repeats in polyQ

disorders depletes available glutaminyl charging tRNAGln-CUG, which pairs exclusively with CAG
codon[388]. This depletion would result in a transcriptome that is prone to mistranslation and could
account for pathological differences observed between pure and interrupted CAG transcripts[388].
This notion provided a potential mechanism to help explain the differences we observe in our own
experiments between both our translated protein and Met-Null versions of ATXN3.
Our initial probe into this hypothesis focused on the availability of glutamine. In order for
tRNAGln-CUG to be charged and contribute to the translation of long CAG repeats, there must also
be an appropriate level of available glutamine to charge tRNAGln-CUG. Perhaps, glutamine is a
bottleneck, decreasing in levels as CAG repeats get longer and causing toxicity as a result of
depletion. We supplemented our normal fly food with 0.00, 12.5, or 50.0 grams of glutamine per
liter of food to determine if increased dietary consumption of glutamine could overcome potential
reductions in this amino acid. Concentrations for glutamine supplementation were based on
previous studies of amino acid supplementation in flies[389,390].
We tested the effect of increasing amounts of available glutamine in the fly diet using
ubiquitous expression of ATXN3-Q80(CAG) and ATXN3-Q80(CAGCAA) that resulted in high
toxicity (Supplemental figure S5.1). By tracking developmental deaths, we were able to rapidly
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assess if there is any benefit from increasing amounts of glutamine. Additional dietary glutamine
did not provide any detectable benefit to developing flies expressing ATXN3-Q80(CAG) or
ATXN3-80(CAGCAA) (Supplemental figure S5.3). These data suggest that glutamine itself is not
a limiting factor in our models.
While glutamine supplementation does not appear to be the answer in overcoming the
hypothesized tRNA depletion that results from expanded CAG repeat translation, there are
additional components to the translation machinery that could still be tested in this model. These
components, including the tRNA charging machinery and the tRNAGln-CUG itself, are outside the
scope of this work, but comprise viable candidates for future investigations.
5.4

Discussion
Here, we took aim at identifying the presence and potential influence of RAN translation in

Drosophila models of SCA3. As with previously identified RAN translation-associated diseases,
such as SCA8 and Huntington’s disease, SCA3 is a CAG repeat-expansion disorder with a long
repeat stretch. Based on prior reports on ATXN3 mRNA and that of other CAG repeat
disorders[228,229,231,233,381], SCA3 toxicity may be influenced by the ability of ATXN3 mRNA
to form secondary structures and by the presence of polyA species that have been identified in
SCA3 patient tissue[382]. These studies pointed to the possibility of RAN translation and made
SCA3 a candidate for exploratory research to add it to the growing list of repeat-expansion diseases
influenced by RAN translation.
We utilized transgenic Drosophila lines to express two versions of pathogenic ATXN3 in
the tissues primarily affected in SCA3, neurons and glia. The two versions of ATXN3 had either
an uninterrupted CAG or an alternating CAGCAA repeat in their polyQ-encoding tract and
represented ATXN3 mRNA capable (pure CAG) or incapable (alternating CAGCAA) of forming
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secondary structures for RAN translation. Although we observed differences in toxicity between
the two transgenes, we did not find biochemical evidence of RAN-translated proteins in
Drosophila. This lack of evidence does not preclude the possibility of RAN translation occurring
in the sense, ataxin-3 HA-tagged reading frame, or RAN products in the antisense strand. Detection
of these possibilities is outside the capability of our current model systems; however, our work in
mammalian cells, and the presence of polyA proteins in SCA3 patient tissue[382], supports our
focus on aberrant translation of the polyS and polyA reading frames as a reasonable measurement
of the occurrence of RAN translation in flies.
The absence of evidence of RAN translation in our SCA3 model system led us to consider
mRNA playing a possible role in ATXN3-based toxicity, as previously reported by the Bonini
lab[228]. We tested this non-mutually exclusive alternative to RAN translation by using
redesigned, pathogenic ATXN3 transgenes whose potential start codons were mutated to stop
codons. Expression of these ‘Met-Null’ transgenes yielded minor differences in toxicity that were
not consistent between sexes and between glia and neurons. These results provide some support
for the possibility of mRNA-based toxicity in SCA3, as indicated previously[228], with the caveat
that evidence in our study points to a highly subdued role for pure CAG mRNA toxicity in SCA3.
Differences in extent of mRNA toxicity between our work and prior findings[228] could be
explained by the potentially higher level of expression reached by prior transgenic lines (P
element-based transgenesis that can lead to multiple insertions) compared to the single copy, safeharbor integration of transgenes through the phiC31 integrase system that we employed. Also,
earlier observations were reached by using isolated, hyperexpanded CAG expansions[228], instead
of the patient-range used here. It is possible that mRNA toxicity does not feature prominently in
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the context of patient-range expansions, or that mRNA toxicity from isolated CAG repeats is
stronger than when those repeats are in the context of ATXN3 sequence.
Various mechanisms may explain the contribution in toxicity by CAG repeat-containing
mRNA. The uninterrupted CAG mRNA secondary structure could be more prone to aggregation
than CAGCAA mRNA and help accelerate aggregation of ataxin-3 protein [226,227,241].
Homomeric mRNA could also be more prone to stalling at the ribosome, similar to other repeatexpansion diseases, triggering dysregulation of essential processes [391]. In addition, these
prolonged homomeric repeats could create shortages in the tRNA charging machinery that may
further injure the cellular environment. Together with toxicity stemming from ataxin-3 protein
itself, these mRNA-based mechanism might hasten SCA3.
Pathogenesis from RAN translation and RNA-based toxicity are being increasingly
recognized as key contributors to various diseases. Although we suspect SCA3 to be a likely
member of the RAN translation family, we did not find evidence of it in Drosophila and found
minimal evidence of exclusively RNA-based toxicity. We conclude that the Drosophila model
system is not well suited for studying this type of RNA-based toxicity. Our study introduces to the
field additional tools that can be utilized towards understanding SCA3 and other, similar disorders.
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CHAPTER 6: FUTURE DIRECTIONS

Through the development of novel Drosophila genetics and tools, the work of this
dissertation took aim at understanding the domains and protein-protein interactions of the polyQexpanded ataxin-3 protein that play a role in its toxicity in SCA3 pathogenesis. While I set out to
with the intention of establishing as comprehensive understanding of ataxin-3 protein context as
possible, this work is far from complete. On top of the countless uncategorized protein-protein
interactions waiting to be found and studied, there is an additional, established domain of the
ataxin-3 protein that talented members of the Todi lab have already commenced investigations
into, the first ubiquitin binding site of ataxin-3’s catalytic domain (UbS1). As it relates to my work,
the major questions that remain are centered around investigations into the protein-interactions
with ataxin-3’s UIMs (Chapter 3) as well as the potential role for mRNA-based toxicity in SCA3
(Chapter 5).
The first questions that need to be answered are: what is the nature of ataxin-3’s interaction
with the chaperone protein Hsc70-4 and how does this interaction result in the increased
aggregation and toxicity of polyQ-expanded ataxin-3 toxicity? Initial investigations into these
questions focused on determining if there is a direct interaction between the two proteins and
whether this interaction disrupts the functional capabilities of either protein but, thus far, neither
have yielded promising results. Instead, my focus shifted to the possibility that the interaction
between ataxin-3 and Hsc70-4 was part of a larger functional complex that gets disrupted upon
polyQ expansion. Utilizing the same fly eye scoring system that was used to clarify the impact of
Hsc70-4 on ataxin-3 toxicity (figure 3.6), I conducted a larger screen of genes involved in the
chaperone machinery to find those whose knockdown causes a similar presentation of eye toxicity
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to that of Hsc70-4. Genes of interest from this screen could provide a potential link between ataxin3 and Hsc70-4 and would warrant further investigation.
From this initial screen, I was able to identify two fly genes in the network of chaperone
components that could potentially interact with both Hsc70-4 and ataxin-3 and whose knockdown
impacted ataxin-3 toxicity in a manner similar to Hsc70-4 knockdown, CHIP and Droj2. While
the E3 ubiquitin ligase CHIP (human ortholog, STUB1) has a well reported functional and
proposed pathological interaction with ataxin-3[371,392], the relationship between Droj2 and
ataxin-3 is less studied. As a J-protein (human orthologs DNAJA1 and DNAJA4), Droj2 and its
orthologs has published interactions with heat shock proteins in the chaperone folding
system[393,394], including Hsc70-4[357], making its impact on ataxin-3 toxicity particularly
interesting as a potential link between the two proteins. To further study this trio of interactions, it
will be necessary to lean on the power of the Drosophila genetics system to develop new lines that
express biochemically tagged versions of either Hsc70-4 or Droj2. These new Drosophila lines
would allow for co-expression and co-immunoprecipitation of each protein in order to determine
if there is any association between each set of proteins and, more importantly, if the same
complexes that allow Hsc70-4 to enhance ataxin-3 toxicity also contain Droj2. If an association
between all three proteins is observed, it is possible that Droj2 could be a link between ataxin-3
and Hsc70-4 that helps us better understand this chaperone’s aberrant function in the presence of
expanded polyglutamine tracts. Any associations could then be further validated as direct
interactions in vitro using bacterially produced pure proteins and pull-down assays.
The utility of the RNAi eye screen in flies in identifying interesting ataxin-3 toxicity
modifying proteins in the chaperone machinery inspired an additional future project that focuses
on searching more broadly for proteins that interact with polyQ-expanded ataxin-3 and modulate
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its toxicity. A larger, more general screen would not only provide an alternative approach for any
potential negative results with Droj2 and the Hsc70-4, but it also creates a rapid and reproducible
way to study the ataxin-3 functional interactome in both an expanded and wild-type state.
Additionally, these same screens could be conducted with other polyQ proteins or truncated pure
polyQ protein, as in figure 3.7, to determine if any effects observed are specific to the context of a
given polyQ protein or polyQ disorders as a whole. Figure 6.1 shows a consolidated example of
the target identification power that these screens can offer as you can compare the effects of
knockdown over time to a respective control as well as to each other. Genes with interesting score
trends can be further analyzed for significance and investigated for other hallmarks of disease like
aggregation. Overall, the methodology established in these screens has broad applications in
multiple disease models and will be useful in developing new avenues of research for the lab
moving forward.
The final project that I will discuss in this work is the future of the mRNA-based toxicity
studies started in Chapter 5. In that chapter, I identified a minimal role for mRNA-based toxicity
that did not seem to fully explain the differences in longevity and accumulation observed between
proteins with either homomeric CAG or alternating CAGCAA repeats. There are two theories to
help explain this that are discussed in the chapter that I believe warrant future investigation. The
first is that the secondary structure of the pure CAG mRNA could be more prone to aggregation
which could then help seed the aggregation of ataxin-3 at the protein level more efficiently than
CAGCAA mRNA. This theory could be explored using fly genetics to co-express either MetNull(CAG) or Met-Null(CAGCAA) with ATXN3-Q80(CAGCAA) or ATXN3-Q80(CAG). If
pure CAG mRNA is in fact acting as a seed for ataxin-3 protein aggregation, it is expected that coexpressing it with ATXN3-Q80(CAGCAA) would synergistically enhance toxicity in survival
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analysis beyond the toxicity of the protein or mRNA individually. It is also expected that these
effects would be mirrored, to a lesser extent perhaps, with ATXN3-Q80(CAG) co-expression
models and reduced in models co-expressing either ataxin-3 protein with the Met-Null(CAGCAA)
mRNA.
The other mRNA-based toxicity theory is that the presence of a prolonged and uninterrupted
CAG repeat sequence creates a shortage in the tRNA charging machinery necessary to translate
glutamines[388]. While the first test into this theory substituting excess glutamine into fly food
(supplemental figure S5.3) did not result in any improvements in longevity, there are other
elements to the glutamine charging process that could still be acting as bottlenecks to translation.
These elements include the specific CTG glutamine tRNA that corresponds to the CAG codon and
the glutamine synthetase that aids in the charging of CTG tRNA with a glutamine for translation.
New constructs for each of these proteins could be designed for transgenic expression in flies also
expressing pathogenic ataxin-3. Longevity studies could then be employed to determine if the
over-expression of either has an effect in overcoming any potential translation dysfunction caused
by an expanded repeat CAG repeat sequence.
The importance of protein context is relevant far beyond the study of polyglutamine disease
pathogenesis. Searching outside the known primary contributors to disease progression provides a
more comprehensive view of all that goes into toxicity and should open the door for the discovery
of therapeutic entry points in many diseases that currently lack any form of treatment. This
dissertation, the novel Drosophila tools that were developed in completing it, and the focus on the
entire context of a disease protein represent an approach that I believe to be valuable across the
family of polyglutamine diseases and beyond. Although the work presented here covers many of
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ataxin-3’s most important domains, there is still a great deal of work to be done in what I believe
to be a very exciting avenue of future research.

Figure 6.1 Heat map visualization of effect of gene knockdowns in Drosophila eyes co-expressing pathogenic ataxin-3
Displayed are visualizations of the Mean Rank comparisons from Dunn’s multiple comparison test between each gene knockdown
and their respective controls. A) Knockdowns at the attp40 chromosome 2 insertion site with females and males separated. B)
Knockdowns at the attp2 chromosome 3 insertion site with females and males separated. Legend displayed with green representing
improved eye phenotype (based on score) compared to control upon gene knockdown, and red representing worsening eye
phenotype (based on score) compared to control upon gene knockdown. Brighter color is associated with larger Mean Rank change
in either direction and thus a more prounounced change in eye phenotype.
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APPENDIX

Figure S2. 1
Anti-HA antibody shows similar difference in protein levels compared to the MJD antibody. Whole flies lysates from independent
crosses. Ataxin-3 isoforms 1 or 2 were driven in all fly neurons throughout development and in adults.

Figure S2. 2
Another set of cytoplasmic/nuclear fractionation preparations similar to, but independent of, figure 1G. Results from these blots
were quantified and included in histograms in figure 1G.
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sqh-Gal4 >

Outcome

Neither
Ataxin-3 isoform

Flies develop normally and
emerge successfully as
adults; normal adult longevity

Ataxin-3 Isoform 1

Vast majority die as pharate
adults. Some pupal lethality.
No adults eclose successfully.

Ataxin-3 Isoform 1
+
Ataxin-3 Isoform 2

Vast majority die as pupae.
Some pharate adult lethality.
No adults eclose successfully.

Figure S2. 3
Worsening of phenotype when both isoforms 1 and 2 of pathogenic ataxin-3 are expressed in all fly tissues and at all stages. Driver
was sqh-Gal4. All flies were heterozygous for driver and constructs.

Figure S2. 4
Difference in ataxin-3 levels in pupae. Left: blots from whole pupal lysates where sqh-Gal4 is driving the noted pathogenic ataxin3 variant. Five pupae per lysate were homogenized in hot SDS lysis buffer, sonicated, boiled, centrifuged and loaded on SDSPAGE gel. Each lane is from an independent repeat. Right: quantification of signal from the blot on the left. P values are from
student’s t-test comparing middle and right lanes separately to left lane.
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Figure S2. 5
Isoform 1 protein levels after longer-term autophagy or proteasome inhibition. HEK-293T cells were transfected with isoform 1,
then treated with 20 µM MG132 or 100 µM Chloroquine for the indicated times. Blot from whole cell lysis. Each lane is
independent.

Figure S2. 6
qRT-PCR results from the same experimental set as in figure 7, using HEK-293T cells expressing the constructs noted in the X
axis. N=3 independent biological replicates. No significant differences based on Student’s t-test comparing each group individually
to “Iso 2”.
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Figure S3. 1 Ataxin-3 domains impact the toxicity of its polyQ-expanded variant in glia.
(A) Longevity curves from adults expressing the noted versions of ataxin-3 in all fly glia, throughout development and in adults.
These are the same lines as in Figure 1. P values are from log-rank tests with Holm-Bonferroni adjustment. P values in italics are
not statistically significant. There is no statistical difference for 100% death between flies expressing ‘Intact’ versus ‘Inactive’,
even though 50% lethality is different. This is because each vial with flies is treated as one individual and for statistical purposes
the day when all flies are dead is considered, not the rate of death over the course of time for each vial. (B) Negative geotaxis assay
comparing motility of flies not expressing any pathogenic ataxin-3 versus flies expressing pathogenic ataxin-3 with mutated VBM
in all glial cells. Driver, as in panel (A), was repo-Gal4. No statistical differences are observed at any time point between the groups
based on two-tailed Student’s t-tests. We selected to conduct this assay for the VCP-binding mutations since in longevity curves
we noticed no significant differences in the longevity of flies not expressing pathogenic ataxin-3 compared to ones expressing the
SCA3 protein with the VCP-binding mutation. Note: The ‘Intact’ line shown here is a different transgenic line than the one we
generated for the polyQ studies concerning the UIMs that are shown in Figure 3.2 and beyond. Those lines (Figure 3.2 and on)
have a ‘CAGCAA’ repeat for reasons summarized in main text, compared to a pure 'CAG' repeat for all lines shown in Figure
3.1 and in this figure, which were generated for prior work. The lines generated for Figure 3.2 also have an optimized Kozak
sequence. As we showed earlier[277], the ‘CAGCAA’ repeat-harboring ‘Intact’ line is at higher protein levels and is more toxic
than the pure 'CAG' repeat shown here. For all the work in this study, isogenic sets are compared only to one another, that is, none
of the lines shown here and in Figure 3.1 is directly compared to lines in Figure 3.2 and beyond, since these lines were
conceptualized as isogenic sets from the beginning. However, we remind the reader that all ataxin-3 lines are inserted into the same
chromosomal site of Drosophila, attP2, in the same orientation and as a single copy number.
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Figure S3. 2 Levels of polyQ proteins, related to Figure 3.2D.
Western blots from lysates of whole, dissected fly heads; 25 heads per group. We caution here that the comparison of overall polyQ
proteins is not precise, especially concerning polyQ80-UIM3, which leads to markedly severe eye degeneration. The reason for
generating these truncated lines was to conduct an initial exploration of the role of UIMs on the isolated polyQ of ataxin-3. The
main focus of this work is full-length ataxin-3 and the role of UIMs in its pathogenicity, explored in subsequent figures. Future
work will dissect how individual UIMs impact various properties of the isolated polyQ80 in a tissue- and age-dependent manner.
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Figure S3. 3 Uncropped blot from panel 3.6E.

Figure S3. 4 Relative importance of UIMs on fly longevity.
(A) Longevity curves of adult flies expressing the denoted transgenes pan-neuronally. Continuous curves are the same as in Figure
3.1C; X-axis is extended to 86 days to show the full longevity of control flies. Blue dots are ‘approximated longevity’ of flies
expressing pathogenic ataxin-3 with mutated UIMs, based on data from Figure 3.3C. The UIM* flies are isogenic to the polyQ
truncation transgenes and the full-length ataxin-3 transgene used in Figures 3.2–3.8; therefore, the UIM* flies cannot be directly
compared to the lines used for Figure 3.1, since the Kozak sequence is different; also, the polyQ is encoded by a 'CAGCAA' repeat
for flies used in Figures 3.2–3.8, compared to a pure 'CAG' for flies in Figure 3.1. Lines in Figure 3.1 are all isogenic to each-other.
Calculations for the rough estimation are on the table on the right. (B) Another measure of improvement in fly longevity when the
VBM or the UIMs are mutated, compared to their respective, isogenic ‘Intact’ controls. Columns D and G show percent
improvement in longevity for flies expressing VBM-mutated ataxin-3 compared to their own isogenic ‘Intact’ (column D; data
from Figure 3.1) and flies expressing UIM-mutated ataxin-3 compared to their own isogenic ‘Intact’ (column G; data from Figure
3.1). Green font indicates that UIM* flies showed more improvement than VBM* ones.

155

Figure S4. 1 Motility assays validate non-toxic presence of N-VCP in Drosophila.
Negative geotaxis assays conducted in flies pan-neuronally expressing N-VCP. Driver: elav-Gal4. Tests were performed weekly
starting on day 7 and continuing through day 42. N-VCP-expressing flies were compared to flies with the same genetic background
and pan-neuronal driver but lacking N-VCP. Means -/+ SD. No statistical significance was found under any conditions; two-tailed
student’s t-tests. N>70 flies per genotype.
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Figure S4. 2 Daily alive adult numbers from Figure 4.2C.
Another graphical representation of the survival analyses shown in figure 4.2C. Whereas figure 4.2C shows the ‘probability of
survival’, these curves show the ‘daily alive percentages’ of flies in each group. As discussed in ‘Results’, flies denoted by green
color likely represent the effect of N-VCP more accurately as improvements in longevity begin during development. As the
zoomed-in portion of the longevity curve shows, the strongest flies expressing N-VCP (green) outlive those expressing pathogenic
ataxin-3 alone (red), approaching ‘Control’ flies, denoted by black color in the upper portion of the graph.
A point to address when comparing the results from the ubiquitous driver (this graph and figure 4.2C) to those with the pan-neuronal
drivers (figure 4.2D,E): a handful of flies that co-express pathogenic ataxin-3 alongside N-VCP in all tissues live markedly longer
than those that express the same proteins only in neurons. This outcome may indicate non-neural aspects of lethality from ataxin3, which deserve future attention. Indeed, we recently reported that pathogenic ataxin-3 causes different extents of lethality in
neuronal versus glial cells in Drosophila[343].
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Figure S4. 3 Motility assays with the ‘stronger’ pathogenic ataxin-3.
Negative geotaxis performed with flies expressing the ‘stronger’ pathogenic ataxin-3, without or with N-VCP. Means -/+ SD.
Statistics: one-tailed student’s t-tests comparing “red” and “green” histograms to each other. P value not shown if not <0.05. N>70
flies per genotype.
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Figure S4. 4 VCP increases pathogenic ataxin-3 toxicity in a dose-dependent manner.
(A, B) Longitudinal observation of developmental stage death among flies ubiquitously expressing the noted version of pathogenic
ataxin-3 with zero, one, or two copies of exogenous full-length VCP. Driver: sqh-Gal4. Means -/+ standard deviations. P-values:
one-tailed student’s t-tests, shown below graphs.
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Figure S5. 1 Ubiquitous expression longevity data and individual comparisons from survival analysis in figure 2
(A) Ubiquitous expression of ATXN3-Q80(CAG) and ATXN3-Q80(CAGCAA) individually was developmentally lethal in flies.
Observations of developmental deaths in both lines based on the fly life cycle (shown at top of figure) showed ATXN3-Q80(CAG)
flies dying primarily at earlier developmental stages than flies ubiquitously expressing ATXN3-Q80(CAGCAA). These
observations were confirmed with survival analysis in tissue-specific expression models shown in figure 2. (B) Individual
comparisons of all pan-neuronal expressing fly lines shown in figure 2E. “*”: p<0.0332; “**”: p<0.0021; “***”: p<0.0002; “****”:
p<0.0001. p-values from log-rank test. No adults eclosed in the glial expression analysis in figure 2F, thus no individual
comparisons were made.
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Figure S5. 2 Individual comparisons from survival analysis in figure 6
(A) Individual comparisons of all pan-neuronal expressing fly lines shown in figure 6A. “*”: p<0.0332; “**”: p<0.0021; “***”:
p<0.0002; “****”: p<0.0001. p-values from log-rank test. (B) Individual comparisons of all glial expressing fly lines shown in
figure 6C. “ns”: non-statistically significant; “*”: p<0.0332; “**”: p<0.0021; “***”: p<0.0002; “****”: p<0.0001. p-values from
log-rank test.
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Figure S5. 3 Developmental deaths of ATXN3-Q80-expressing flies with glutamine supplementation
(A) Developmental death tracking based on the percentage of fly deaths at each developmental stage in flies ubiquitously expressing
ATXN3-Q80(CAG) in food with 0.00, 12.5, or 50.0 g/L glutamine supplementation. Driver was sqh-Gal4. Each liter of food made
accounted for 100 fly vials, with each vial then receiving an additional 0.000, 0.125, or 0.500 g/L of glutamine respectively. Means
of percentages at each stage +/- SEM. “ns”: non-statistically significant. p-values of all comparisons shown to the right of graph
from RM two-way ANOVA with Geisser-Greenhouse correction and Tukey’s multiple comparison test. n ≥ 3 vials each. (B)
Developmental death tracking based on percentage of fly deaths at each developmental stage in flies ubiquitously expressing
ATXN3-Q80(CAGCAA) in food with 0.00, 12.5, or 50.0 g/L glutamine supplementation in food. Means of percentages at each
stage +/- SEM. “ns”: non-statistically significant. p-values of all comparisons shown to the right of graph and from RM two-way
ANOVA with Geisser-Greenhouse correction and Tukey’s multiple comparison test. n ≥ 3 vials each.
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Spinocerebellar Ataxia Type 3 (SCA3) is a member of the family of polyglutamine (polyQ)
neurodegenerative disorders that includes Huntington's Disease and several other SCAs. SCA3,
the most common dominant ataxia in the world, is caused by polyQ tract expansion in the protein,
ataxin-3. How SCA3 occurs and how to treat it remain unresolved issues. The primary culprit of
toxicity in all polyQ diseases is the glutamine repeat: its abnormal expansion leads to neuronal
dysfunction and death. With that said, there is indisputable evidence that the way polyQ-dependent
toxicity presents—areas impacted, cellular processes perturbed—is predicated in large part on
regions outside of the polyQ tract, i.e., protein context. Defining the role of non-polyQ regions of
ataxin-3 in the toxicity of its expanded glutamine tract will increase our understanding of the
biology of disease in SCA3. Functions including ubiquitin binding, proteasome shuttling, and
aggregation depend heavily on these non-polyQ regions. The work highlighted in this dissertation
expands on the current understanding of protein context in SCA3 by providing a detailed
investigation into the importance of various ataxin-3 domains and interactions to disease
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pathogenesis. It leans on the genetic versatility of the Drosophila melanogaster model organism
to develop novel methods of studying the ataxin-3 interactome and its impact on polyQ expanded
ataxin-3 toxicity. All this in hopes that it will help uncover potential therapeutic targets for this
currently incurable disorder.
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